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ABSTRACT 
Coronary heart disease (CHD) is the single largest cause of death and disability in 
most modern western societies and poor diet is a significant risk factor in the 
pathogenesis of this disease. Despite significant advances in the treatment of 
CHD, effective primary prevention approaches remain elusive largely due to the 
difficulty of sustaining significant and long term dietary changes. In this doctoral 
program, the hypothesis that the use of functional foods is an effective strategy in 
the primary prevention of this lifestyle disease was examined. Methodological 
approaches grounded in the field of nutrition science and behavioural psychology, 
incorporating both quantitative and qualitative studies were used.  
Results of a dietary trial in 25 patients, reflective of ‘free-living’ clinical practice 
conditions, found that a functional food-led intervention using plant sterol enriched 
margarine was an effective approach in the management of hypercholesterolemia. 
Sixty percent of subjects counselled on the inclusion of 25g per day of plant sterols 
achieved >15% reduction in total serum cholesterol, compared to none receiving 
standard dietary advice. In another dietary trial that was a randomised placebo 
controlled dietary intervention with parallel groups, 86 overweight, but otherwise 
healthy, subjects where asked to choose at least eight serves per day from a 
selection of either long chain omega-3 fatty acid (LCn-3) enriched foods (~125 mg 
LCn-3 per serve) or matched control foods. After six-months, participants were 
able to increase their dietary LCn-3 intake 4-fold (to ~1200 mg/day) and this was 
confirmed by a corresponding increase in the erythrocyte LCn-3 levels by 20%. 
This has implications for CHD reduction given the importance of dietary LCn-3.  
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Consumer and social research also suggest that functional foods can have an 
important role in public health. The Theory of Planned Behaviour (TPB) was used 
as a theoretical framework for a study examining prediction of intention to use n-3 
enriched functional foods, using a purpose designed questionnaire and follow up of 
recorded intake. Regression analysis was able to show that the model was a 
significant predictor of intention (R2 = 0.725, P < 0.001) and to a lesser extent 
behaviour (R2 = 0.298, P < 0.001). Attitude was significantly positively associated 
with intention, whereas subjective norms and control beliefs were not. These 
results imply that the best prospects for modifying behaviour are likely to come 
through a change in attitude. Beliefs and attitudes of key influencers are a 
significant determinant of consumer attitude. Semi-structured interviews with 
stakeholders (e.g. nutrition professionals, scientists, regulators, media personnel 
and food industry representatives) revealed there are a number of areas of 
agreement in their attitudes towards functional foods, including the need for safety, 
taste, bioactivity and extensive evidence for claims. Divergent views were 
expressed in relation to the regulation of health claims and the levels of evidence 
required substantiating these claims. A strong feature of the areas of disagreement 
was lack of clear scientific evidence available to form opinions, and stakeholders 
often relied on pre-existing ideology. These differing views may impact negatively 
on consumer attitude to the use of functional foods. 
In conclusion, analysis of clinical and consumer research suggests that use of 
functional foods can be an effective preventative health strategy for CHD as long 
as the maintenance of positive consumer confidence can be achieved.  
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CHAPTER 1  
 
INTRODUCTION 
Coronary heart diseases (CHD) collectively are the major cause of death and 
disability in most modern western societies. Primary prevention strategies are 
founded on the doctrine that prevention is better than cure. It has been 
demonstrated that population-based healthy eating primary prevention programs 
cost £14 - 560 (~AUD$ 34 -1373) per life year gained which is substantially 
cheaper than the cost of treatment (1). This would suggest that effective primary 
prevention strategies have the potential to reduce both the personal and financial 
burden of many lifestyle diseases. However, primary prevention programs are seen 
by many as achieving marginal gain at best and at worst are seen as ineffective 
(2).  
To date, approaches to reduce CHD which have been largely based on 
educational and behavioural models of intervention, have met with limited success 
(2). They are underpinned by the rational premise that people, once given 
appropriate education and skills will make sound decisions regarding their long-
term health status. Although there have been a number of programs which have 
successfully demonstrated improvements in knowledge, skill application and 
occasionally behaviour, they have seldom demonstrated improvements in risk 
factor reduction or improvements in morbidity and mortality outcomes (2). With 
tertiary treatment institutions under mounting resource and financial pressures, 
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there needs to be a redress of effective strategies that can potentially prevent 
these debilitating lifestyle diseases (3).  
Recent advancements in food technology provide a new range of options for 
intervention programs which are only beginning to be explored. At the forefront of 
this technological boom are functional foods. These are foods which provide 
nutritional benefits beyond basic nutrition (4, 5). Currently there is no universally 
accepted definition. In its broadest definition functional foods can include not only 
newly formulated foods but also traditional whole foods (e.g. oats and walnuts) (5). 
Central to this research is the hypothesis that the use of functional foods is an 
effective primary prevention strategy as it applies to CHD. 
With the unlikelihood that functional foods singularly will prevent CHD, it is 
important to place functional foods within an existing health promotion framework. 
Egger and Swinburn urge us to view lifestyle diseases as an epidemic, and state 
that epidemics historically have only been controlled after environmental factors 
have been modified and that existing intervention strategies for lifestyle diseases 
will only have limited impact if environmental factors are not addressed (6). There 
proposed model (epidemiological triad) supports a devotion of effort into three 
distinct, yet interrelating domains: host, environment and vector. For CHD, “host” 
refers to the biological and behavioural influences on diet and other lifestyle 
behaviours. “Environment” can be described in terms of the macro-environment 
and the micro-environment which are located in the physical, economic and socio-
cultural environmental context (7). And finally the “vector” is represented by the 
food and its associated nutritional profile. It is suggested that effective interventions 
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need to address each of the components of the triad. By superimposing a 
functional food-led intervention onto components of the epidemiological triad 
model, effects of functional foods (vector) on biological and behavioural outcomes 
(host) as well as the effects of these on the interface with policy and legislation 
(environment) were investigated. In this thesis, evidence for the effectiveness of a 
functional food-led approach was gathered using dietary intervention studies, 
behavioural studies and a stakeholder analysis.  
1.1 Methodological issues 
Establishing evidence for effective CHD prevention using dietary intervention 
studies provides a number of unique challenges. Firstly, the pathophysiology of 
CHD develops over a long period of time and absolute rates of mortality in the 
populations are relatively small. In order to detect the effect of an intervention on 
mortality rates, trials require large sample sizes with long intervention and follow up 
periods. This is usually cost prohibitive, leaving the definitive studies unavailable. 
Secondly, there is no single cause for the development of this disease, and as 
such a number of attributable risk factors have been described. These include diet-
related factors such as type 2 diabetes mellitus, obesity, elevated cholesterol, 
particularly LDL-cholesterol and high triglyceride levels, lifestyle-related risk factors 
such as physical inactivity and smoking and genetic factors such as gender and 
family history (8) and more recently a low level of erythrocyte eicosapentaenoic 
acid (EPA) + docosahexaenoic acid (DHA) (9). Often these intermediate markers 
of disease do not necessarily answer questions of mortality. Despite our best 
efforts to provide evidence of the effectiveness of primary prevention interventions, 
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there will always be uncertainty because of the lack of definitive evidence related to 
the disease endpoint itself. This should not lead to abandonment of research into 
primary prevention programs, but does serve as a cautionary tale which needs 
addressing through appropriate trial design and a reasoned approach to the 
application of newly acquired knowledge. 
Another concern for research design is that the utility of findings from the research 
setting to a ‘real life – free living’ context is not always assured (10). Caution is 
required when interpreting results from controlled clinical contexts and transferring 
them into free-living settings. For this reason it is important to design intervention 
trials that are grounded in a free-living context ensuring that the study outcomes 
are not overly inflated due to the tightly controlled design where compliance is 
assured. Also, extrapolating scientific evidence from one paradigm to another may 
falsely raise expectations. For example, positive results obtained from a sample of 
hypercholesterolaemic patients cannot be extrapolated to the general population. 
Therefore, consideration of the use of functional foods for public health benefits or 
as part of individual therapeutic regimens requires certain distinctions to be made. 
Dietary interventions designed to promote health may be categorised two ways: 
those that aim to modify dietary behaviour and reduce the level of risk factors in 
individuals, and those that aim to address the underlying determinants of health in 
populations as a whole (11). Each category of dietary intervention has specific 
considerations with respect to study design as well as the conclusions which can 
be drawn from the results. In relation to CHD, primary prevention interventions can 
be categorised as those targeted toward individuals that aim to reverse the 
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condition of diagnosed dyslipidaemia and those that aim to improve the dietary fat 
intake (reduce saturated fat and increase essential fatty acids) in the population.  
Despite the favourable results that individual counselling has on patients with 
elevated cholesterol in controlled studies (where food is provided) the results in a 
clinical environment are far less impressive (12). This has led to the undermining of 
nutrition counselling as the front line treatment of dyslipidemia in favour of more 
expensive drug therapy (13). However, the recent release of plant sterol/stanol 
enriched food products has renewed interest in dietary therapy, culminating in the 
recommendation of plant sterol/stanol use as part of medical nutrition therapy by 
the authors of the US National Cholesterol Education Program (14). However, 
there are no studies in the context of clinical practice that support this statement. 
1.2 The utility of functional foods in clinical practice 
In this thesis the first study was designed to test the hypothesis that specific dietary 
prescription of margarine enriched with 2g/day of plant sterols/stanols is more 
effective than standard dietetic advice in achieving an improved lipid and nutrient 
profile in free-living subjects with hyperlipidaemia. A randomised parallel design 
trial of comparative 12-week interventions was conducted with patients referred by 
a general practitioner to a dietary outpatient clinic for the management of 
hyperlipidaemia. In total, twenty-five patients (15 women and 10 men) completed 
the study. The control group received counselling regarding diet for 
hyperlipidaemia was based on the National Cholesterol Education Program 
(NCEP) guidelines (14), whereas the intervention group was instructed to 
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incorporate ~25 g/day of margarine containing plant sterols/stanols, which 
delivered ~2 g of plant sterols/stanols. Changes in diet, body weight and serum 
total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides were 
measured and reported at baseline and at three months. The number needed to 
treat (NNT), which is an index of effectiveness of the intervention, was calculated. 
This study gave an indication of the utility of functional foods in clinical practice. 
1.3 The utility of functional foods in population interventions 
Independent of the favourable effect that a reduction of hypercholesterolemia has 
on CHD risk, an adequate long chain omega-3 fatty acid (LCn-3) intake (EPA + 
DHA) has also been found to be beneficial for the prevention of CHD (15-17). 
Australians eat ~ 1/3 of the suggested intake of 650mg/day (18). Thus, from a 
population perspective there could be significant population health benefits from 
increasing the intake of this essential fatty acid in a large portion of the population. 
Therefore, in this thesis a second study was designed, this time with a population 
scope in mind, to test the hypothesis that a dietary strategy based on foods 
enriched with microencapsulated LCn-3 (fish oil) is more effective than a diet with 
non-enriched foods in achieving the target dietary recommendations of 1g/day of 
LCn-3 as well as providing cardioprotective benefits. An evaluation of reported 
dietary intakes in a 6-month randomised controlled parallel design supplemental 
trial was carried out. 86 overweight men and women with elevated triglycerides 
who reported low baseline fish intake were recruited and all subjects were supplied 
with a range of processed foods enriched with LCn-3 and instructed to consume 8 
serves per day (equivalent to ~ 1 g/day LCn-3), or matched control foods. 
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Reported energy, macronutrient and fatty acid intakes were measured by diet 
history and 3-day food records in conjunction with red cell fatty acids and surrogate 
markers of CHD. Food preferences were also determined along with the impact of 
this style of eating on the whole diet. The effect that this functional food-led 
intervention had on the total diet and dietary biomarkers was assessed and the 
feasibility and practicalities of the widespread application of this approach 
discussed.  
The ability to extrapolate results from these studies is somewhat limited by their 
design. In order to achieve the study design objective of placebo-controlled, 
randomised interventions subjects were provided with all test foods. The relatively 
high compliance in this study may not be achieved outside of the confines of such 
a controlled environment. Therefore, two more studies were designed for this 
thesis to investigate consumer beliefs, attitudes and ultimately predict the 
consumer behaviour in relation to functional foods.  
1.4 Consumers beliefs and behaviours with respect to functional foods 
There are a number of theories which aim to explain and predict human behaviour. 
These include, but are not limited to, the transtheoretical model (TTM), health 
belief model (HBM) and theory of planned behaviour (TPB). All have valid use in 
specific areas, with no one theory universally recognised. After a review of the 
literature the TPB was chosen as the model of choice to help understand 
consumer behaviour in relation to omega-3 (n-3) enriched functional foods. In brief 
TPB suggests that the best predictor of human behavior is a person’s conscious 
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decision to perform the behavior. This behavioural intention is determined by 
several factors, including the attitude they hold towards the behavior, the degree of 
social pressure felt by the person to perform or not perform the behavior, and the 
degree of control that the person feels they have over performing the behaviour 
(19). These three factors in turn are determined by a number of beliefs and 
subsequently how each is evaluated. It has been demonstrated that the TPB, or 
modified versions of it, is applicable in explaining consumers’ food choice (20-22), 
including supplement use (23) and genetically modified products (24), however this 
is the first time it has been applied to the area of functional foods. 
The first step in testing the hypothesis that the TPB predicts intention and use of 
functional foods enriched with n-3 was the implementation of exploratory focus 
group research. As suggested by the authors who described the TPB, the first step 
in exploring behaviour is to unveil the salient beliefs toward the behaviour of 
interest, which in this case is toward functional foods enriched with n-3 fatty acids 
(19). Focus group interviews were conducted with adult community based 
residents living in the Illawarra region of New South Wales, Australia. Forty-two 
participants (29 female; 13 male) aged 30-80y were recruited by advertisement 
and attended one of six focus groups which were recorded and transcribed 
verbatim. Content analysis was carried out and sub-categories were developed to 
capture the emerging themes according to the TPB model. Each aspect of the 
model was explored and salient behavioural, normative and control beliefs were 
discussed and reported. The consumer attitudes and purchase intentions identified 
in this study will be helpful to educators as they plan messages and strategies to 
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guide dietary choices related to products with n-3 fatty acids. In addition the beliefs 
identified and categorised from this study were then used to formulate a 54 item 
questionnaire which was used in the subsequent study. The questionnaire, in 
conjunction with information on dietary intake, was used to quantify responses 
regarding intention to use, beliefs and attitude toward n-3 enriched functional 
foods. A cross-sectional self-administered questionnaire was completed by 
community based residents living in the Illawarra region of New South Wales, 
Australia. Two sub-samples were surveyed via questionnaire: community members 
who responded to a local media advertisement (n = 79), and subjects in a dietary 
intervention trial for type 2 diabetes mellitus (n = 50). Using dietary intake data in 
conjunction with the TPB variables, questionnaire items were constructed to 
measure behaviour as well as intention to consume n-3 enriched functional foods. 
Results from sub-samples did not differ and were combined for analysis. Using 
regression analysis it was demonstrated that the model was a significant predictor 
of intention as well as being externally valid when intake data was considered. This 
work will help identify cognitive targets for the promotion of n-3 enriched foods, 
which are important to identify if we are to increase the population intake of n-3 
through the addition of this active ingredient through a range of processed foods. 
However, primary prevention strategies based on education and promotion alone 
will be ineffective if the environmental factors highlighted in the epidemiological 
triad are not addressed (6).  
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1.5 Environmental influences on the utility of functional foods 
In order for a functional food-led intervention to have a significant impact on CHD a 
supportive environment through effective policy and legislation is required. 
McConnon et al (2002) argue that the success of functional foods in both 
commercial and health promoting terms is reliant on the resolution of incongruence 
between stakeholder beliefs and attitudes towards these foods as this will have an 
effect of consumer confidence (25).  
The final study of this thesis tested the hypothesis that beliefs about functional 
foods are related to underlying ideology. Using semi-structured interviews the 
beliefs and attitudes of stakeholders towards the development and promotion of 
functional foods were unveiled. A sampling frame was drawn up of potential 
stakeholders in Australia using the categories as outlined by McConnon et al (25). 
A purposive sample of individuals was used representing general practitioners 
(GP’s), nutritionists, industry, media, regulatory bodies and authoritative 
organisations from various States. Interviews were audio taped and later 
transcribed to allow systematic analysis of the discussion. Using the theoretical 
framework proposed by McConnon et al (2002)(25) as well as reviewing the 
literature pertinent to this area (26, 27), ten open ended questions were devised to 
determine stakeholder awareness, beliefs, attitude issues regarding the 
development and promotion of functional foods. The results of the stakeholder 
interviews are discussed in relation to current national and international trends in 
food policy and regulation. Outcomes from this study provide a better 
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understanding of the areas of agreement and disagreement between the various 
stakeholders, and ways to reconcile incongruence are suggested.  
1.6 Summary 
The primary prevention of CHD presents us with two challenges: to treat those with 
overt symptomatic risk factors and to prevent CHD in people with no identifiable 
risk factors. Neither of these challenges is currently being met with any widespread 
effect (28). The studies reported here present an alternative primary prevention 
paradigm using innovations in food technology as an underlying driver. To answer 
the question as to the effectiveness of a functional food-led intervention this work 
has gone beyond the traditional approach of controlled clinical studies to 
incorporate dietary and behavioural psychology methodologies. In addition, the 
interface between functional foods, consumer behaviour and policy has been 
investigated and some of the implications of this intervention approach for food 
regulation have been discussed.  
1.6.1 Hypotheses  
The advent of functional foods is an important technological innovation which has 
the potential to help overcome the natural aversions humans have to dietary 
change. However, evidence of the effectiveness of a functional foods-led 
intervention is required. In addition, the use of functional foods by consumers must 
be congruent with the socio-cultural beliefs of the target population and supported 
by appropriate public policy. To confirm the central hypothesis that the use of 
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functional foods is an effective primary prevention strategy, the following 
hypotheses were tested: 
1. Specific dietary prescription of margarine enriched with 2g/day of plant 
sterols/stanols is more effective than standard dietetic advice in achieving 
an improved lipid and nutrient profile in free-living subjects with 
hyperlipidaemia. 
2. A dietary strategy based on foods enriched with microencapsulated fish oil 
is more effective than a diet with non-enriched foods in achieving the target 
dietary recommendations of 1g/day of LCn-3 and providing the 
cardioprotective benefits of fish oils. 
3. The behaviour model, Theory of Planned Behaviour, can be used to predict 
consumer’s intention and use of functional foods enriched with LCn-3. 
4. Stakeholder beliefs about functional foods will influence the consumer 
environment. 
1.6.2 Aims 
More specifically the aims of this thesis are to: 
i. Determine the effectiveness of prescribing 25g of margarine per day 
(containing 2 g plant sterols/stanols) to hypercholesterolaemic patients 
referred to an outpatient clinic on biochemical and dietary outcomes. 
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ii. Describe the feasibility of incorporating LCn-3 enriched foods in the diets of 
people with low fish intakes and the subsequent impact on the total diet, 
making clear reference to the quality and validity of the dietary data through 
the use of biomarkers.  
iii. Gain an understanding of the salient beliefs underlying Australian consumer 
attitudes and purchase intentions with regard to n-3 enriched functional 
foods using focus group discussions.  
iv. Identify the nature, strength and relative importance of influences on 
intentions to consume foods that are good sources of n-3 fatty acids using 
the Theory of Planned Behaviour (TPB).  
v. Ascertain the beliefs and attitudes of key leaders (stakeholders) towards the 
development and communication of functional foods. 
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CHAPTER 2  
 
LITERATURE REVIEW1 
2.1 Coronary Heart Diseases  
Coronary heart diseases (CHD), also known as coronary occlusion, ischemic heart 
disease (IHD), atherosclerotic heart disease or coronary thrombosis, are the 
leading cause of death in most Western societies including Australia (29). This has 
wide public health implications. In 2002, CHD was the single largest cause of death 
and the most common cause of sudden death, and accounted for 26,063 deaths 
which represent 19.5% of the total number of deaths and accounted for 51.8% of 
cardiovascular deaths in Australia (29). Over half of the CHD deaths were from 
sudden heart attacks (acute myocardial infarction) (29). Overall, males are twice as 
likely as females to die from CHD (29). From the results of the Australian 2001 
National Health survey, 1.9% (355,600) of those surveyed individuals reported 
having manifestations of CHD (29), whereas in 2001-02 it was estimated that there 
were 48,700 fatal and non-fatal CHD events (29). Cardiovascular diseases are the 
                                             
1 A portion of this chapter has been published in the following peer reviewed journal: 
Patch CS, Tapsell LC, Williams PG. Dietetics and Functional Foods. Nutrition & Dietetics. 2003, 61;1:22-29.  
CP was responsible for the literature review, preparation and critical discussions of the manuscript. LT and PW were 
responsible for critical discussions of the manuscript. 
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most costly disease for the health system and in 1993-94 it accounted for $3,719 
million or 12% of total direct health system costs in that year (29). Coronary heart 
diseases were the major contributor to this cost, accounting for 25% ($894 million) 
of the total (29). Furthermore cardiovascular drugs accounted for 16.8% of all costs 
of prescription drugs listed on the Pharmaceutical Benefits Scheme in 1994 ($27.3 
million per year) (29). From 1992-1994, there was an average increase of 4.0% per 
year in these prescription drugs (29). 
The clinical manifestations of CHD are chronic arterial obstructions or acute arterial 
occlusions in various territories, which ultimately lead to the condition where there 
is an inadequate supply of blood to the heart muscle leading to ischemia (30). In 
some cases ischemia may become so severe that it causes a myocardial infarction 
(coronary infarction, coronary thrombosis, or heart attack). This may result from the 
progression of atherosclerosis within the coronary arteries, or result from the 
formation of a blood clot within the arteries (thrombosis), or most likely a 
combination of both that ultimately leads to a necrosis of the cardiac muscle cells 
(30). Atherosclerosis is a disease of the tunica intima (arterial inner lining of the 
lumen) of the large and medium sized arteries, characterised by the development 
of fibrous, fatty deposits called plaques or atheromas (31). These atheromas 
eventually become calcified, rendering them rigid and narrow. 
The pathogenesis is only understood in part as yet. The development of an 
atheroma (or plaque) in the intima of the major arteries marks the development of 
the pathogenesis of atherosclerosis. Arterial wall abnormalities, blood composition 
abnormalities and haemodynamic alterations are generally accepted to be 
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causative (Virchow’s triad) (8). There is strong support for a causative relationship 
between hypercholesterolaemia and atherosclerosis originally evidenced by the 
premature development of CHD in younger individuals with familial 
hypercholesterolaemia (32). There is also direct evidence from animal models of 
the effect of elevated LDL-cholesterol on atherogenesis (32). Research suggests 
this forms a cytotoxic compound and initiates the cascade of events eventually 
leading to atherosclerosis (33). Shear-stress induced micro injuries of the 
endothelium in hemodynamically compromised regions together with local 
coagulation activation associated with microinflammation of the plaque are 
currently thought to cause plaque rupture (8). The resultant local clot formation is 
the ultimate reason for organ failure. 
2.2 Dietary risk factors  
No authentic cause of atherosclerosis has been isolated, but is believed to be 
multifactorial (34). To date, aetiologic research has only established risk factors 
which provide the basis for some efficient but incomplete means for prevention. 
Most of this evidence relating to risk factors is epidemiologic and therefore consists 
of statistical evidence for probability of evidence (34). The three factors most 
consistently associated with an increase in the incidence of CHD include 
hypertension, hypercholesterolemia and cigarette smoking. Other modifiable risk 
factors include obesity, lack of exercise, hypertriglycerideaemia and low HDL 
cholesterol levels. There are also a number of non-modifiable risk factors such as 
male sex, diabetes mellitus, and family history of premature CHD and the presence 
of definitive atherosclerosis. 
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There is considerable evidence that dietary fats lead to increases in blood levels of 
cholesterol, and ultimately to atherosclerosis, and in the past this has been the 
theoretical underpinning to many health promoting and dietary prevention 
strategies (35). Initially, expert committees from major scientific associations such 
as the National Heart, Lung and Blood Institute and the American Heart 
Association initiated clinical trials with the aim of decreasing plasma cholesterol 
levels in an attempt to decrease the risk of atherosclerotic disease (the diet-heart 
hypothesis) (36). However it is now becoming apparent that the role of diet in the 
prevention of CHD is more complicated than this simple cause and effect 
relationship would suggest. 
2.3 The diet-heart disease hypothesis 
Keys et al first suggested the link between serum cholesterol, dietary fat intake and 
cardiovascular disease in the landmark Seven Countries study (37). Populations 
living in Japan and Crete were shown to have the lowest rates of CHD and tended 
to have a lower serum cholesterol and consume a diet low in saturated fat, while 
being high in polyunsaturated fatty acids (PUFA) (38). However, it is apparent that 
although there was a positive relationship between serum cholesterol and rates of 
CHD, there was wide inter-population variation in CHD rates at all levels of serum 
cholesterol. For example, at a cholesterol level of 6.00mmol/l, the US and Finland 
had an incidence of cardiovascular disease (CVD) between 30-45%, whereas 
Japan and Crete had an incidence of <10% (39).  
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In addition to elevated levels of plasma cholesterol (TC), increased levels of 
triglycerides (TG), as well as a reduced level of high-density lipoprotein cholesterol 
(HDL) have been linked to the development of premature CHD (40-42). In a 
prospective observational study, the Framingham Study, it was concluded that 
coronary risk starts to increase with total cholesterol values over about 5.00 
mmol/L (41). In addition, for patients with established CHD, elevated lipids and 
lipoprotein remain predictive of future CHD events and even death (43). Elevated 
triglycerides have also been suggested as having a predictive role in CHD (44). 
The authors concluded that high plasma cholesterol; high blood pressure and 
cigarette smoking are predictors of coronary risk. In addition, the Strong Heart 
Study (2003) found the ratio of total and HDL cholesterol to be a good predictor of 
CVD in both male and female type 2 diabetics, although a stronger predictor in 
men (45). However the investigators acknowledged that they could only 
demonstrate ‘guilt by association’ and could not prove that they cause CHD (46).   
Hu et al followed 85,941 women from 1980 to 1994 from the Nurses’ Health study 
and investigated the incidence of CHD (15). The age specific incidence rates of 
coronary disease showed a decline in over time. The relative risk of all coronary 
disease decreased by 31% from 1980 – 1992. This model suggested that an 
improvement in diet explained a 16% decrease while the increase in body-mass 
index explained an 8% increase in the incidence of CHD. Researchers noted that 
the dietary changes were from a decrease in the intake of saturated and trans fatty 
acids, whereas the intake of polyunsaturated fatty acids (PUFA), cereal fibre, 
marine n-3 polyunsaturated fatty acids (LCn-3) and folate increased (15). In 
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summary they concluded that a 10% decrease in serum cholesterol levels is 
associated with a 30% reduction in CHD after adjusting for confounders and 
measurement errors (47) which is consistent with earlier risk modelling which 
reported a 2-3% relative risk reduction with each 1% reduction in serum cholesterol 
(37). In addition, there is a wealth of observational, experimental and genetic 
evidence to suggest that increasing HDL cholesterol will also lower the risk of CHD 
(48-51). The ratio of total to HDL cholesterol is now considered more important 
than these individual factors alone in estimating the risk of CHD (52-54). Therefore 
it is important to assess the effects of dietary interventions on both of these 
biomarkers. 
Using these epidemiological associations as a theoretical base, drug intervention 
trials have been carried out since the 1970’s. In 1994, the Scandinavian 
Simvastatin Survival Study conducted a double-blind trial using 4444 patients with 
existing CHD (55). Those patients receiving 3-hydroxy-3-methylglutaryl coenzyme 
A reductase inhibitors (HMGCoA reductase inhibitor (statin)) showed total 
cholesterol, LDL-cholesterol, HDL- cholesterol changes of –25%, –35% and +8% 
respectively. Using the combined end-points of coronary deaths and nonfatal 
myocardial infarct (MI), a reduction in incidence of 37% was achieved over the 
entire study (5.4 years) (55). Comparable results were reported by using 
Pravastatin (56). Similarly, dietary studies into the secondary prevention of heart 
disease have shown a reduction in serum cholesterol by 8 -12% through dietary 
manipulation – aiming for low saturated fats, high n-3, high fruit and vegetables – 
has resulted in a 25 - 45% reduction in cardiovascular mortality (57-59). 
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Can the same benefits be achieved with dietary interventions aimed at reducing 
total cholesterol in primary prevention? Epidemiological and experimental evidence 
indicate that a diet high in SFA is associated with high levels of serum cholesterol 
which are in turn related to CHD, although there are some significant anomalies in 
the evidence where some of the earlier intervention studies failed to improve CHD 
prognosis (60). However, it can be noted that the trials were conducted on low risk 
patients and used high fat diets (~ 40% of energy as lipids), comprising of low 
saturated fat and cholesterol levels, but very high level of PUFA (15 to 20% of 
energy), particularly n-6 (60). An epidemiological investigation into the relationship 
between dietary intake and CHD mortality could not find any significant association 
between any of the dietary components and mortality (61). It was concluded that a 
better understanding of the pathway between dietary intake and coronary disease 
is needed, as the current diet-lipid-heart hypothesis may be overly simplistic (61). 
Furthermore a number of primary prevention trials failed to determine this 
association. In the Multiple Risk Factor Intervention Trial, 12,866 high risk males 
between the ages of 35 and 57years were recruited to a randomised primary 
prevention trial (62). Men randomly assigned to the intervention group were 
counselled on lowering cholesterol, received dietary advice for reducing 
hypertension, and instructed to cease smoking, whereas those in the usual care 
group were referred to usual community follow up. After an average of 7 years, and 
despite significant reductions in risk factors in the intervention group, both CHD 
mortality and total mortality did not differ between groups (62).  
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In summary, the diet – heart disease hypothesis is characterised by the following 
syllogism:  that an elevated intake of saturated fat, and total fat, and dietary 
cholesterol will raise serum cholesterol, which in turn leads to atherosclerosis and 
ultimately results in CHD morbidity and mortality (63). As this hypothesis would 
suggest, a reduction in dietary saturated and total fat should result in a reduction in 
morbidity and mortality from CHD. It is the lack of direct evidence that is missing in 
order to prove the hypothesis that has prompted others to question its validity (64). 
2.4 The diet – heart disease hypothesis revised 
Although research has focused on the role of SFA, serum lipids and 
atherosclerosis for the last 3 decades, more recent attention has turned to the role 
of specific dietary fats, and in particular n-3 on specific manifestations on CHD, 
namely sudden death (65-67). N-3 fatty acids are a family of naturally occurring 
PUFA. It is in the position of the double bonds within their hydrocarbon chain that 
gives n-3 fatty acids their name and also their physical and physiological 
properties. For example, in n-3 the terminal double bond (i.e. closest to the methyl 
end of the hydrocarbon chain) is on C3. In n-6 the terminal double bond is on C6. 
The n-6 and n-3 families of PUFA have a range of members, ranging from linoleic 
acid (LA; 18:2n-6) and α-linolenic acid (ALA; 18:3n-3), both of which are plant-
derived oils. In fact, n-6 and n-3 double bonds can not be inserted into fatty acids 
by animal enzymes, only by plants through the action of the ∆12- and ∆15-
desaturase respectively (68). Although animals cannot derive these fatty acids, 
mammals have a requirement for these, and thus they are regarded as essential 
fatty acids. Although mammalian cells cannot synthesis these fats, they can 
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metabolise them by further saturation and elongation. For example linoleic acid can 
be converted to γ-linolenic acid (18:3n-6) by ∆6-desaturase and then γ-linolenic 
acid can be elongated to dihomo- γ-linolenic (68). This can be further desaturated 
by ∆5-desaturase to yield arachidonic acid (20:4n-6). Using the same series of 
enzymes α-linolenic acid is converted to EPA (20:5n-3) (68). Because the n-6 and 
n-3 series utilise the same enzymatic pathways (∆6-desaturase reaction) which is 
a rate limiting step, there is competition between these fatty acid families. 
Further metabolism of EPA to DHA (22:6n-3) is mediated by the formation of 
docosapentaenoic acid (DPA; 22:5n-3), then the addition of two additional carbons 
(24:5n-3) and desaturation at the ∆6 position to form 24:6n-3 and finally β-oxidation 
to yield DHA (69). It is important to note that recent studies have revealed that the 
conversion of ALA into its longer chain derivatives is not efficient in humans, and 
some suggest that conversion of ALA to DHA is around 15% (70-72). Similarly 
arachidonic acid can be metabolized by the same enzymatic series to yield, in turn, 
22:4n-6, 24:4n-6, 24:5n-6 and 22:5n-6 (73).  
The long-chain derivatives of LA and ALA acid (AA and EPA respectively) are 
important biologically as they exert potent physiological effects (68). EPA and AA 
are competitively metabolized via the cyclooxygenase, lipoxygenase and 
cytochrome P450 pathways to eicosanoids such as prostaglandins (PG), 
thromboxanes (TX) and leukotrienes (LT) (74). Arachidonic acid is the substrate for 
the synthesis of 2-series PG, 2-series TX and 4-series LT, whereas EPA is the 
substrate for the 3-series PG, 3-series TX and 5-series LT. The competitive 
metabolism of these substrates has important implications in the regulation of 
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smooth muscle contraction, platelet aggregation, inflammation, immune function 
and cell proliferation (74). For example, EPA-derived TXA 3 shows reduced 
proaggregatory and vasoconstricitive properties compared to the AA-derived TXA 
2, while the antiaggregatory and vasodilative efficacy of PGI 3 equals that of PGI 2 
(74). Because ALA and LA compete for the ∆-6-desaturase enzyme in the 
desaturation chain elongation pathway, both incorporation of ALA into the tissues 
and plasma as well as the conversion of EPA and DHA, are influenced by LA 
levels. The net result of a higher ALA levels and subsequent EPA metabolite is the 
suppression of TXA 2 (and promotion of TXA 3) which has a proaggregatory 
vasoconstrictor, as LA conversion to arachidonic acid is decreased (64). In 
addition, PGI 3, the antiaggregatory prostaglandin derived from EPA, has effects 
comparable to those AA-derived PGI 2 (75). Subsequent research revealed that 
the other 3-series eicosanoids derived from EPA (e.g. PGE 3, LTB 5) also have 
reduced physiological activity compared to their 2-series counterparts (75).  
Thus the net results in prostanoid synthesis from n-3 results in reduced 
proaggregatory and vasodilatory effects (74). The differences between the EPA 
and AA metabolism are likely to be the basis for the observed reduction in 
thrombosis and anti-inflammatory properties of dietary n-3 fats (75). Thus it is 
thought that a lower n-6:n-3 ratio has a beneficial effect on primary and secondary 
prevention of atherosclerosis, thrombosis and embolic phenomena, 
hypertriglyceridaemia and hypertension (74).  
Presently most Western countries consume diets with relatively low levels of this 
LCn-3. A good dietary source of LCn-3 is fish. Fish can be classified as either lean 
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fish, where fat is stored in the liver (e.g. whiting, cod) or fatty fish, where the oil is 
contained in the flesh (e.g. salmon, tuna, herring, mackerel). Essentially all fish oil 
is high in LCn-3, although the proportions of EPA, DPA and DHA can vary. The 
major dietary source of AA is from meat and meat products, but most AA comes 
from the conversion of LA rather than from the diet (76). In contrast, major sources 
of LA come in the form of cooking oils (e.g. corn oil, sunflower oil and rapeseed oil) 
and margarines made from these oils, which make a significant contribution to the 
intakes of these fatty acids (68). This results in a higher intake of n-6 in modern 
Western societies over the last 35 years (68). For example in the UK the average 
intake of LA among adults increased from ≈ 11g in 1970 to ≈ 14g in 1990 (68). 
However, more recently margarines derived from canola and flax have been 
introduced into the food supply and contain more ALA. ALA can be metabolized to 
EPA and DHA through the desaturation chain elongation pathway (64). The 
physiological action of the n-6 series is interwoven with the actions of the n-3 
series, and it is an imbalance between the two that has a detrimental effect on 
vascular health. The correction of this n-3 imbalance and LCn-3 deficiency in the 
modern diet is a key step to improving the cardiovascular risk in our population 
(77). 
Interest in n-3 and their health benefits were stimulated by earlier research into the 
dietary habits of Greenland Eskimos. It was suggested that the reasons for the low 
cardiovascular disease rate, which was <10% of that predicted given their high 
intake of fat, was due to a diet which was high in seal meat and whale blubber (17, 
78). The suggested cardioprotective component was LCn-3, with the intakes being 
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estimated to average as much as 5-15g/day (78). In comparison to Danes, 
Eskimos ate a diet that was lower in linoleic acid (LA) and higher in n-3; had 
platelet phospholipids that contains proportionately less LA, less AA, and more 
EPA; and had a lower mean platelet count and longer mean bleeding (79). The 
Japanese also exhibit a low mortality from CHD, with fatty fish also contributing 
significantly to the traditional Japanese diet (80). These results have been 
replicated in population studies that have found a positive association between 
communities with a high fish intake and lower rates of CHD (17, 81). Data from a 
number of epidemiological and case-controlled studies dating from the 1960’s have 
strongly supported the inverse relationship between high LCn-3 blood 
concentration and intake on CHD mortality rates in Western countries (65-67, 79, 
82-100). For example, the Zutphen study provided early epidemiological evidence 
of the importance of fish oil in the prevention of CVD (100). This study, conducted 
in 1960, observed a cohort of 852 middle aged men who had no history or 
symptoms of heart disease. After 20 years the incidence of heart disease was 
inversely related to fish intake. The authors concluded that 35 g fish/day equated to 
a 50% reduction in mortality from coronary artery disease (100). However, this 
area is not without controversy as others have failed to show significant benefits of 
modest intakes of fish oil on CHD rates (96, 101, 102). 
Further support for an increase in LCn-3 comes from research into Paleolithic 
nutrition. N-3 fats were abundant in the diet of our Paleolithic ancestors (103). The 
original sources of n-3 in the food supply were from ubiquitous algae in the sea and 
of grasses and leaves on the land (104). This small amount of n-3 in the algae and 
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grasses became more concentrated as it was consumed up the food chain, 
particularly in fish and larger grazing animals (104). With modern domestic animal 
generally being fed on cereal based products, meat is generally low in these 
essential fatty acids (105). Although interesting, evidence from controlled 
intervention trial is needed to substantiate the hypothesis. 
A secondary prevention study, the Diet and Reinfarction Trial (DART) randomised 
2033 survivors of myocardial infarction who were at very high risk of dying from a 
heart attack with the next few years into a low fat diet or high fibre diet. The 
intervention group consumed ~2.3g EPA/day, whereas the control group 
consumed ~0.7g EPA/day. After 2 years of intervention the low dose fish oil group 
had a reduced mortality (29%), with no effect on blood pressure, serum lipids and 
no difference in ischaemic events, and the authors concluded that this suggests an 
antiarrhythmic effect (58, 106). Similar results have been reported by Singh et al 
(1992) (107). The clinical effectiveness of fish oil was most strikingly demonstrated 
in the GISSI Prevenzione study (108). This was also a secondary prevention study, 
but this time using a fish oil supplement, Marchioli et al (2002) randomised 11,323 
survivors of myocardial infarction to either n-3 supplements (885mg of EPA + 
DHA/day), vitamin E (300mg/day), both or neither (control) (108, 109). After 12 
months, compared to the control group, they demonstrated a significant reduction 
of cardiovascular deaths by 30% and a significant reduction of sudden death by 
45% in the fish oil group, but not the others (108). There were no effects on 
cholesterol, blood pressure and a small reduction in triglyceride. Survival curves for 
the n-3 treatment group diverged early after randomisation and mortality was 
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significantly lowered after 3 months of treatment. The authors concluded that the 
early effect of low-dose (~1g/day) n-3 on total mortality and sudden death supports 
the hypothesis of an antiarrhythmic effect of this therapy (108). Equally impressive 
results have been reported with ALA. The Lyon heart study was a prospective, 
randomised single-blinded secondary prevention trial and compared the effect of a 
Mediterranean diet rich in ALA (precursor of long chain n-3 fatty acids) rich diet to 
the usual post-infarct prudent diet. Overall mortality was reduced and an adjusted 
risk ratio of 0.30 achieved (38, 110). An interesting addendum in these studies was 
the finding that significant reductions in CHD death were observed with little or no 
reduction in serum cholesterol (111).  
When comparing these results to those obtained through drug interventions, the 
clinical validity of fish oils therapy in the secondary prevention of CHD becomes 
apparent. A recent meta-analysis of patients with CHD to determine the 
effectiveness of HMGCoA inhibitor (Statin) therapy concluded that there was a 
reduction in CHD mortality or non-fatal myocardial infarction of 25% (RR, 0.75; 
95% CI 0.71-0.79), all cause mortality 16% (RR, 0.84; 95% CI, 0.79-0.89), and 
CHD mortality 23% (RR, 0.77; 95% CI, 0.71-0.83) (112). These values are no 
better that the results achieved in the fish oil supplementation trials. 
There are a number of mechanisms via which LCn-3 may reduce the risk of heart 
disease. It may protect against both the pathological processes leading to the 
disease (i.e. atherosclerosis) and the process leading to death (i.e. stroke and 
myocardial infarction). Dietary n-6 and n-3 reduce triglyceride accumulation in the 
skeletal muscle and potentially in the cardiomyocytes and β cells (75, 113-116). 
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Elevated triglycerides are regarded as an independent risk factor of CVD and has 
been outlined in a number of reviews (117-119). The resultant lower tissue lipid 
levels are associated with an increase in insulin sensitivity (120). PUFA 
concomitantly suppress lipid synthesis in the liver, up regulating fatty acid oxidation 
in liver and skeletal muscle and increasing body glycogen (120). This repartitioning 
activity of PUFA has been observed in both animal and human models (120-122). 
LCn-3 are also anti-inflammatory (123), which is recognized to be a contributing 
factor to atherosclerosis, starting off the cascade of vessel wall intima damage 
culminating in leukocyte and smooth muscle migration (124). Further down 
regulatory pathways, protective actions attributed to LCn-3 include decreasing 
growth factor (125) and adhesion molecules (126-128). Long chain n-3 have also 
been found to reduce blood pressure (129-131) and as revealed in a recent meta-
analysis, an intake of a median dose of 3.7g/day of LCn-3 can reduce systolic and 
diastolic blood pressure of 1.7 mmHg (95% CI: 0.3, 3.1) and 1.5 mmHg (95% CI: 
0.6, 2.3), respectively (132). LCn-3 have also been shown to promote arterial 
compliance which is also an athero-protective benefit (133). Finally, as 
demonstrated in a recent study by Erkkila et al (2004) fish intake is associated with 
a reduced progression of coronary artery atherosclerosis (134). 
In addition to the beneficial effects of PUFA which are exerted through changes in 
vascular membrane fatty acid composition and subsequent alterations in hormone 
signaling, fatty acids exert a direct effect within the heart. For example diets rich in 
PUFA from both plant (n-6) or marine (n-3) origin reduce the incidence of fatal 
cardiac arrhythmias after induced simulated myocardial ischemia in rat models 
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(135-138) and in the marmoset monkey (139). Also, a comparison of the effect of 
the different PUFA indicates an enhanced antiarrhythmic effect of dietary fish oils 
(140). Fish oils typically contain 30-40% PUFA, mainly as EPA or DHA, and 
provide the greatest antiarrhythmic protection (67, 141, 142). Furthermore, due the 
preferential accumulation of DHA in myocardial cell membranes, its association 
with arrhythmia prevention and metabolic efficiency and the selective ability of pure 
DHA to prevent ventricular fibrillation, suggest that DHA is the bioactive component 
of fish oil in the heart (143). There is also strong evidence to suggest that these 
effects rely on the incorporation of DHA into the myocardial cell membranes and 
are dependent upon habitual intake (143). Given that sudden ventricular fibrillation 
accounts for up to 50% of cardiovascular deaths in developed nations (29) coupled 
with the fact that prior symptoms often do not occur, prevention may best be 
approached through community wide nutritional changes (141). 
For a putative risk factor to be clinically useful several requirements need to be met 
(144) and LCn-3 fulfils many of these (9). There is substantial epidemiological data 
(145). A relationship between membrane EPA + DHA and cardiac death is also 
biologically plausible which is characterised by the following hypothesised 
relationship: 1. dietary n-3 intake increases cell membrane and free fatty acid n-3 
levels, 2. higher n-3 levels favourably alter cardiac ion channel function, 3. altered 
ion channel function modifies the cardiac action potential, and 4. alteration in the 
action potential reduces myocardial vulnerability to ventricular fibrillation, which is 
the major life threatening arrhythmia that results in sudden cardiac death (67). In 
addition, LCn-3 may enhance plaque stability as well as being anti-atherosclerotic 
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via other mechanisms (146, 147). Most importantly secondary prevention trials 
have shown that by changing a risk factor a disease outcome is altered (109). 
These results culminate in a strong association between this biomarker and 
disease which is independent of other risk factors (87) and systematic review 
evidence concludes that dietary advice to those with CHD can reduce morbidity 
and mortality (148). 
Although these results provide substantial evidence for the LCn-3 in secondary 
prevention of CHD, the prevention of sudden cardiac death in the community in 
patients without clinically recognised CHD remains a challenge. Currently there is 
no primary prevention intervention trial linking fish intake or fish oil and the reduced 
incidence of CHD and this area is not without conflict. For example, the Cochrane 
Collaboration published a review on the role of n-3 for the prevention of CVD and 
concluded that it was not clear that n-3 alter cardiovascular mortality in high risk 
populations (149). Nevertheless there is enough evidence to support population-
wide guidelines about fish consumption (150).  
2.5 Summary of dietary risk factors for CHD 
What is emerging from the literature is that there are a number of dietary factors 
which have been implicated in either the promotion or prevention of CHD via two 
potential mechanisms – atherogenicity and thrombogenicity. Saturated fatty acids 
(SFA) have been shown to be cholesterol raising (and by inference atherogenic) as 
well as thrombogenic (30, 151). PUFA of the n-6 series, and PUFA of the n-3 
series (152), monounsaturated fatty acids (MUFA), dietary fibre (153, 154) and 
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antioxidants (155) have demonstrated protective effects. In addition, both clinical 
and animal-experimental evidence suggests that the effect of n-3 on the risk of 
sudden cardiac death relates primarily to reduced vulnerability to ventricular 
fibrillation, rather than to a reduction in atherosclerosis or nonfatal myocardial 
infarction (63). Doses of 3-5g/d of EPA + DHA have been shown in experimental 
studies to decrease triglycerides (75, 113-116), decrease inflammation (123) and 
blood pressure (132), whilst increasing vessel relaxation and increasing 
erythrocyte deformability (133). However, excessive n-6 intake, through direct 
competition, has been shown to increase thrombogenicity via the promotion of 
platelet aggregation (126-128) and decreasing levels of growth factor (125). It is 
worthy of noting that all of the doses in these studies that have been shown to be 
effective are significantly higher than what is usually associated with prevention of 
heart disease, suggesting that it may be the combined, or even synergistic effects 
of all of these marginal effects that is important, although this is yet to be fully 
understood. With this basis of scientific evidence a number of authoritative 
organisations, using expert panels, have published dietary recommendations to 
guide dietary therapy.  
2.6 Dietary recommendations for the primary prevention of CHD 
In a recently published review of some 150 studies on the link between diet and 
cardiovascular health, the authors concluded by suggesting three major 
approaches as being the most effective in preventing cardiovascular health: 1. 
replacing SFA and trans-fats (solid fats produced artificially by heating liquid 
vegetable oils and has similar effects to SFA) with MUFA and PUFA; 2. Increasing 
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consumption of n-3 from either fish or plant sources such as nuts; and 3. eating a 
diet high in a variety of fruits, vegetables, wholegrain, nuts and avoiding foods with 
a high glycaemic load (156). 
The Adult Treatment Panel (ATPIII) of the National Cholesterol Education Program 
(NCEP) recommend as part of their Therapeutic Lifestyle Changes for the 
reduction of CVD risk, a diet which contains 25 - 30% of total calories from fat (< 
7% SFA, up to 10% PUFA, and up to 20% MUFA, 50 - 60% of total calories from 
carbohydrates (CHO), ~ 15% of total energy from protein (PRO), < 200mg 
cholesterol/day, dietary fibre 20 –30g/day and total energy to be balanced with 
energy expenditure to maintain desirable body weight or prevent weight gain (14). 
There is a recommendation to include 2g per day of plant sterols into the diet for 
those with elevated serum cholesterol (14).  
In addition, the International Society for the Study of Fatty Acids and Lipids 
(ISSFAL) makes the official statement that the consumption of LCn-3 may reduce 
the risk of CHD (157). More recently the Food and Drug Administration in the US 
(FDA) has agreed to a qualified health claim for n-3, stating “supportive but not 
conclusive research shows that consumption of EPA and DHA omega-3 fatty acids 
may reduce the risk of coronary heart disease” (158). Although to date there are no 
human studies that support the direct effect of LCn-3 and the primary prevention of 
CHD, these uncertainties have been addressed by a number of secondary 
prevention randomised controlled trials (RCT). Therefore, based on the balance of 
evidence ISSFAL supports the use of LCn-3 in the prevention of CHD, and intakes 
of 800-1000 mg per day appear to be a prudent approach (75). Safety of intakes 
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up to 3000 mg per day of DHA/EPA has been approved by the FDA and this level 
in generally regarded as safe (GRAS) in the American food supply (75). 
Recommendations from the UK and Europe after an experts meeting suggested 
values of up to 650 mg per day for the general population (75). In fact, recently the 
American Heart Association recommended that n-3 be consumed as a supplement 
if the diet contained an insufficient amount of this fat (159). In summary, for a 
8360kJ (2000kcal) diet, ISSFAL recommends a daily intake of n-3 fatty acids of 
0.65g EPA + DHA and 2.22g ALA, with the n-6:n-3 ratio reduced to substantially 
less than 10 (157, 160). 
2.7 Behaviour change theory in dietary interventions to prevent CHD 
The goal of primary prevention is defined as the treatment of risk factors when no 
clinical manifestations of atherosclerosis are apparent yet (8). Primary prevention 
of CHD can either be individually oriented involving screening for and treating risk 
factors (high-risk approach) or it can be directed to the whole population (161). 
Although the priorities of primary prevention programs are to: 1. educate people 
about risk factors and lifestyle changes to reduce risk; 2. identify and alter risk 
factors to prevent the onset of CHD leading to heart attack or stroke, primary 
prevention strategies in the past have taken on many forms which have resulted in 
mixed results, therefore undermining the perceived benefits of this approach. 
Much progress has been made in recent years in improving the cardiovascular 
health of Australians. Death rates from CHD have fallen substantially, by around 
70% since the late 1960’s (29). However, despite this CHD remains Australia’s 
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greatest health concern. As most of the improvements in this rate have been on 
the impact of cardiac survival (advances in treatment and care) there are huge 
gains to be obtained through primary health care strategies (28). 
Epidemiological observational studies, both prospective and case control, show 
repeatedly that dietary factors are associated with CHD (79, 162-164), and 
therefore contribute substantially to the preventable burden of this lifestyle disease. 
Clinical trials have confirmed many of these associations leading to the notion that 
people’s dietary intake can affect health (68). The scientific consensus is 
supportive of an approach to improving dietary intake, and as dietary change 
remains an important modifiable behaviour, it follows that primary prevention 
intervention is advisable (165). However, non-pharmacological treatments such as 
smoking cessation, exercise and improved nutritional habits are generally poorly 
followed and their effectiveness is widely questioned (166, 167).  
Nutrition intervention programs focus on foods people eat (168) as well as 
employing behavioural science theory and methods to understand dietary 
behaviour and design and evaluate dietary change programs (169). Early 
behavioural nutrition research used basic learning theory to address issues of how 
much and when a person chose to eat (169). These interventions included 
nutritional counselling and adult learning theory in program design.  
More recently, nutritionists and nutrition researchers have been exploring 
behaviour change models and intervention strategies to find ways of having a 
greater impact on behaviour change (170). The theories most commonly employed 
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in primary prevention nutrition programs include Social Cognitive Theory (SCT) 
also sometimes called Self Efficacy Theory and previously called Social Learning 
Theory; Theory of Planned Behaviour; Health Belief Model (HBM); the 
Transtheoretical Model (TTM), also called the stages of change; Health Belief 
Model; and Self Control Theory (170). Population approaches have also been 
employed using a number of theories from Community Education Theory to Health 
Education and more recently Social Marketing (170). Each of these will be 
reviewed briefly. 
2.7.1 Nutritional counselling 
Nutrition counselling is the process of guiding a client toward a healthy nutrition 
lifestyle by meeting normal nutritional needs and solving problems that are barriers 
to change (170). To alter food habit successfully, counsellors work with clients to 
change behaviour based on a range of psychological, socio-cultural and 
physiological factors. During the 1980’s, the focus was on behaviour modification, 
giving way to goal setting and client centered counselling in the 1990’s (170). 
There is an array of counselling philosophies, theories and models that are 
available to deal with the complex field of behaviour change. The range includes 
Person-centered therapy which involves clients actively participating in clarifying 
needs and exploring potential solutions (171); Behaviours therapy which is based 
on the premise that behaviours are learned and therefore new behaviours can be 
re-conditioned (170); Gestalt therapy which operates in the present and aims for 
clients to take responsibility for their own actions (172); Cognitive therapy which is 
based on the premise that negative self-talk and irrational ideas are self-deflating 
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learned behaviours and most frequently the source of their problems (173); and 
Family therapy which aims to assist the individuals within the context of the family 
to change themselves (174).  
2.7.2 Adult Learning Theory 
Historically, adult learning theory was regarded as an extension of childhood 
learning theory. Approximately 25 years ago the concept of andragogy was 
introduced into the field of education (175). Andragogy, “the art and science of 
helping adults learn”, was contrasted with pedagogy, the art and science of helping 
children learn (175). Adults can learn from a continuum of approaches from 
teacher-directed learning to student-directed learning depending on the situation 
(175). 
2.7.3 Theory of Planned Behaviour 
The Theory of Planned Behaviour (TPB) provides a model that can help explain 
behaviour and intention to perform a given behaviour. In turn, a person’s 
behavioural intention is determined by the attitude they hold towards the behaviour, 
the degree of social pressure felt by the person to perform or not perform the 
behaviour as well as the degree of control felt by a person over performing the 
behaviour (19). These three factors are determined by a number of beliefs and 
subsequently how each is evaluated. The TPB, or modified versions of it, has been 
applied to a range of health related behaviours (20-22). 
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2.7.4 Health Belief Model 
This is probably one of the most influential models governing health related 
interventions. It postulates that cognitive factors influence an individual’s decision 
to make and maintain a specific health behaviour change. The individual’s 
behaviour will change if they believe that they are susceptible to a health concern 
which will impact on their life, and they are capable of making the necessary 
behavioural changes to reduce the risk (176). Traditional approaches to dietary 
management of cholesterol lowering are largely based on this premise. 
2.7.5 Transtheoretical Model (TTM) 
The TTM (also known as the stages of change model) states that people progress 
through five distinct motivational stages in attempting to change their behaviour: 
pre-contemplation, contemplation, preparation, action and maintenance (177). In 
addition to helping understand behaviour, this model can be used as a counselling 
guide, as strategies will have varying effectiveness depending on the stage of 
change the individual is at. In addition this model can be used as a measure of 
outcome effectiveness. For example, an intervention may be considered effective if 
a client moved from “I do not need to make a change” to “maybe I should give 
some thought to change”. 
2.7.6 Self-Efficacy Theory 
Self-efficacy has been used as a stand alone model, as well as incorporated into 
other behavioural change models. Self-efficacy has been defined as “our personal 
belief of how capable we are of exercising control over events in our life” (178). As 
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strong self-efficacy has been found to correlate with the attainment of health 
behaviour change, it is believed that a person’s confidence in ability to accomplish 
behavioural change is more important than the skill per se (179). 
2.7.7 Social Cognitive/Learning Theory 
Social cognitive theory states that people are neither driven by inner forces nor 
automatically shaped and controlled by external stimuli. Rather, human functioning 
is explained in terms of a model of triadic reciprocally in which behaviour, cognitive 
and other personal factors, and environmental events all operate as interacting 
determinants of each other (180). Here, it is said, that behaviour change occurs 
through taking action, observations of others taking action, and evaluation of the 
results of those actions. 
2.7.8 Social Marketing Theory 
Kotler et al (2002) define social marketing as “the use of marketing principles and 
techniques to influence a target audience to voluntarily accept, reject, modify or 
abandon a behaviour for the benefit of individuals, groups or society as a whole” 
(181). This relies on the voluntary compliance of consumers and often cannot 
promise a direct benefit for this change. Despite distinctions in scope, social 
marketing shares many similar techniques with commercial sector marketing. 
A review of some of the individual randomised trials and other individual-level 
intervention studies that have examined the effectiveness of various nutrition 
interventions will be presented, including those conducted with healthy individuals 
as well as at risk individuals. Also, a review of interventions focusing on both 
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community groups (e.g. family, providers, worksites, point-of-purchase) and entire 
communities will be presented. These studies will be presented with reference to 
the theoretical model underpinning the intervention and discussed in relation to the 
outcome achieved. 
2.8 Individual-level dietary intervention studies 
A large number of individual-randomised studies have been conducted to test the 
efficacy on outcome measures such as food based outcomes (e.g. fish intake or 
fruit and vegetable intake), dietary goal based outcomes (e.g. percent fat intake) 
and CHD biomarker outcomes (e.g. serum cholesterol levels). 
The 1990’s saw a large number of individual interventions aiming to increase fruits 
and vegetables reporting largely positive results. Significant increases in fruit and 
vegetable (F/V) intake were reported in an individual case study using behavioural 
therapy over a relatively short time frame of 5 months (182) as well as in a 6 month 
intervention with 33 women with low F/V intake (183). Lutz et al (1999) conducted 
a 6 month intervention using 710 males and females using interventions based on 
social cognitive theory and transtheoretical model with the aim of increasing F/V 
intake (184). Subjects were randomised to receive regular newsletters, tailored 
messages or goal setting advice at monthly intervals. Significant increases in F/V 
intake in all intervention groups was achieved (184). Similar results have been 
reported using telephone calls (185), nutritional counselling (186), coupons along 
with educational programs (187), messages about change (188), and multiple 
mailed contacts which resulted in significant decreases in fat scores (an indirect 
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measure of fat intake) (189). Another personalised health promotion program using 
targeted counselling demonstrated improvements in diet scores over a 2 year 
period, but not 5 years (190). In the Netherlands, significant increases in fish 
consumption were achieved in both group sessions and tailored letters after a 16 
week intervention (191).  
Similarly there have been a number of studies which have reported similar 
successful outcomes in reducing both total and saturated fat intake. The MRFIT 
trial was a randomised intervention of 12,866 males at high risk of CHD who 
received nutrition counselling to reduce total fat, saturated fat and low fat foods or 
control and were followed up for an average of 6 years. The intervention group 
achieved significantly greater decreases in all outcome measures (192). Large 
reductions in fat consumption in relation to controls have been reported by Boyd et 
al (1997) after a two year period of nutrition counselling of 220 premenopausal 
women (193), by Coates et al (1999) after 18 months provision of group education 
to 2208 women (194) and in trials on men undergoing nutritional counselling (195) 
and a prescription of dietary plans (196). Another trial found that dietitian-led 
interventions produced significant reductions in dietary fat and cholesterol intake 
compared with material and videotape intervention groups (197). While these 
studies predominately used nutrition counselling as a theoretical underpinning, 
White et al (1994) investigated the effect of using a program based in cognitive 
theory (198). Using group sessions with self monitoring tools in conjunction with 
nutritional and behavioural strategies they were able to demonstrate significant, 
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large reductions in fat intake, which was maintained for at least one year after 
intervention in 1050 women aged between 45-69 years (198). 
Several studies have targeted individuals with risk factors for chronic disease. The 
Oslo Study found that regular dietary counselling produced significant long-term 
declines in serum cholesterol compared to control participants (199). However, a 
community-wide screening and follow-up project in a low-socioeconomic area 
produced significant changes in diet following group education compared with 
pamphlet intervention, but no difference in serum lipids or CHD risk (200).  
Metabolic ward studies have shown that dietary changes can reduce blood total 
cholesterol concentration by 10-15% in settings with very strict dietary control (201-
204). However these results should be used with caution when extrapolating to 
free-living populations. For example, Denke et al (1995) showed that dietary 
counselling could achieve cholesterol reductions of up to 10%, and therefore would 
prove value as a clinical treatment option (205). However, a study published in 
1991 suggested that dietary advice to individuals produced small reductions in total 
cholesterol concentration (less than 4%) rendering it of little value in clinical 
management (206). Tang et al (1998) published a systematic review of 19 
randomised controlled dietary intervention trials under free-living conditions aimed 
at lowering total cholesterol (12). The overall weighted mean reduction in blood 
cholesterol across all dietary comparisons was only 5.3%, using trials of at least six 
months duration (12).  
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A meta-analysis of randomised controlled trials of dietary interventions of at least 
3-months concluded that dietary interventions in primary prevention can achieve 
only modest improvements in diet and cardiovascular disease risk status that are 
maintained for 9 – 18 months (207). For example, after 3 – 6 months dietary fat as 
a percentage of energy reduced by -2.5% (CI - -3.9%, -1.1%) in the intervention 
groups and serum cholesterol, -0.22 (CI = -0.39,-0.05) mmol/L in the intervention 
groups (207). Dietitians are specifically trained and motivated to provide high-
quality dietary advice. Having a battery of approaches available for individual 
clients, dietitians appear to achieve better outcomes than doctors at lowering 
cholesterol in the short to medium term, though clinically the difference is small, 
and there is no evidence to suggest that this strategy is better than self-help 
resources or nurses (208). 
2.9 Community-level dietary intervention studies 
Community level interventions using a range of theoretical models such as SLT 
(209), TTM (210-212), participatory strategies model (213), community 
organisation (214, 215), socio-ecological (216), social marketing theory (217) and a 
multitude of models (218) appear successful in improving fruit and vegetable 
intakes as well as the selection of low fat products. Some studies, although not 
stating the theoretical underpinning of the study, but using similar techniques such 
as counselling, print material, advertising and food policy changes, have reported 
similar positive effects of interventions (219-224), although others using similar 
approaches and theoretical behaviour change models have reported little or no 
effect (225-232). Also, a large number of interventions designed to reduce total fat 
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and saturated fat intake as a percent of energy have all achieved positive 
outcomes using TTM and Educational theory (233-235) and without an underlying 
intervention strategy specified (236-239).  
Now turning attention to population interventions targeting a reduction of serum 
cholesterol, of the 6 published studies, half showed a positive effect whereas the 
other half showed no significant impact of the intervention. In 1994, Luepker et al 
used an intervention based on SLT employing mass media, health professional 
training, screening and education across three separate communities and found no 
sustained differential change in total cholesterol (240). Two subsequent 
interventions using nutrition education and training in counselling found a similar 
result (241, 242). However, positive effects have been reported in interventions 
using mass media campaigns in 5 cities (243), community counselling and 
screening (244) and food policy changes along with educational programs in a 
contained community of a Kibbutz in Israel (245). 
Several community interventions aimed at reducing CHD have not achieved 
desired outcomes that would be predicted from the individual dietary behaviour 
change interventions. In the Malmö preventive project (2000) between 1974 and 
1992, a total of 22 444 men and 10 902 women attended screening. Around 25% 
of the screened subjects underwent various interventions (lifestyle modification and 
drug therapy) aimed at treatment of hypertension, hyperlipidaemia, IGT etc (161). 
The behavioural approach was an individually oriented, high-risk approach with 
resources for both screening and intervention. Although positive effects on risk 
factors such as hyperlipidaemia were found, no effect of intervention on mortality 
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and cardiovascular morbidity in the intervention group as a whole was reported 
(246, 247). The authors concluded that risk factor screening and intervention in an 
urban setting such as the one in Malmö, and the use of contemporary methods of 
the trial, are not enough to reduce all cause mortality more than implied by the 
population trends. They did note that it is important to consider the heterogeneity in 
the determinants of disease, as people living in more socially deprived areas have 
more risk factors and a higher incidence of CHD than found in the less deprived 
areas (161). In a similar trial in another part of Sweden, middle aged men were 
screened and treated for cardiovascular risk factors (248). However, no overall 
beneficial effect could be detected in total or CHD mortality in comparison with a 
predetermined control group. The MARGARIN study (2000) investigated the 
impact of an intensive group education on the Mediterranean diet and after one-
year of intervention a posted leaflet with dietary guidelines was provided (249). 
Beneficial changes in dietary habits were recorded in the intervention group, 
however, saturated fat and total fat was still too high. Of the 262 
hypercholesterolaemic persons with at least 2 other cardiovascular risk factors, the 
intensive program of dietary education did not significantly lower cholesterol (-3%) 
more that the control (-2%) and after 1 year both groups gained ~1% body weight. 
2.10 Limitations of primary prevention strategies 
With this background in mind it reinforces the fact that changing life-long behaviour 
is a complex process, and the results are often disappointing. Despite the 
increasing knowledge about the pathophysiological processes and resultant risk 
factors of CHD and subsequent awareness and education about nutrition and 
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exercise, CHD remains our number one lifestyle disease. Evidence from lifestyle 
trials, in which both individual and population based preventative strategies have 
been successful is limited (161). With the absence of disease symptoms it may be 
difficult for individuals to change and adhere to a prescribed treatment. A large gap 
exists between research and practice in the effective implementation of validated 
lifestyle primary health initiatives to reduce the incidence of CHD.  
Prevention of CHD represents a great challenge with the potential to reduce a 
considerable portion of the global burden of this disease (250). Results obtained 
from a number of trials (248, 251) lead us to believe that a hospital-based 
prevention program alone is not effective in reducing the incidence of CHD, nor is 
individual screening due to the vast numbers of at-risk individuals and lack of long 
term resources (251). Therefore an individual approach is encouraged to be 
combined with population-based approaches (161). These programs are required 
to be based on evidence, noting that evaluation of larger scale community projects 
will always be much more difficult than evaluation of individually targeted projects.  
This raises the question about why primary prevention strategies fail. Possibly 
there is a lack of compliance thus rendering interventions ineffective. In part this 
can be attributed to the lack of knowledge of the psychological and social 
mechanisms involved in changing attitudes and behaviours, not only of individuals 
but of the entire population (161). Similar concerns have been raised by others, 
and in part, this was the reason why a long term primary prevention trial was 
abandoned because of the poor ability of free-living subjects to adhere to long-term 
dietary recommendations to reduce saturated fat, highlighting the perceived 
    
46   
difficulty of achieving dietary change (161). In addition the resource burden of 
primary prevention strategies may be too great for patients, clinicians and the 
health care system (252). Finally, lifestyle trials have traditionally been narrow in 
their scope. They rely on singular contexts (individual or community) are based on 
singular theoretical models (TTM, SCM, social marketing) and rarely consider the 
wider political or environmental factors. To this end, the World Health Organisation 
(WHO), the National Institute for Heart , Lung and Blood Disease (NHBLI), as well 
as other organisations have all recommended radical changes in diet and lifestyle 
interventions (161). The authors recognise that population-based interventions 
need the development of a new methodology, not least within the social and 
behavioural processes involved in preventive efforts in the population. Thus a new 
intervention paradigm is required that helps individuals overcome the natural 
aversion to dietary change and one that is going to be supported by a large portion 
of the population.  
2.11 A new paradigm for the primary prevention of CHD 
Mortality from several causes has been reduced through prevention programs that 
changed population behaviours (7). Examples in Australia and New Zealand are 
smoking related diseases (253), road deaths (254), lung cancer (255), cervix 
cancer (256) and sudden infant death syndrome (SIDS) (257). Mortality rates from 
CVD provide a mixed picture. Mortality rates peaked in 1968 and have since fallen 
by over 60%, and this is consistent in industrialised countries (29). However, it has 
been reported that more than 70% of this overall decline in mortality has occurred 
amongst patients with existing coronary heart disease (258). Evidence suggests 
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that emergency care, medical (259) and surgical treatment and follow-up care (58, 
260, 261) have influenced this rate due to the survival of cardiac events which 
underscores the importance of secondary prevention (15). However, it is much 
more difficult to detect a positive preventative effect of interventions directed 
toward relatively healthy populations (192, 240, 248, 262).  
Of the range of theoretical frameworks in common usage in health promotion for 
influencing population behaviours and disease end-points the ‘epidemiological 
triad’ has been widely used in addressing both communicable and non-
communicable epidemics and only recently has it been applied to lifestyle diseases 
(7). Figure 2-1 shows how it relates to CHD specifically (7). The agent (the final 
common pathway) for CHD is an imbalance of dietary fatty acids. Host factors are 
a combination of non-modifiable, such as, genetic factors, age, gender, whereas 
others such as beliefs, attitudes and behaviours are modifiable.  
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Figure 2-1  The epidemiological triad as it applies to cardiovascular disease (the ‘agent’ is 
dietary fatty acid imbalance) (6) 
Behaviours are a complex interaction of psychological factors, including habits, 
emotions, beliefs and attitudes developed through a background of learning history 
(263). The vectors for a poor dietary profile are high saturated fat foods (264) and 
foods low in n-3 (265). The environment is external to the individuals and provide a 
structure within which people live and is considered a powerful determinant of 
behaviours (7). 
Host-related activities to date have been the focus of primary prevention strategies, 
and tend to be education based (individuals or group education) or medical 
Host 
Vectors Environment 
Education; behavioural & medical 
interventions 
Policy, social change Technology 
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(pharmaceutical). Technological innovations such as novel food enriched with 
bioactive ingredients or modified in fat content provide vector-related solutions. 
These novel foods are commonly referred to as functional foods. A functional food 
is defined as “… any modified food or food ingredient that may provide a health 
benefit beyond that conferred by traditional nutrients the food contains” (266) or 
“foods with health benefits beyond basic nutrition” (267). In this instance, vector-
related solutions could be physical (making functional foods widely available), 
economic (making the costs of functional foods affordable), policy (altering rules 
related to the promotion of these foods i.e. health claims) and sociocultural 
(influencing attitudes, beliefs and perceptions). Whilst there is overlap between the 
different sectors of the triad, interventions historically focus on one corner.  
What has been learned from ameliorating other epidemics is that population 
behaviour change can be achieved knowing that: knowledge itself is a weak 
determinant of behaviour but well communicated, action specific messages 
influence behaviours; television-based communications are effective but 
expensive; and environmental strategies are powerful. All elements of the triad 
must be addressed simultaneously. In the case of CHD, vector innovations such as 
low fat food were the first phase; now food innovations which include bioactive 
ingredients provide new opportunities. Social attitudes are influenced and shaped 
by policy changes (again nutrition claims and fat claims provided first phase 
opportunities, now health claims legislation changes offer new opportunities); here 
advocacy from powerful commercial groups often influence policy. Finally, the 
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normalisation of consumers’ behaviours (e.g. acceptance of eating novel foods 
enriched with fish oil) is powerful in sustaining long term behaviour changes. 
2.11.1 Vector-based innovations 
There has been an incremental increase in research into the bioavailability and 
application of functional foods and food ingredients (268). Interest in functional 
foods is increasing because of higher health care cost and recent scientific 
discoveries linking dietary habits with the development of many diseases (269). 
Functional foods have been designed with health improvement in mind.  
Dietary guidelines are pointing nutrition educators to two priorities in the prevention 
of CHD, namely promoting dietary habits that reduce serum cholesterol as well as 
increasing their dietary LCn-3 intake. However, it has been widely acknowledged 
that individuals find it difficult to adhere to stringent dietary goals for elevated 
cholesterol (12) and the there is an inability of the population at large to consume 
enough LCn-3 from fish alone (18). Thus the combined efforts of food 
technologists, scientists, nutritionists and food industry have led to the 
development of a number of functional foods, of particular note products enriched 
with plant sterol/stanol and LCn-3.  
Since the 1950’s plant sterols were found to have cholesterol-lowering properties. 
The major plant sterols in the diet are β-sitosterol, campesterol and stigmasterol. 
Research over the past decade has focused on the esterified form of plant sterols 
which is added to food products - for reasons of effectiveness and safety. 
Esterification renders plant sterols soluble in dietary fat which is the most effective 
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vehicle to deliver sterols to the small intestine where cholesterol absorption occurs 
(270). Plant sterols reduce the absorption of both dietary and biliary cholesterol 
from the intestinal tract by 30-50% (271). The exact mechanism is yet to be 
elucidated, however it is generally assumed that the presence of increased 
quantities of plant sterols in the gut lowers the micellar solubility of cholesterol 
thereby, lowering the amount of cholesterol available for absorption. Recent 
advancements in food technology have seen the emergence of food products such 
as margarine, milk, yoghurt and cereal products being enriched with plant 
sterols/stanols and promoted as a food which can help lower serum cholesterol. 
Another food innovation has been the development of LCn-3 enriched foods such 
as margarine, bread, eggs and yoghurt. This has been made possible by the 
advent of microencapsulation which allows for LCn-3 to be added to a range of 
food stuffs (272). Microencapsulation is the process whereby small particles of oil 
are encased in a secondary material (encapsulent) which is usually a complex 
carbohydrate compound (272). This increases the shelf life of the oil as it reduces 
exposure to the environment which would oxidise the n-3 and eliminates the ‘fishy’ 
taste that is accompanied by LCn-3 (272, 273). This has the net effect of protecting 
the organic structure throughout all phases of the processing and in addition to 
ensuring that taste and texture is not affected (272, 273). Both the bioavailability 
and taste is not affected by oil that is microencapsulated (272-274).   
There is little doubt that these two food types are a triumph of food technology, 
however their effectiveness in promoting health is yet to be confirmed. There is 
therefore an opportunity to use these recent advances in food technology and the 
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development of functional foods (Vector) and test them against the elements of the 
theoretical model. To demonstrate the effectiveness of these products in a 
functional food-led intervention, an examination of both the biological and 
psychological effects of these foods (Host) is required along with the consideration 
of the wider social context (Environment). 
2.11.2 Host-based considerations 
Clinical studies on the effects of spreads enriched with plant-sterol-esters or plant-
stanol-esters (hydrogenated form of sterols) have consistently shown reductions in 
serum total and LDL-cholesterol, with little or no change in serum HDL-cholesterol 
or triglyceride. In controlled situations, plant sterol intake of up to 2g per day - 
added to products such as margarine, oils, spreads and milk - have been shown to 
reduce serum cholesterol by up to 15% (270, 275-278). The cholesterol lowering 
effects of plant sterols is independent of, and additive to, the effects of dietary 
manipulation and cholesterol lowering medication. A recent study showed that the 
reduction in LDL-cholesterol by 10% achieved by a low-fat diet was enhanced by a 
further 12% when plant sterols were added to the diet through salad dressing 
(279). Since the hypercholesterolaemic action of sterols is mechanistically different 
from the statin class of drugs, it might be expected that the effects are also additive 
to those of drug therapy, however one study comparing the efficacy of sterol-
enriched spreads between subjects with and without cholesterol lowering 
medication revealed that the relative fall in LDL-cholesterol was the same in both 
groups (280). Despite the favourable results reported so far, all studies to date 
have been in controlled settings where subjects have been supplied with sterol 
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containing products. Translation of these efficacy trials into the clinical setting has 
been slow. One reason is that evidence is still required from studies investigating 
subjects who assemble the diets for themselves on a routine basis, thus 
determining the true applicability of this strategy in the clinical setting (281). 
Despite the body of evidence suggesting the importance of LCn-3, dietary goals 
are difficult to achieve through the consumption from fish alone (18). Although 
there have been a wide range of foods enriched with this essential fatty acid, only a 
few studies have investigated their efficacy. A study by Mantzioris et al (2000) 
investigated the effectiveness of a diet that incorporated foods rich in n-3 fatty 
acids (282). Healthy male volunteers were supplied with foods enriched with α–
linolenic acid (cooking oil, margarine, salad dressing, and mayonnaise) and EPA 
and DHA (sausages and savory dip) as well as foods naturally high in n-3 (flaxseed 
and fish). Intake averaged 9.0 g/day of ALA and 1.8 g/day of EPA and DHA which 
was confirmed by an increase in plasma, platelet and monocellular phospholipids 
(282). However, this was a pre test – post test study, with 15 subjects over 4 
weeks (282). Metcalf et al (2003) took this concept one step further and tested the 
effects of providing a wide range of foodstuffs containing n-3 from fortification 
(283). Foods enriched with LCn-3 included margarine spread, milk, sausages, 
luncheon meat and French onion dip was provided to 16 subjects. Again this was a 
before-after study for duration of 4-weeks. The consumption of ALA increased from 
1.4 to 4.1 g/day and EPA and DHA increased from 1.2 to 1.52 g/day which was 
confirmed by corresponding increases in serum and platelets (283). There has 
been a suggestion by these authors and others that a range of novel foods 
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provides the opportunity for wider public consumption of LCn-3 (282, 283), but this 
may be a little premature. Although Mantzioris et al reported positive effects on 
monocyte-derived eicosanoids and cytokine production, the design of these studies 
require caution in interpretation of these results. The short time frame limits the 
assertion that these foods could “support large-scale programs on the basis of the 
therapeutic and disease-preventive effects of n-3 fatty acids”(282). Finally, the 
effects of these foods on the composition of the total diet as well as other 
biomarkers of CHD warrant attention. 
A general principle in relation to vectors is that small changes in high volume 
vectors can have significant population impacts (7). However at the core of this 
principle is the assumption that a modified vector will be widely accepted by 
consumers as well as being accessible in terms of location and cost. In this case 
there is an assumption that these foods will be incorporated into the diet such that 
the other dietary considerations are not compromised. Therefore for this class of 
functional food to support large scale programs for the primary prevention of CHD 
an understanding of consumer acceptance is fundamentally important. Factors that 
promote or constrain the use of these foods need to be understood. The unveiling 
of psychosocial variables can be used to maximise interventions, predict the 
potential impact of an intervention and help guide future interventions. Whilst there 
have been a few studies that have investigated consumer views towards functional 
foods in general, (284-288) there are no studies that have investigated the factors 
that prevent or promote the use of LCn-3 functional foods in the wider community.  
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2.11.3 Environment – based considerations 
To date the food industry has responded to public health guidelines and has 
contributed to influencing the food supply (Vectors) in several ways. For example, 
in response to a rapid rise in CHD there was a national call in Finland for the 
Government to intervene (289). The results were a removal of saturated fat from 
the food supply or its replacement with unsaturated fats. The results were exciting; 
with mean cholesterol levels in Finland dropping by 15% along with rates of CHD 
by about 75% of their peak levels (289). In many westernised countries farmers 
and processors have responded more recently by producing leaner meat and dairy 
whilst manufacturers have provided a number of foods substantially reduced in 
harmful components. At the heart of this issue is the ability of companies to gain a 
marketing advantage from nutritionally enhanced foods and nutrition and health 
claims are one way to achieve this (11, 26). Countries such as the US, Canada, 
UK, Europe, Japan have established processes for the management of health 
claims. In contrast Australia has been slower in adopting this policy, with the Health 
ministers of the Australian New Zealand Food Standards Council (ANZFSC) 
agreeing in May 2002 and again in December 2003 to set policy principles for a 
new regulatory system that will allow the use of health claims within a risk 
management framework (290).  
Health claims bring with them the concerns about the level of honesty and 
accuracy of claims and label information generally (291). Examples show us that 
the regulators are often behind the marketers in this regard (292, 293). In Australia, 
where health claims are currently prohibited with one exception, a study found that 
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7.4% of food and drink advertisements contained illegal health claims (26). In 
addition, a major threat to the effective use of functional foods is the exaggerated 
and often contradictory health claims observed in Europe, Asia and the US. For 
example, only 1% of Japan’s functional foods are directed at the significant health 
problems such as high blood pressure, with adequate scientific justification (294). 
In part the problems relate to the strength of the evidence base for these claimed 
benefits which range from very strong, based on multiple clinical trials, to the 
merely suggestive, relying on epidemiological or in vitro studies (295). A strong 
scientific base is a necessary requirement for any health claims about functional 
foods (295). Furthermore consideration needs to be given to the ethical and social 
consequences of their introduction into the food supply (296). For example, who 
has access to these foods and what will be the cost to the consumer? Thus, careful 
consideration is required about our future regulatory frameworks to ensure that 
consumers are not misled about the potential benefits of functional foods. 
McConnon et al suggests that in order for functional foods to reach their maximum 
potential the food industry, government and health professionals must work 
together to improve communication between themselves and consumers (25). An 
initial step in this process is the clear articulation of the beliefs and attitudes of 
these stakeholders and the identification of incongruence which may ultimately 
affect this communication process.  
In summary, in this thesis the effectiveness of a functional food-led intervention will 
be measured against each component of the epidemiological triad model. Two 
dietary interventions, behavioural studies using both qualitative and quantitative 
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methods and a stakeholder analysis were conducted and the methodological 
considerations will now be discussed.  
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CHAPTER 3  
 
METHODOLOGY 
3.1 The concept of ‘evidence’ in relation to primary prevention interventions 
Despite the postulation that functional foods can be used to improve health, it is 
highly unlikely that these novel foods alone will be the solution. For functional foods 
to be effective they must be placed within the context of current primary health 
intervention frameworks. Thus an important conceptual issue concerns the type of 
scientific evidence required to substantiate the effects of primary prevention 
strategies (297).  
Traditionally, in evidenced based medicine there has been an emphasis on a 
hierarchy of evidence to rank recommendations according to the available type and 
amount of evidence, of which the randomised controlled trial carries the greatest 
weight (298). There is little doubt that the push by medical societies and federal 
agencies to ensure practice was governed by this type of evidence in clinical and 
pharmaceutical research has improved the quality of clinical practice. Unfortunately 
this has motivated medical and nutrition societies to try to apply this scheme to all 
research questions in the medical field, including public health. 
A critical evaluation of these hierarchies of evidence and their application is 
required. Because they were originally developed out of a specific type of research 
question – mainly the evaluation of therapeutic treatments – their utility in the 
evaluation of primary prevention strategies is questioned (297). The hierarchies are 
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based on the ranking of studies according to their susceptibility to bias (297). This 
means that hierarchy refers to the internal validity of the study designs. Although 
internal validity is important in terms of experimental design, its external validity is 
the relevance to the research question (297). For example, a randomised 
controlled trial can be designed to test the effects of eating 10 tubs of yoghurt a 
day on health, but obviously very few people would actually eat this. There is thus 
a trade off between vulnerability to bias and external validity (297). The question 
here is whether existing schemes for levels of evidence and grading 
recommendations are appropriate for recommendations /guidelines dealing with 
behavioural lifestyle modifications. To answer this question we firstly have to 
differentiate between studies on therapeutic effectiveness or clinical preventive 
measures on the one hand and observational studies on the relationship between 
lifestyle and disease on the other (297).  
A clinical preventive measure such as a vaccine or a clinical treatment or the 
prescription of a pharmaceutical has to be applied before the treatment can be 
evaluated. Therefore, assessment via an experimental study is appropriate. In 
contrast, primary behaviour change interventions usually advise people how to 
modify their behaviour (such as eating low fat foods or more fish or abstaining from 
alcohol) within a common range of behaviours. For example, the recommendation 
to stop smoking for lung cancer prevention was implemented without the support of 
a RCT. Because lifestyle behaviours are observable in populations it suggests that 
the assessment of the overall effect of specific patterns can often be obtained from 
observational studies (297). In addition, there are significant barriers if an 
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experimental design were required to prove insights from observation. For 
example, apart from ethical barriers of exposing some individuals to an adverse 
behaviour (e.g. smoking) some studies take years if not decades to complete 
because of the latency periods of many of these lifestyle diseases. There is also an 
inherent impossibility of blinding of many nutrition or other lifestyle interventions. 
Finally, dietary interventions that may involve the increase of one food group (e.g. 
fish) will inevitably result in the decrease of another, for example red meat. Thus 
the effects of the whole diet are important and often it is difficult to disentangle 
whether benefits are due to an increase in one food or the corresponding decrease 
in another. 
Reliance solely on RCTs is both not feasible and not able to provide adequate 
answers for the effectiveness of dietary primary prevention interventions. Recently 
levels of evidence have been published which take into account that different 
medical areas require a different set of levels of evidence (299). However this 
approach relies heavily on Cohort design studies. Another approach to cope with 
the uncertainty in evaluating observational study results on disease relationships is 
the application of causal criteria that includes aspects such as consistency, 
temporality, biological gradient, biological plausibility and coherence (300). It has 
been suggested that contemporary approaches to evaluation of evidence are 
based on systematic summaries of all available data on a given topic rather than 
on single studies or results from single study types (297). In addition innovative 
designs, models and methodologies are needed for each research setting including 
consumer research (301). 
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In summary, RCTs are not available to establish the effectiveness of most primary 
prevention interventions, but still an answer is needed and recommendations are 
required. In order to assess the effectiveness of a functional foods-led intervention 
as a primary prevention strategy a different set of research questions need to be 
answered and therefore different types of study design are required. A paradigm 
shift from the traditional hierarchy of evidence to an application of causal criteria is 
required for guiding public health interventions.  
This research drew from medical, dietetic, psychological and sociological 
methodologies to answer the antecedent hypotheses. Firstly, in order to evaluate 
the effectiveness of functional foods, trial design resembled ’free-living’ conditions 
as this is the context where these products will exert their potential health benefits. 
It was therefore important in evaluating effectiveness to design trials as close to 
free-living conditions as practical. Secondly, dietary assessment approaches 
needed to quantify not only the functional nutrient of interest, but also the total diet, 
and here attention to dietary methodology was given. Also, in order to ascertain 
consumer beliefs and attitudes toward functional foods as well as determinants of 
behaviour, both a qualitative and quantitative approach were applied to fully 
understand the reaction of consumers. Finally, to understand the wider political 
environment, qualitative methodology provided useful tools in investigating 
stakeholder views. Each of these approaches will be considered in turn.  
    
62   
3.2 Dietary interventions 
Generally, evidence-based dietary interventions are hampered by 3 factors: a lack 
of nutritional intervention studies; the difficulty of translating nutritional interventions 
into practice; and the difficulty of translating interventions into a primary prevention 
setting (302). Compared with research into the efficacy and safety of 
pharmaceuticals, which is based on hard clinical endpoints, the study of food and 
mixed diets is more complex. In fact, due to the heterogeneity of the population 
and the different amounts and compositions of foods used by different populations, 
objective definitive trials are almost unfeasible (303). Providing proof of 
effectiveness is difficult due to the delay between the application of an intervention 
and the observation of its effects, which may be many years (303).Therefore 
upstream pathophysiological (304) and nutritional indicators (73, 305) may be used 
as surrogate endpoints. 
While evidence of the efficacy of dietary components are required from clinical 
trials, it is equally important that evidence of the effectiveness from research in 
practice environments is obtained, since the applicability of controlled studies to 
general community settings needs to be confirmed (10). It is often believed that the 
positive results obtained in controlled trials can be extrapolated into a free-living 
context, as it is assumed that efficacy equates to effectiveness. However, efficacy 
aims to establish a relationship between a bioactive component and therapeutic 
benefit, whereas effectiveness also establishes this relationship whilst considering 
the question of compliance. In order to determine the effectiveness of functional 
foods, behavioural issues relating to the belief in the benefit of use, taste, 
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preference and price need to be investigated as they can ultimately affect 
compliance (20, 22). In addition, the net effect on the whole diet needs to be 
considered given the importance of other dietary aspects involved in reducing CHD 
risk (306). 
3.2.1 Trial design 
Historically dietary interventions have been evaluated on the basis of a hierarchy of 
evidence, such as that of the National Health & Medical Research Council 
(NH&MRC) (298). Because of the unique ability of randomised controlled trials to 
control for confounders, which are either known or unknown, they provide the best 
evidence of efficacy for interventions. Traditionally clinical nutrition practice has 
used results to from RCT research to develop health promotion strategies. 
However, this has not always led to the outcomes that have been promised. In part 
this is due to the assumption that efficacy equates to effectiveness. This is an 
important distinction if we are to determine the effectiveness of interventions for 
diseases with a multitude of aetiologies. For example, confounders such as 
compliance and the total diet profile can markedly reduce the predicted viability of 
an intervention under investigation.  
It is for these reasons that the dietary intervention studies that were used in this 
research were designed to resemble as close to a free-living context as possible. 
The first dietary trial investigated the effectiveness of plant sterol prescription within 
a clinical context (Chapter 4). As previously summarised, although there were 
numerous publications of the efficacy of plant sterols/stanols in reducing serum 
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cholesterol and LDL, no studies had investigated effectiveness in a free-living 
context where subjects had to purchase and consume products containing this 
functional ingredient. The design used an existing outpatient clinic to recruit, 
manage and follow up subjects. All outcome measures were those obtained 
through routine practice (i.e. blood chemistry was collected by accredited 
laboratories at the direction of the medical practitioner) which would be used as 
markers for clinical decision making. The second dietary trial (Chapter 5) 
investigated the effectiveness of LCn-3 enriched foods on biomarkers of 
cardiovascular health. Within the study design considerations ensured that 
subjects were free to incorporate these foods into their diet at will. There was no 
specific counselling other than a brief instruction on how much of the products they 
should consume. Also, to increase the power of this study, a variety of prototype n-
3 enriched food products were provided free to the subjects as additional foods not 
currently available on the market. 
Despite the very best of intentions to design trials that mimic real life situations 
there will always be limitations. For example, recruitment bias, where certain 
individuals are more likely to participate in trials because of a personality trait can 
lead to an overestimation of compliance and ultimate effectiveness of a treatment. 
In the fish oil trial, food products were provided and as a result real life barriers 
such as cost, access and availability of these foods were removed. 
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3.2.2 Dietary recording methods 
In order to address secondary questions about the adherence to intervention goals, 
and about the differences in observed outcomes between groups in trials, the 
accurate assessment of diet is important (301). To do this there is a reliance on 
dietary assessment methods such as the DH and FR. The DH is considered to be 
the benchmark method used to assess dietary intakes (307). The DH is designed 
to estimate subjects’ usual intake over a specified period of time, usually 3-months 
(308). It has an established place as a dietary assessment method and lends itself 
well to clinical practice (309). The DH method is also valuable in intervention trials 
where dietary manipulation is required at the time of assessment (310). 
Furthermore, the DH method has demonstrated its ability to produce reliable group 
means for energy and macronutrients (309, 311). The FR on the other hand has a 
greater precision in determining food amounts, is cheaper to administer and has 
less reliance on memory (312). 
It is common practice to validate methods for measuring intakes of a particular 
nutrient on the basis of a positive correlation between individuals using different 
dietary assessment techniques (313-315). However, measurement errors 
associated with multiple assessments are most likely to also be correlated, making 
an accurate assessment of nutrient exposure problematic (301). For example, 
limitations in the DH method include interviewer bias, inaccuracy of portion size 
reporting, errors in reporting of frequency, and a need for subjects to follow regular 
eating habits (316). In contrast, FRs tend to underreport dietary intake, are a poor 
representation of usual diet due to the limited number of days recorded, and distort 
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food habits due to the recording process (317). Despite these obvious limitations, 
the use of multiple dietary assessment measures, combined with the use of 
biomarkers allow for comprehensive assessment of dietary intake that is less likely 
to be skewed by common biases or errors.  
With error in self-report of dietary intake being the single greatest impediment to 
understanding the effect of diet on disease risk, the reliance on biomarkers has 
received recent attention (301). The Women’s’ Health Initiative program in the US 
was designed to demonstrate the feasibility of collecting a comprehensive panel of 
biological markers of dietary intake (318). That study reviewed biomarkers for 
energy (doubly labelled water), protein (24-hour urine collections) and 
carbohydrate (plasma vaccenic acid). The authors propose that fat (and alcohol) 
intake should be determined by subtracting protein and carbohydrate (as 
measured by biomarkers) from the estimation of energy (318). Our primary dietary 
outcome of interest was n-3 intake, and as such a biomarker for this fatty acid 
class was required. 
Biochemical validations make it possible to compare assessed dietary intake of 
some nutrients against biochemical markers (319). In the case of fatty acid 
compounds, demonstrated correlations between dietary intake and erythrocyte cell 
membrane concentrations have been found, and provide a useful biomarker which 
was used in the fish oil study (Chapter 5) (319-321). However, It is important to be 
aware that the biochemical marker method itself is prone to error with results often 
confounded by the fact that they reflect relative percentage and not absolute 
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amounts as well as different methods of collection, sampling site and analytical 
technique used (322).   
In the sterol/stanol study no biomarkers were used to validate dietary data or 
determine plant sterol/stanol intake. This obvious limitation was a trade off with the 
experimental design which was to replicate real-life clinical conditions. 
3.2.3 Sample 
Two trials were used to look at the important primary prevention strategies aimed 
at reducing the prevalence of CHD, namely cholesterol reduction in those with 
hypercholesterolemia and increasing LCn-3 in low fish eaters. For the plant sterol 
study, those identified as ‘at risk’ groups but with no overt cardiovascular 
comorbidities provided the basis for investigation. Samples have been drawn from 
patients identified with hypercholesterolaemia (TC ≥ 5.50 mmol/L) by General 
Practitioners. Those who were of non-English speaking background, taking lipid 
lowering medication for less than 3-months prior to referral or had changed dosage 
within the last 3-month period were excluded, along with subjects following dietary 
regimens for allergy or intolerance, renal disease and diabetes mellitus. 
For the fish oil study, low fish eaters who had a BMI ≥ 25 kg/m2 and plasma 
triglycerides > 1.6 mmol/L were included. Although healthy subjects were selected, 
a criterion of elevated triglycerides was included as a triglyceride lowering effect of 
LCn-3 is considered as a potentially important cardiovascular biomarker. Potential 
subjects with a diagnosis of diabetes, recent symptomatic heart disease; angina 
pectoris; history of myocardial infarction or stroke; peripheral vascular disease; 
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major surgery within the last 3-months; BP >170/100; liver or renal disease 
(plasma creatinine >120 mmol/L); regular non-steroidal anti-inflammatory drug 
therapy; antihypertensive drugs, lipid lowering or other drugs affecting lipid 
metabolism; those eating more than one fish meal per week or regularly taking fish 
oil supplements; or an inability to consume the test foods were excluded. Both of 
these samples represent sub-sets of the population which have well established 
risk factors for CHD for whom targeted primary prevention strategies are 
advocated. 
3.3 Consumer research 
In this thesis the primary interest in consumer research was to predict behaviour in 
relation to the use of functional foods. Qualitative research methods have long 
been used in the social sciences and are the principle methods used by 
researchers interested in studying behaviours as well as customs. They are 
particularly useful in answering complex questions confronting health researchers 
and health care practitioners. The term “qualitative research” refers to specific 
research techniques used to gather data about the social world (such as 
questionnaires in survey research or focus groups) (323). Although qualitative 
research may appear neither unified nor well defined, it is often characterised by 
three distinguishing features. Firstly, qualitative research generally deals with talk 
text or words rather than numbers, which does not preclude measurement, or that 
it cannot be explanatory. A second feature is that it studies people in their natural 
setting, rather than an experimental situation. This has particular relevance to this 
research given the importance of establishing evidence in a ‘real life’ context. And 
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finally, the use of a “multi-method” approach where questions are asked of social 
phenomena from a range of perspectives is also a distinguishing feature. In a 
health behaviour context, such as the use of functional foods, we have therefore 
added a range of qualitative research methods to address the important questions 
about this social phenomenon. 
A frequent criticism is that qualitative methods are necessarily subjective (and, 
therefore biased) and that such research is difficult to replicate and amounts to little 
more than anecdote, personal impression or conjecture (323). This concern can be 
allayed by ensuring that these techniques are applied appropriately and interpreted 
cautiously (324).This research uses qualitative techniques to play a role in both 
validating quantitative research findings as well as providing a alternate 
perspective on the same social phenomena. So instead of viewing quantitative and 
qualitative approaches as methodological opposites, each can be used to 
complement the other. 
An important feature of qualitative research is the link between theory and method. 
The choice of research methods is inextricably linked to a particular theoretical 
perspective or set of explanatory concepts that provide a framework for thinking 
about the issue of consumer research.  
3.3.1 Theoretical model of behaviour 
The Theory of Planned Behaviour (TPB) (325) was used in this thesis and provides 
a model that can help explain consumers’ purchase behaviours in relation to 
functional food products. It has been demonstrated that the TPB, or modified 
    
70   
versions of it, has been applied to areas of consumers’ food choice (20-22), 
supplement use (23) and genetically modified products (24). In addition, 
Baranowski et al (1999) published a review article on the psychosocial correlates 
of dietary intake and concluded that models with psychosocial variables predicting 
dietary fat and fruit and vegetable intake had a generally low predictive power (R2 < 
0.30), with no single model out predicting others (168). However, they went on to 
note that when models predicted narrower categories of behaviour such as the 
TPB (e.g. milk consumption), predictive power tended to be higher (168). Thus it 
could be predicted that this model will perform well against single action behaviour 
such as consumption of n-3 enriched functional foods. It was also suggested by the 
authors that in order to increase the predictive power of models, future research 
should combine variables from separate theories and incorporate variables that 
moderate the relationship of psychosocial to dietary behaviour (e.g. genetics of 
taste, stage in the life course).  
3.3.2 Qualitative methods 
As the TPB model had not been applied to consumer behaviour related to 
functional food use, beliefs and attitudes need to be determined. It has been 
suggest that for each behaviour under investigation it is important to determine the 
salient beliefs related to the behaviour in question (19). Focus group methodology 
is recommended and others have reported using this technique to assist with 
questionnaire design when using the TPB (23, 326, 327). Therefore, results 
obtained from a set of focus group interviews served to define the parameters of 
the TPB model and to test the language for questionnaire design.  
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Focus groups are a form of group interview that capitalises on communication 
between research participants in order to generate data. Here people are 
encouraged to talk to one another as well as the researcher, exchanging questions 
concerns and anecdotes to express points of view (328). Group work also assists 
in understanding an issue through the different ways people communicate with one 
another through the use of jokes, arguments and teasing which is useful as 
people’s attitudes are not necessarily encapsulated in reasoned, logical responses 
to direct questions (328).  
In this research, focus group procedures adhered to the guidelines as suggested 
by Krueger (1994) (329). Firstly, an interview guide was developed using the TPB 
theoretical framework. Questions were devised to determine consumer awareness, 
beliefs, attitude and barriers to using n-3 fatty acid functional foods. All focus 
groups interviews were conducted in a neutral setting (a community hall). Each 
group was heterogeneous for age, sex, socioeconomic status and occupation. All 
focus groups were recorded and transcribed verbatim and transcripts were 
analysed using a computer software package (Chapter 6). 
3.3.3 Focus group sample and group composition 
Focus groups studies consist of anything from half a dozen to over 50 groups, 
depending on the aims of the study and the resources available (328). It was 
reasoned that a sample of 12 groups would generate enough data to suit our 
needs. The aim of the study was to work with a representative sample of 
consumers with each group composition being heterogeneous in order to explore 
    
72   
the different perspectives within each group setting. It is inappropriate to assume 
that these group data are representative of the population, in the sense that these 
views would be expressed in the community independent of the group structure. In 
this sense the data obtained from the groups can be viewed metaphorically as a 
“guidepost” rather than a “landmark”.   
Using the TPB model, transcribed focus group conversation was categorised into 
one of the three areas of belief related to behaviour: behavioural beliefs, which are 
assumed to influence attitudes toward the behaviour; normative beliefs, which 
constitute the underlying determinants of subjective norms; and control beliefs, 
which provide the basis for perceptions of behavioural control. Content analysis 
was carried out and sub-categories were developed to capture the emerging 
themes. These themes provided the basis for questionnaire design. 
3.3.4 Quantitative methods 
To be able to test the ability of the model to predict behaviour a questionnaire 
needed to be developed. Questionnaire development followed the process outlined 
by Ajzen & Fishbein (1980). As recommended by the authors, clarity of the single 
action behaviour is critically important (325). The behavioural criteria are 
comprised of four elements: the action, the target at which the action is directed, 
the context in which it occurs, and the time at which is performed. In this study the 
single target behaviour was defined as “eating foods enriched with omega-3 fats in 
the proceeding 2 weeks”. Even though clinical research points to LCn-3 (from fish) 
as being more bioactive than ALA (from plants), this distinction was not made in 
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the questionnaire as it was apparent from focus group research that consumers did 
not distinguish the different classes of n-3. In order to measure behaviour we 
surveyed the subjects 2 weeks after completion of the survey to ascertain the 
behaviour under question, namely the consumption of n-3 enriched foods.  
One of the advantages of this model is the ability to predict behaviour from 
intention. Although intentions are immediate antecedents of actions, the observed 
relationship between intention and behaviour depends on two factors: first, the 
measure of intention has to correspond to the behavioural criterion in action, target, 
context, and time; second, a measure of intention will predict behaviour only if the 
intention does not change before the behaviour is observed. Here the careful 
selection of intention is required. For this research intention was ascertained using 
the following measure of intention, “I intend to eat one or more foods with added 
omega-3 oils over the next two weeks”. 
As outlined by the theory, a person’s intention to perform a given behaviour is the 
immediate determinant of that behaviour. According to the TPB model, a personal 
or attitudinal component, a social or normative component and a control 
component determine behavioural intention (325). To assess a person’s attitude 
toward behaviour a standard 7-point Likert scaling system was used. This alone 
does little to explain the complexity of behaviour, therefore the factors that 
determine these intentions are of interest. Beliefs can be viewed as underlying a 
person’s attitudes, subjective norms and control that may ultimately determine 
intention and behaviour (325). A number of possible salient beliefs obtained from 
focus group interviews were used and converted into statements, anchored on a 7-
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point bi-polar Likert scale. The implementation of the questionnaire was via postal 
survey and is also reported in detail in Chapter 7. 
Whilst the reduction of behaviour to a set of statistical relationships is tempting, 
caution in interpreting these results is required. At best statistical models have 
been shown to explain about 30% of behaviour (168, 330). With the area of 
functional foods being a contemporary issue, very little research has been 
published on the psychosocial correlates which determine behaviours about their 
use. For these reasons this research is as much exploratory as it is explanatory. 
3.3.5 Questionnaire sample 
As with the dietary intervention studies this research drew samples from an adult 
population that would benefit most from the introduction of n-3 enriched functional 
foods in reducing CHD risk. In addition, recruitment targeted a mixture of both 
consumers without existing disease as well as with morbidities that may increase 
the likelihood of developing CHD (e.g. diabetes mellitus), varieties of 
socioeconomic backgrounds, age brackets and income ranges. The literature has 
suggested that these factors may be independent determinants of healthy foods 
choice (331). 
Samples meeting these criteria were drawn from the general community of 
interested consumer’s via media (print and radio) as well as subjects with type 2 
diabetes mellitus (otherwise healthy) participating in an unrelated dietary 
intervention trial. Stratifying the sample based on co morbidities as well as 
recruiting from a general sample facilitated the investigation of socioeconomic and 
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health factors, in addition to beliefs and attitudinal factors about functional food 
use. 
3.4 Stakeholder study 
Although the collaboration of the food industry, government and health 
professionals is regarded as being important for functional foods to reach their 
maximum potential, no studies have investigated the attitudes of these stakeholder 
groups in the Australian context. Theoretically stakeholders are of interest because 
their needs, wants, desires, perceptions and conceptualisations differ (324). We 
can view stakeholders as networks of human beings, actors or agents with distinct 
roles to play based on distinct ideology which is defined as “scheme of ideas at 
basis of political etc. theory or system” (332). It is the interest in the underlying 
assumptions of these ideologies which is fundamental to this research. A 
qualitative methodology was used to expose and challenge underlying 
assumptions and making ideologies explicit. 
3.4.1 Analytical strategy 
From the literature five key domains which were derived which are regarded as 
being key issues of likely controversy between stakeholders. These were related to 
issues surrounding processing and production, the ability of functional foods to 
achieve tangible health benefits, evidence required for health claims, the regulatory 
environment (including substantiation authority, health claim wording authority and 
public disclosure of evidence) and intellectual property and propriety issues (25, 
333). This framework provided a foundation for analysis.  
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Although focus group methodology could be used in this study, semi-structured 
interviews have been suggested as a more viable option for eliciting views from 
professional groups (324). Reasons cited are that professionals tend to be less 
likely to express true beliefs in an open forum, and there is a strong probability that 
discussion will end in verbal point scoring between opposing views, as opposed to 
an exploration of these issues (324). An interview guide was developed using the 
theoretical groupings of McConnon et al (2002) and Kwak et al (2001) to develop 
the categorisation of key issues to be investigated with stakeholders (25, 333). All 
interviews (except for two face-to-face interviews) were conducted over the phone, 
recorded and transcribed verbatim by an independent third person. Transcripts 
were analysed using a computer software package for qualitative research 
analysis, NVivo 2.0 (2002, QSR International Pty Ltd), which was used for data 
management and coding (334).  
Stakeholders may present themselves as people, as role occupants, as groupings, 
as occupational groupings and pressure groups and many more categories. 
Identifying stakeholders for this research presented a number of hurdles. The 
general guideline is that a stakeholder is any interest group affected by or affecting 
the phenomena, which in this case is the development and communication of 
functional foods. In addition, the stakeholder grouping is usually constructed based 
on those having a relatively consistent experience and point of view. Practically, 
where an imagined stakeholder interest group (e.g. dietitians/nutritionists) has 
significant internal differences of opinion (e.g. between dietitians employed in 
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clinical, public health and food industry settings) the grouping should be further 
broken down. 
The process of conducting qualitative, stakeholder analysis, involves making 
continuous skilled researcher craft judgments – whom to talk to and what to ask 
(324). When researching complex social areas orientating advice can be 
significantly shaped by these fine judgments. Furthermore, this research, as in any 
kind of applied research, is sponsored by, and intended to serve the interests of, 
one or more of the stakeholders. Whilst this does not automatically invalidate the 
process it needs to be stated and considered when drawing conclusions from the 
research. Perhaps stakeholder analysis is a clearer method than many other forms 
of research about these difficult but crucial underlying choices. 
3.4.2 Sample 
Stakeholders were first identified, using the literature as a guide. McConnon et al 
(2002) identified key stakeholders when considering the development of functional 
foods (25). These were defined as the food industry, consumers, health sector and 
government. These categories were further subdivided into eleven categories 
regarded as representing the key stakeholders in relation to functional food 
development in Australia. Key leaders in the field of Nutrition and Dietetics were 
consulted to structure a sampling frame based on these key groupings. The 
objective was twofold; firstly to sample a wide range of views from a variety of 
states and territories within Australia, and secondly to recruit equal numbers of 
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subjects presumed to have positive and negative views about functional food 
development. 
One approach to identifying stakeholders identified in the literature is to follow a 
process of sequential sampling. This process involves collecting information from 
one interested party who will identify other stakeholders who can be followed up. 
This process is followed until nothing new turns up (324). This process was 
rejected in favor of a more structured form of sampling described above for two 
reasons. Firstly, the sequential sampling approach can be regarded as an optimal 
but requiring considerable effort and resources that were not available within the 
time frame (324). Secondly, with the recently established National Centre of 
Excellence in Functional Foods, there was the unique opportunity to draw on the 
expertise of Centre members in identifying key stakeholders within the Australian 
context. Specific details of the stratification are outlined in Chapter 8. 
3.4.3 Limitations and quality issues in qualitative research 
Qualitative research suffers from the “stigma of the small n” (335) because of the 
small samples under investigation and due to not seeking statistical 
representiveness. However this feature is irrelevant to the strength of this approach 
(335). Nonetheless, as with all forms of research attention to the quality of research 
is important. 
The first issue of quality is with validation. There are no easy methods of validating 
qualitative research. There are ways to improve the validity which requires the 
exercise of judgment on the researcher. Firstly, since methods used in research 
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influence the objects of enquiry, it is important to provide a clear account of the 
process of data collection and analysis. This helps the reader judge the 
conclusions made from the methods used and the way the data was collected. 
These details have been included in the methods section of the qualitative studies 
presented in this thesis.  
Closely related to this concept is the issue of reflexivity. This means the ways in 
which the researcher and the research process have shaped the data collection, 
including the role of prior assumptions and experience, which may influence the 
interpretation of the results (335). In view of this, personal and intellectual biases 
are declared at the outset of any research reports, which enhance the credibility of 
the findings. The final technique that has been employed to reduce bias is termed 
“fair dealing”. By this the researcher ensures that the research design explicitly 
incorporates a wide range of different perspectives so that the viewpoint of one 
group or person is not presented as if it represents the sole truth of the situation 
(336).  
An additional dimension of relevance is the extent to which findings can be 
generalised beyond the research setting. In this sense forms of stratified sampling 
were used in order to ensure that the range of settings chosen was representative 
as well as the reporting of results with sufficient descriptive detail for the reader to 
be able to judge whether or not the findings apply to other situations. 
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CHAPTER 4  
 
FUNCTIONAL FOODS ARE RELEVANT FOR INDIVIDUALS IN MANAGING 
CHD RISK2 
4.1 Introduction 
Despite extensive evidence for the efficacy of plant sterols/stanols in reducing 
serum cholesterol, evidence of effectiveness in a practice setting is absent. Forty-
one clinical trials have studied the efficacy of plant sterol esters and plant stanol 
esters in reducing mean total cholesterol (TC) and low-density lipoprotein 
cholesterol (LDL) (337). When plant sterols/stanols are added to foods such as 
margarine, up to a 15% reduction in serum TC and LDL has been reported and the 
effect is additive with diet and drug interventions (337). To this end the Adult 
Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) 
recommend the addition of plant sterols (2g/day) to the diet (14). However, all 
                                             
2 A significant portion of this chapter has been accepted for publication in the following peer reviewed journal: 
Patch CS, Tapsell LC, Williams PG. Plant sterol/stanol prescription is an effective treatment strategy for managing 
hypercholesterolemia in outpatient clinical practice. Journal of the American Dietetic Association. 2005;105:46-52.  
CP was responsible for the design of the study, organisation and leading the study, data collection and analysis, critical 
discussion of the analysis and preparation of the manuscript. LT and PW were responsible for critical discussions of the 
study design, critical discussions of the analysis and preparation of the manuscript. 
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studies to date have been in controlled settings using willing volunteers and 
providing subjects with sterol containing products. These results are yet to be 
replicated in subjects who assemble the diets for themselves on a routine basis, 
thus determining the true effectiveness of this strategy in the clinical setting (281). 
It is commonplace when determining evidence for functional foods to equate 
efficacy with effectiveness. Whereas efficacy aims to establish a relationship 
between a bioactive component and a therapeutic benefit, effectiveness goes one 
step further in answering the question of compliance i.e. do subjects comply with 
the therapy and does the therapeutic relationship hold. Whilst it may be correct to 
assume that efficacy often equates to effectiveness with therapeutic drugs, with 
functional foods, issues relating to the belief in the benefit of use, taste, preference 
and price may affect intake and ultimately compliance (20, 22). In addition, the net 
effect on the whole diet needs to be considered in those who select functional 
foods, given the importance of other dietary aspects such as restricting saturated 
fat and cholesterol and increasing n-3 fatty acids, in reducing CHD risk (306). It is 
therefore important in evaluating effectiveness to design trials in free-living 
contexts. 
A clinical setting with standard practices is a useful setting for this research. 
However, the problem associated with recruitment in clinical trials has been 
acknowledged in the literature and obtaining the numbers needed to achieve 
statistically significant results can be problematic (338). The Number Needed to 
Treat (NNT) is becoming increasingly popular as an index for reporting results of 
randomised controlled trials and other clinical trials (339). The NNT represents the 
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clinical effort that is required by treatment in order to achieve a positive outcome, 
compared to the expected response in a control group. This provides a useful 
measure of effectiveness and overcomes some of the issues of recruitment of 
large numbers of subjects. 
The aim of this study was to test the effectiveness of plant sterol/stanol prescription 
in consenting patients referred to an outpatient clinic that were randomised to 
either standard practice (a low fat, low saturated fat, high fibre diet) or standard 
practice with the additional prescription of 25g of a plant sterol or plant stanol 
containing margarine. This was a free-living trial. No food products were supplied 
to subjects, and the margarines prescribed were available commercially. 
4.2 Methods 
4.2.1 Participants and Study Design 
Subjects were recruited through an established dietary outpatient clinic over an 18 
- month period (Appendix A & B), from February 2001 to August 2002. Subjects 
were included if they were aged between 30 - 75 years and had a fasting serum 
total cholesterol concentration > 5.50 mmol/L. Those who were of non-English 
speaking background, taking lipid lowering medication for less than 3 months prior 
to referral or had changed dosage within the last 3-month period were excluded, 
along with subjects following dietary regimens for allergy or intolerance, renal 
disease and diabetes mellitus. Details of the study were explained to all subjects 
and written informed consent provided before participation in the study. The goal 
was to recruit 80 participants (allowing for 10 drop outs); on a sequential basis 
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using a blocking protocol for total serum cholesterol to ensure the cholesterol 
levels at baseline did not differ between the groups. Within each block, the 
allocation to treatment or control group was random. The study was conducted on 
an outpatient basis over 12 weeks and no foods or supplements were provided to 
subjects. At baseline (week 0) and week 12 subjects filled out a 3-day food record 
(two week days and 1 weekend day). One week later (week 1 and 13) a detailed 
dietary history was conducted along with weight, waist circumference 
measurement and an activity questionnaire. Fasting blood samples were collected 
prior to baseline ~2-3 weeks and at 12 weeks. The human research ethics 
committee of the University of Wollongong and the Illawarra Area Health Service 
approved the study (Appendix C). 
4.2.2 Treatment Conditions 
Control group 
Subjects were individually instructed by the same Accredited Practising Dietitian to 
consume a diet low in saturated fat, consistent with the Therapeutic Lifestyle 
Changes dietary approach as outlined by NCEP (14). In summary, the diet aims for 
25 - 30% of total calories from fat (<7% saturated fatty acids, up to 10% 
polyunsaturated fatty acids, and up to 20% monounsaturated fatty acids), 50 - 60% 
of total calories from carbohydrates, ~15% of total energy from protein, <200mg 
cholesterol/day, fibre 20 – 30g/day and total energy balanced with energy 
expenditure to maintain desirable body weight or prevent weight gain (14). 
Sterol/stanol use was not included as part of dietary instruction, however if subjects 
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were currently using plant sterol/stanol containing margarine they were 
encouraged to continue. This was regarded as standard practice and there would 
be ethical implications to actively discouraging the use of these products. Subjects 
were provided with information sheets offering practical suggestions and an 
individual diet plan. Furthermore, all subjects were encouraged to exercise (e.g. 
30-minute brisk walking) at least 3 sessions per week. Counselling sessions 
consisted of a 1-hour session at week 1 and two 30-minute sessions at week 3 and 
6. 
Intervention group 
The intervention diet was identical to the control diet in all but one aspect. All 
subjects on the intervention diet were instructed to consumer 25g (5 teaspoons) of 
either Flora’s Pro-active® (Unilever Australasia, Sydney, Australia) or Meadow 
Lea’s Logicol™ (Goodman Fielder, Sydney, Australia) margarine (these were the 
only plant sterol and plant stanol containing products respectively on the Australian 
market at the time of the study). The information sheets and diet plans explicitly 
stated these products and the amount to be consumed each day (Appendix D). 
Subjects were instructed to modify their fat intake to accommodate the sterol/stanol 
dosing and encouraged to consume additional carotenoid containing vegetables to 
prevent a possible decrease in plasma carotenoids as a result of the sterol/stanol 
intake (340). This message was the focus of each follow-up clinic visit. 
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4.2.3 Dietary Measurement 
A dietary history (DH) (Appendix E) interview was conducted by the same dietitian 
(CP) at baseline and at 12 weeks. The DH method lends itself well to clinical 
practice where it provides clinicians with an opportunity to subjectively examine 
meal patterns and provide dietary advice while the patient is still present (309). 
Furthermore the utility of this method has been demonstrated in a number of 
sample groups, including short-term intervention studies (311, 341, 342). The 
approach taken was a narrative style DH interview (open-ended) described in 
detail elsewhere (341). In summary, the meal based diet history interview noted the 
types, amounts and frequency of consumption of all foods consumed routinely 
within a 3-month reference time. The interview was completed with a food 
frequency checklist of major food categories, snack and drink items (including 
alcohol), and sources of n-3 fatty acids (fish, nuts, soy foods), as well as questions 
on food preparation practices. The same assessor was the interventionist in this 
study; therefore the DH was not blinded. Subjects were also required to keep an 
estimated 3-day food record (FR) (Appendix F) (two weekdays and one weekend 
day) after the collection of the DH. Forms were provided along with instructions on 
how to estimate food portion sizes using standard kitchen measuring equipment. 
Food records were checked for missing values and clarification.   
4.2.4 Anthropometric Measurement 
Weight and height was recorded at each interview using calibrated balance scales 
and a wall mounted stadiometer. All subjects were clothed (light shirt). Height was 
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measured to the nearest 0.5cm and weight to the nearest 0.1kg. Waist and hip 
circumferences were measured at each time point. Waist circumference was 
measured using a standard cloth measuring tape (units in centimeters and inches); 
at natural waist when clearly identifiable or midway between the lower rib and iliac 
crest) and hip circumference measured at the greater trochanter. For each 
circumference, measurements were recorded to the nearest 0.5 cm. Activity level 
was obtained from a self-reported description of usual activity, including details of 
number of sessions a week of activity, the duration of each session and the 
intensity of each activity. 
4.2.5 Biochemical Measurement  
In keeping with standard clinical practice, a trained phlebotomist at accredited 
pathology laboratories within the Illawarra region (Southern IML Pathology) drew 
blood samples from subjects after an overnight fast. Subsequently, samples were 
analysed for concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, 
and triglyceride. The pathology laboratories were fully accredited with the National 
Association of Testing Authorities (NATA) and the Royal College of Pathologists of 
Australasia (RCPA), which is a mandatory requirement for pathology laboratories 
in Australia. 
4.2.6 Analysis and Statistics 
Dietary data were analysed with Foodworks nutrient analysis software package 
(Professional Version 3.1, Xyris Software, Highgate Hill, Brisbane Australia), which 
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is based on the Australian Nutrient Database (AUSNUT 2000, Department of 
Human Services and Health, Canberra).  
The required sample calculation of n = 80 was based on detecting a difference in 
TC between the groups of 10% at 80% power. A Bland Altman plot (343) was 
prepared to determine possible bias between actual and recalled total fat (%kJ) 
with the two dietary assessment methods. As described by Bland and Altman (343) 
the average of the reported fat intake in the DH and the FR (x axis) are plotted 
against the difference between the DH and FR recorded fat intake (y axis). The 
limits of agreement were set at 2 s.d. of the difference above and below the mean. 
Comparing the reported intake using the DH and FR using Pearson’s correlation 
coefficient assessed the validity of sterol/stanol intake. Changes between week 0 
and week 12 were studied for all variables. Dietary data and baseline 
measurements were assessed using a two-factor analysis of variance with diet and 
sex as fixed factors. The effect of dietary intervention was assessed using paired 
Student’s t-tests when comparing the change in variables (dietary, anthropometric 
and biochemical data) between groups. For non-normally distributed data, 
Wilcoxon signed ranks test was used for within group comparisons, and Mann-
Whitney U test were conducted to determine the proportion of subjects reaching 
dietary and biochemical goals between the groups. Changes in clinical outcomes 
were analysed with an intention to treat model-using analysis of variance i.e. 
subjects were included in the analysis whether or not they consumed the 
prescribed dose of plant sterol/stanol. The relationship between plant sterol intake 
and serum cholesterol was determined using Pearson’s correlation coefficient. The 
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number needed to treat (NNT) index as described elsewhere was used to report 
effectiveness of the intervention (339). The NNT was calculated using the 
proportions of subjects on the control or experimental treatment who achieve a 
total cholesterol reduction of ≥ 15%. NNT is defined as (339): 
 
         
 
Here π1 and π2 are defined as the proportions of subjects on the control or 
experimental treatment (respectively) that experience the defined outcome. A P - 
value less than 0.05 were considered to be statistically significant. SPSS for 
Windows (version 10.0, 1999, Chicago, IL) was used for all statistical analyses. 
4.3 Results 
4.3.1 Subject demographics 
During the 18-month time course of the study forty-two participants met the 
eligibility criteria, 32 agreed to participate producing a group randomisation of 15 
control and 17 intervention subjects. Twenty-five subjects (15 women, 10 men) 
completed the study producing a group randomisation of 11 control and 14 
intervention subjects. One subject withdrew after a myocardial infarct, another 
subject was hospitalised for psychiatric illness and was unable to complete the final 
assessment phase, the clinic lost contact with another subject, and four withdrew 
after the initial assessment. Baseline characteristics of all subjects admitted to the 
π1 - π2  
1 
NNT = 
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study are shown in Table 4-1. The groups did not differ in terms of age, sex, body 
mass index, level activity, and waist: hip ratio, medication use, or serum lipid 
levels.   
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Table 4-1  Participant characteristics at baseline 
 Control Group 
(n = 15) 
Intervention Group 
(n = 17) 
Age (y) (mean ± s.d.) 59.2 (±13.2) 55.2 (±13.4) 
Female/Male 11/4 8/9 
BMI (kg/m2) (mean ± s.d.) 29.8 (±3.3) 31.4 (±5.9) 
Waist/Hip ratio (mean ± s.d.) 0.92 (±0.1) 0.94 (±0.12) 
Cholesterol lowering medication (n)† 2 3 
Frequency of activity 
  Nil 
  1-2 times per week 
  3-4 times per week 
  5-6 times per week 
  >6/7 times per week  
 
5 
3 
2 
1 
0 
 
6 
3 
2 
2 
1 
Total cholesterol (mmol/L) (mean ± s.d.) 
*LDL cholesterol (mmol/L) (mean ± s.d.) 
**Triglyceride (mmol/L) (mean ± s.d.) 
***HDL cholesterol (mmol/L) (mean ± s.d.)
6.64 (±0.8) 
4.25 (±0.6) 
2.40 (±1.4) 
1.27 (±0.3) 
6.89 (±1.1) 
4.35 (±0.8) 
2.28 (±1.1) 
1.26 (±0.3) 
*n = 23, **n = 30, ***n = 27 
There were no significant differences between any of the groups at baseline using Student’s t-test 
for normally distributed data and Wilcoxon sign ranked test for categorical data. 
†Refers to number of patients taking cholesterol lowering medication who had not reported a 
change in dose for >3 months. 
4.3.2 Dietary data 
Using the Bland-Altman plot there was no relationship between the average of the 
reported fat intake using DH and FR with the difference between the two methods 
(Figure 4-1). All but one value was within the 2 s.d. confidence limits as 
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recommended by Bland and Altman (343) indicating that there was no systematic 
bias. Strong correlations were found between the DH and FR method (r = 0.782, P 
< 0.001) for plant sterol/stanol consumption. Results of the dietary analyses using 
DH data are reported in Table 4-2. Overall, nutrient intakes were not significantly 
different between the two groups at baseline and at the end of the study (12 
weeks). However, the change in protein was higher in the intervention group (22%) 
compared to the control group (5%) as well as the change in alcohol intake (-
7g/day, 2g/day in the intervention and control group respectively). The average 
intake of plant sterols/stanols increased by 1.3g/day in the intervention group and 
reduced by 0.3g/day in the control group (P < 0.05), and 20% achieved the goal 
intake of ≥ 2g/day compared to none in the control (P < 0.05). After the intervention 
period, 43% (P < 0.05) of the intervention subjects achieved a polyunsaturated fat 
intake within the NCEP Step 1 diet recommendations (≥ 7%kJ) whereas none 
achieved this goal in the control. There were no other differences between the 
groups in achieving the NCEP recommendations (Table 4-3).  
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Figure 4-1  Bland-Altman plot of the mean difference between the DH and FR for fat (%kJ) 
versus the mean of the DH and FR, with limits of agreement of 2 s.d. from the mean 
difference  
    
93   
Table 4-2  Mean (± s.d.) of dietary composition at week 0 and 12 as determined by DH  
Lipid Control group
(n = 11 ) 
Intervention group 
(n = 14) 
Energy   
  Week 0 (kJ) 8059 (±2658) 8899 (±3298) 
  Week 12 (kJ) 7700 (±2395) 7219 (±1718)  
  ^Change % -4.5 (±21) -18.9 (±30) 
Protein   
  Week 0 (%kJ) 19.7 (±2.3) 17.2 (±3.2) 
  Week 12 (%kJ) 20.7 (±2.0) 21.0 (±3.0) 
  ^Change % 5.2 (±13.8) * 21.9 (±21.4) * 
Fat   
  Week 0 (%kJ) 29.7 (±5.3) 31.9 (±8.9) 
  Week 12 (%kJ) 27.4 (±5.4) 29.9 (±6.4) 
  ^Change % -8.0 (±14.8) -6.4 (±34.3) 
CHO   
  Week 0 (%kJ) 47.4 (±4.8) 44.4 (±6.8) 
  Week 12 (%kJ) 48.0 (±4.7) 44.1 (±7.0) 
  ^Change % 1.2 (±8.7) -0.7 (±31.2) 
SFA   
  Week 0 (%kJ) 10.1 (±2.9) 10.9 (±6.9) 
  Week 12 (%kJ) 8.0 (±2.3) 7.3 (±2.1) 
  ^Change % -20.8 (±27.5) -32.1 (±37.5) 
MUFA   
  Week 0 (%kJ) 12.4 (±2.6) 12.9 (±3.3) 
  Week 12 (%kJ) 11.7 (±2.6) 13.3 (±3.6) 
  ^Change % -5.6 (±17.8) 2.9 (±37.9) 
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PUFA   
  Week 0 (%kJ) 4.4 (±1.1) 5.3 (±1.5) 
  Week 12 (%kJ) 4.0 (±1.2) 6.3 (±2.4) 
  ^Change % 10.1 (±32.4) 18.6 (±56.2) 
Cholesterol   
  Week 0 (mg) 201.3 (±106.4) 236.7 (±166.1) 
  Week 12 (mg) 170.8 (±58.4) 153.1 (±64.9) 
  ^Change % -15.1 (±34.6) -35.3 (±41.4) 
Dietary fibre   
  Week 0 (g/day) 28.5 (±10.1) 24.2 (±8.5) 
  Week 12 (g/day) 35.3 (±17.3) 26.5 (±8.9) 
  ^Change % 24.1 (±69.4) 9.5 (±40.9) 
Alcohol   
  Week 0 (g/day) 3.4 (±6.1) 15.2 (±24.1) 
  Week 12 (g/day) 5.6 (±8.8) 8.4 (±16.7) 
  ^^Change (g/day) 2.2 (±3.9) * -6.8 (±10.7) * 
Sterol/stanol intake   
  Week 0 (g/day) 0.8 (±1.0) 0.2 (±0.5) 
  Week 12 (g/day) 0.5 (±0.8) 1.5 (±0.8) 
  ^^Change (g/day) -0.32 (±0.7) * 1.26 (±0.9) * 
*P < 0.05, **P < 0.01, significantly different between the groups 
 
^Change % =                               X 100%.   
 
^^Change =                      
week 0 
week 12 – week 0 
week 12 – week 0 
    
95   
Table 4-3  Number of subjects meeting selected fatty acid targets at baseline and 12 weeks 
(n = 25) 
Time Group Plant sterol/stanol Saturated fat intake Polyunsaturated fat 
intake 
  ≥ 2g/day < 2g/day ≥ 10%kJ < 10%kJ ≥ 7%kJ < 7%kJ 
Baseline Control 0 0 4 7 0 11 
 Intervention 0 0 7 7 2 12 
12 weeks Control 0* 11 2 9 0* 11 
 Intervention 3* 11 2 12 6* 8 
*P < 0.05, **P < 0.01, significantly different between the groups, Mann-Whitney U Test. 
4.3.3 Serum lipids in response to treatment 
Total cholesterol, plasma triglyceride, HDL cholesterol and LDL cholesterol 
concentrations did not differ significantly over time or between groups. 
Concentrations of plasma lipids at the beginning and end of the trial are shown in 
Table 4-4 and Figure 4-2. After the 12-week intervention the reductions in total 
cholesterol and LDL cholesterol were more than double in the intervention group 
compared to the control group, but these differences did not reach statistical 
significance. There was a strong inverse relationship between 12-week dietary 
sterol/stanol intake and change in serum cholesterol (r = -0.62; P = 0.001) and 
serum LDL cholesterol (r = -0.58; P = 0.019). 
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Table 4-4  Mean (± s.d.) plasma lipid concentrations at week 0 and 12 with each dietary 
intervention. 
Lipid Control group Intervention group) 
Total cholesterol   
  Week 0 (mmol/L) 6.64 (± 0.8) 6.89 (± 1.1) 
  Week 12 (mmol/L) 6.29 (± 0.7) 6.10 (± 1.0) 
  Change % -5.3 (± 11.5) -11.5 (± 13.9) 
LDL cholesterol (n = 17)   
  Week 0 (mmol/L)  4.25 (± 0.6) 4.35 (± 0.8) 
  Week 12 (mmol/L)  4.06 (± 0.9)  3.82 (± 0.9)  
  ^Change %  -4.5 (± 15.7) -12.2 (± 13.1) 
Triglyceride (n = 24)   
  Week 0 (mmol/L)  2.40 (± 1.4) 2.28 (± 1.1) 
  Week 12 (mmol/L)  2.20 (± 1.3) 2.20 (± 0.9) 
  ^Change %  -8.3 (± 28.7) -3.5 (± 34.7) 
HDL cholesterol (n = 19)   
  Week 0 (mmol/L)  1.27 (± 0.3) 1.26 (± 0.3) 
  Week 12 (mmol/L)  1.29 (± 0.3) 1.27 (± 0.3) 
  ^Change % 1.6 (± 8.7) 0.7 (± 13.1) 
LDL:HDL ratio (n = 18)   
  Week 0 (mmol/L)  3.37 (± 0.9) 3.49 (± 1.0) 
  Week 12 (mmol/L)  3.29 (± 1.1) 3.21 (± 1.1) 
  Change %  -2.4 (± 14.7) -8.0 (± 10.0) 
*P < 0.05, **P < 0.01, significantly different from baseline 
^Change % =                                       X 100%.   
week 12 – week 0 
week 0 
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Figure 4-2  Mean (± SEM) percentage change in serum lipids from baseline to the end of the 
12 week dietary intervention.   
4.3.4 Clinical indexes 
At the completion of the 12-week study 5 of 14 subjects in the intervention group 
achieved ≥ 15% change in total cholesterol compared to 0 of 11 in the control (P < 
0.05). No other significant changes were observed between the groups. Both 
groups showed a mean weight change of < 1.0 kg and there were no significant 
differences in body weight from the baseline to the end of the study. The NNT was 
calculated to be 2.8.   
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4.4 Discussion 
This present study is the first to investigate the utility of using plant sterol/stanol 
enriched margarine in a free-living clinical context. While evidence-based nutrition 
recommendations attempt to translate research data into nutrition care (344), 
research in clinical settings are paramount, as the applicability of controlled studies 
to the general community is often questioned (10). For example, in the effective 
management of hyperlipidaemia there are a number of dietary approaches that can 
achieve moderate results; these include reducing the saturated fat in the diet, 
increasing n-3 polyunsaturated diet and increasing dietary fibre (345). It is 
important that the introduction of novel dietary strategies do not adversely affect 
the dietary profile. 
In conjunction with dietary advice consistent with the NCEP guidelines, the 
inclusion of ~1.5-2g/d of plant sterol in margarine did not adversely affect the 
dietary fat or plasma lipid profiles (Tables 4-2 and 4-4). Of particular interest was 
the increase in the proportion of fats coming from polyunsaturated fat in the 
intervention group. Intervention trials have shown that visible fats (such as 
margarine and nuts) are often excluded from the diet in preference to hidden fats 
that are often saturated (346). The net effect is a decrease in the P:S ratio. There 
is increasing evidence of the importance of polyunsaturated fats as an important 
dietary component in reducing the risk of CVD and the need to increase the P:S 
ratio is of importance (347). A serendipitous result of prescribing a daily dose of 
plant sterol/stanol enriched margarine was the delivery of extra n-3 
polyunsaturated fatty acids. As plant sterols/stanols have an additive effect with 
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other dietary modifications (348), prescribing enriched margarine is an effective 
strategy to achieve both of these targets. 
The dietary assessment measures had some limitations. In pursuit of designing a 
study resembling ‘real life’ conditions there was a trade off by un-blinding the DH, 
as the assessor was also the interventionist. The impact of this on the 
interpretation of data is marginal as it was demonstrated that there was a strong 
agreement between the DH and FR methods for dietary fats and sterol/stanols, 
indicating relative validity.  
Although compliance to the dietary regimen is a key component of determining 
effectiveness, the ability to show the therapeutic benefit is also important. The 
mean percent reduction in total cholesterol and LDL cholesterol in the intervention 
group was ~11% and ~12% respectively compared to ~5% and ~4% in the control 
group. This difference however was not statistically significant either within groups 
or between groups over time, probably because the final sample size was 
significantly smaller (n = 25) compared to the original sample size power 
calculations (n = 80). The study was underpowered to reject the null hypothesis 
that is, there was not enough evidence to say there was a significant difference 
between the groups. 
Results showed that dietary prescription of plant sterol/stanol margarines in 
conjunction with the NCEP guidelines for the management of blood lipids resulted 
in an intake of 1.3g sterol/day, whereas in the control group plant sterols reduced 
their intake by 0.4g/day. Although studies have shown that 2g/day of plant sterol is 
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the therapeutic optimal dose, the response curve is linear suggesting that an intake 
of around 1.5g/day is still clinically useful and the levels achieved would be 
predicted to achieve a change of ~10% in total serum cholesterol and LDL 
cholesterol (348).  
A significant limitation to clinical practice in the dietary management of 
hyperlipidaemia is that despite studies in controlled environments achieving up to 
15% reductions in total cholesterol, results in a free-living context have at best 
shown a 5% reduction (12). This study showed that 5 of 11 (36%) in the 
intervention group achieved a reduction in serum cholesterol levels ≥ 15% 
compared to none in the control. This has an important clinical implication, which 
can be summarised using the NNT statistic. Using this index one can predict that if 
clinicians routinely prescribe 2g/day of plant sterol/stanol margarine, then for every 
2.8 patients given this advice, an extra patient will achieve cholesterol reducing 
effect ≥ 15%, compared to a more conventional approach to dietary therapy. 
However, these results can only be viewed as preliminary at this stage as the small 
sample size makes generalising beyond the bounds of this clinical context 
inappropriate. Further research is required in this area which would involve a larger 
sample, drawn over multiple clinical sites before conclusive evidence can be 
provided. 
What has been known for many years regarding the efficacy of plant sterol/stanol 
enriched food products in the management of hyperlipidaemia can now be 
extrapolated into a free-living, clinical context. Plant sterol/stanol margarines 
provide a useful and significant adjunct to medical nutrition therapy. However, 
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while these positive results may be relevant to at-risk individuals, the utility of 
functional foods applied to a population approach needs to be verified. The 
following study investigated the effectiveness of n-3 enriched functional foods in a 
lower-risk group.  
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CHAPTER 5  
 
FUNCTIONAL FOODS ARE RELEVANT TO POPULATION BASED APPROACH 
TO MANAGING CHD RISK3,4 
5.1 Introduction 
Population intakes of fatty fish remain suboptimal and functional foods enriched 
with LCn-3 may be an effective population approach in managing this risk. Diets 
high in fish has been found in epidemiological studies to protect against heart 
disease (15-17). In addition, a number of experimental studies have demonstrated 
the efficacy of LCn-3, which is found in fish, in reducing triglycerides, blood 
pressure, arrhythmia and thrombotic risk (145, 349, 350), and it is this combined 
effect that is believed to be cardioprotective (147). This study was a 6-month 
                                             
3A significant portion of this chapter has been submitted for publication in the following peer reviewed journal: 
Patch CS, Tapsell LC, Mansour J, Noakes M, Murphy KJ, Mori TA, Meyer BJ, Clifton PA, Puddey IB, Beilin L, Annison G, 
Howe PRC. (In Press) The use of novel foods enriched with long chain omega-3 fatty acids to increase dietary intake. 
Journal of the American Dietetic Association. 2005. 
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assessment, critical discussions in the analysis and discussions of the manuscript. MN and IP were responsible for critical 
discussions of the study design, critical discussions of the analysis and discussions of the manuscript. PH, BM, TM, GA & LT 
were responsible for the grant submission, study design and administration and, critical discussions of the analysis and 
discussions of the manuscript. In addition, LT supervised the dietary assessment. 
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nutritional intervention study investigating the effects of foods enriched with (LCn-
3) on cardiovascular biomarkers. In order to substantiate the dietary effects of 
these processed enriched foods, evidence of actual changes in fatty acid intakes is 
required. In addition, the net effect on the whole diet needs to be considered in 
those who select these foods, given the importance of other dietary aspects on 
cardiovascular disease risk. For example, authorities recommend 25 - 30% of total 
calories from fat (< 7% saturated fatty acids (SFA), up to 10% polyunsaturated fatty 
acids (PUFA), and up to 20% monounsaturated fatty acids (MUFA)), 50 - 60% of 
total calories from carbohydrates (CHO), ~15% of total energy from protein (PRO), 
< 200mg cholesterol/day, fibre 20 –30g/day and total energy to be balanced with 
energy expenditure to maintain desirable body weight or prevent weight gain (14) 
and for a 8360kJ (2000kcal) diet, a daily intake of n-3 fatty acids of 0.65g 
eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) and 2.22g α-linolenic 
acid (ALA), with the n-6:n-3 ratio reduced to substantially less than 10 (160). 
Therefore, in assessing dietary interventions, proper dietary assessment 
methodology is essential as a cornerstone to evaluating the overall dietary profile. 
The DH is considered to be the gold standard of methods used to assess dietary 
intakes (307). It has an established place as a dietary assessment method and 
lends itself well to clinical practice (309). The DH method is also valuable in 
intervention trials where dietary manipulation is required at the time of assessment 
(310). However, as with all dietary assessment methods there are limitations, 
which include interviewer bias, inaccuracy of portion size reporting, errors in 
reporting of frequency, and a need for subjects to follow regular eating habits 
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(316). Due to the limitations of collecting intake data, the quality of dietary 
assessment methods needs to be assessed in the context of each study (310). 
This can be assessed using a number of methods such as reporting the degree of 
over- and underreporting, assessing bias to over- or under report and the relative 
validity between dietary intake data and erythrocyte fatty acid biomarker data. In 
this study we developed multiple strategies to determine dietary intake. The aim of 
this study was to evaluate the impact of incorporating LCn-3 enriched foods in the 
diets of individuals, whose usual diet was low in fish, making clear reference to the 
quality and validity of the dietary data. 
5.2 Methods 
5.2.1 Recruitment and screening 
The study was approved by the Human Research Ethics Committees at the 
University of Western Australia, the University of Adelaide and the CSIRO 
(Appendix G). Ninety-four overweight men and women were recruited, age range 
between 20 to 65 years through local media advertisements at two sites – Perth 
and Adelaide (Australia). During a screening interview those who had plasma 
triglycerides < 1.6 mmol/L, a diagnosis of diabetes, recent symptomatic heart 
disease; angina pectoris; history of myocardial infarction or stroke; peripheral 
vascular disease; major surgery within the last 3-months; BP > 170/100 mmHg; 
liver or renal disease (plasma creatinine > 120 µmol/L); regular non-steroidal anti-
inflammatory drug therapy; antihypertensive drugs, lipid lowering or other drugs 
affecting lipid metabolism; eating more than one fish meal per month or taking fish 
    
105   
oil supplements; or an inability to consume the test foods were excluded. All 
participants gave their written informed consent. Of the 94 volunteers who attended 
screening, 86 volunteers were randomly allocated to either the intervention group 
(n = 42) or the control group (n = 44). A block randomization scheme was used to 
balance groups according to baseline triglyceride concentration and body mass 
index (BMI). 
5.2.2 Study procedures 
The goal of the intervention was to consume 8 serves of study foods per day 
equivalent to 1g LCn-3. Each serve of the enriched foods provided 125mg EPA + 
DHA The objective was for subjects to replace current foods with study food 
equivalents. A variety of LCn-3 enriched foods and matching control foods, which 
included cheese spread, chocolates, instant oats, milk, dip (pepper, tzatziki, salsa), 
biscuits (Anzac and ginger), pancakes, muffins, bread, salad dressing and soup 
(chicken laksa and vegetable) were prepared by Goodman Fielder Ltd Sydney, 
Australia. The fatty acid composition of the n-3 enriched foods provided to the 
participants is detailed in Table 5-1. Intervention foods (enriched with LCn-3) and 
equivalent control foods (not enriched) were supplied to all subjects in unmarked 
packages with one of two codes. The content of the study foods was blinded to 
subjects as well as researchers. Subjects were provided with two weeks supply of 
study foods and instructed on how to incorporate at least 8 portions of study foods 
into their daily eating pattern (Appendix H), but were not prescribed menus. The 
background diet was ad libitum, however after the first month of the study, those 
subjects who gained weight were advised by a qualified dietitian on ways to reduce 
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their energy intake whilst accommodating the study foods. This was monitored 
throughout the study. 
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Table 5-1  Estimated fatty acid content of the study foods provided to subjects in the intervention and control groups 1 
Food (Serve size) Group Oleic (18:1n-9) Linoleic (18:2n-6) α-linolenic (18:3n-3) Eicosapentaenoic (20:5n-3) Docosahexaenoic (22:6n-3) 
  mg/ serve mg/ 100g mg/ serve mg/ 100g mg/ serve mg/ 100g mg/ serve mg/ 100g mg/ serve mg/ 100g 
2.04 5.43 0.45 1.19 0.09 0.23 0.05 0.14 0.07 0.20 Biscuita 
(2 biscuits ~ 40g) 
Intervention 
Group 1.95 5.19 0.44 1.16 0.08 0.21 0.00 0.00 0.00 0.00 
0.53 0.63 0.71 0.85 0.06 0.07 0.05 0.06 0.07 0.09 Bread 
(2 slices ~ 90g) 
Intervention 
Group 0.44 0.52 0.70 0.83 0.05 0.06 0.00 0.00 0.00 0.00 
2.30 9.19 1.20 4.80 0.29 1.15 0.05 0.21 0.07 0.30 Cheese spread 
(25g) 
Intervention 
Group 2.21 8.84 1.19 4.76 0.28 1.12 0.00 0.00 0.00 0.00 
2.01 8.37 0.19 0.79 0.03 0.11 0.05 0.22 0.07 0.31 Chocolate 
(25g) 
Intervention 
Group 1.92 8.00 0.18 0.75 0.02 0.83 0.00 0.00 0.00 0.00 
1.12 3.69 1.23 4.10 0.13 2.34 0.05 0.18 0.07 0.25 Dipa 
(30g) 
Intervention 
Group 1.02 3.40 1.22 4.07 0.12 0.40 0.00 0.00 0.00 0.00 
2.41 2.68 1.06 1.18 0.63 0.70 0.00 0.00 0.15 0.17 Egg 
(2 ~ 90g) 
Intervention 
Group 4.35 4.83 1.00 1.11 0.02 0.02 0.00 0.00 0.04 0.04 
5.53 27.65 2.19 10.96 0.97 4.85 0.05 0.24 0.07 0.36 Margarine 
(20g) 
Intervention 
Group 5.42 27.10 2.18 10.90 0.96 4.80 0.00 0.00 0.00 0.00 
0.98 0.39 0.06 0.02 0.04 0.02 0.05 0.02 0.07 0.03 Milk 
(250ml) 
Intervention 
Group 0.89 0.36 0.05 0.02 0.03 0.01 0.00 0.00 0.00 0.00 
0.95 2.11 0.91 2.02 0.07 0.15 0.05 0.12 0.07 0.16 Muesli 
(30g) 
Intervention 
Group 0.86 1.91 0.90 2.00 0.06 1.33 0.00 0.00 0.00 0.00 
0.23 0.46 0.39 0.78 0.07 0.14 0.05 0.11 0.07 0.15 Muffin 
(1 muffin ~ 75g) 
Intervention 
Group 0.14 0.28 0.38 0.76 0.06 0.12 0.00 0.00 0.00 0.00 
0.72 1.80 0.15 0.38 0.03 0.07 0.05 0.13 0.07 0.18 Oat cereal 
(30g) 
Intervention 
Group 0.63 1.58 0.14 0.35 0.02 0.05 0.00 0.00 0.00 0.00 
0.85 0.77 1.13 1.03 0.08 0.07 0.05 0.05 0.07 0.07 Pancake 
(3 pancake ~ 30g) 
Intervention 
Group 0.76 0.69 1.12 1.02 0.07 0.06 0.00 0.00 0.00 0.00 
5.17 12.94 4.95 12.37 1.13 2.82 0.05 0.13 0.07 0.18 Salad dressing 
(40ml) 
Intervention 
Group 5.09 12.73 4.94 12.35 1.12 2.80 0.00 0.00 0.00 0.00 
0.56 1.86 1.32 4.40 0.22 0.73 0.05 0.18 0.07 0.25 Salsa 
(25g) 
Intervention 
Group 0.47 1.57 1.31 4.37 0.21 0.70 0.00 0.00 0.00 0.00 
1.02 1.20 0.99 1.16 0.04 0.44 0.05 0.60 0.07 0.09 Soupa 
(1 sachet ~ 85g) 
Intervention 
Group 0.94 1.10 0.98 1.15 0.03 0.04 0.00 0.00 0.00 0.00 
aMean value of two separate varieties within this category 2 
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At baseline, at 3-months and at the end of the 6-month intervention, fasting blood 
samples were taken by venipuncture for erythrocyte fatty acid and lipid 
compositional analysis. Height, weight, waist circumferences (at natural waist when 
clearly identifiable or midway between the lower rib and iliac crest) and hip 
circumference (at greater trochanter) were measured at each of the three time 
points. 
5.2.3 Dietary Measurement 
A modified Burke style DH (Appendix I) (351) was administered to each subject by 
trained dietitians using a standardised tool at baseline, 3-months and 6-months. 
Dietitians asked subjects to describe a typical day’s intake, as well as amounts, 
frequencies and variations in consumption. Quantities were assessed using 
familiar volumes, dimensions or purchasing units, or with food models representing 
volumes and serving sizes. A standardised questionnaire was then used to gather 
information about the types of meals consumed, the frequency of meals, eating out 
and formal entertaining. A daily checklist of foods and brands was also used to 
identify or clarify intakes of fatty foods and foods containing n-3 fatty acids. Using 
each of these tools, a 7-day pattern of consumption was constructed. In addition, 
all subjects, prior to the DH at baseline, completed FR (Appendix J) after 3-months 
and 6-months. Subjects kept records of all foods consumed over a period of three 
days including two weekdays and one weekend day. All foods were either weighed 
by the subjects or listed in common serving or package sizes. Subjects were 
instructed to be as detailed as possible when reporting food items, weights and 
sizes. FR was checked with each subject by a different dietitian to that which 
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performed the DH. Analysis of the DH and FR were performed by an independent 
dietitian. Both methods were assessed against erythrocyte fatty acid levels with 
strong correlations (particularly with the DH) achieved for EPA, DHA, total LCn-3 
and total n-3 at 3 and 6-month time points. As additional measure of compliance 
each subject was asked to record the number of study food portions consumed per 
day and the average weekly portions consumed were calculated for each subject. 
At the conclusion of the study participants were asked to rate the taste of each 
product on a 7-point Likert scale ranging from -3 (extremely dislike) to +3 
(extremely like) (Appendix K). 
DH and FR were entered into the Foodworks™ nutrient analysis software package 
(Xyris Software, Highgate Hill, Brisbane Australia, Professional Version 3.2,2002), 
using the Australian nutrient database AusNut Rev 0.14 (AusNut 2000, Department 
of Human Services and Health, Canberra) and the Australian Fatty Acids Rev 0.6 
(Royal Melbourne Institute of Technology, 2002) to produce values for energy and 
macronutrient intakes and fatty acids. All study foods (controls and intervention) 
were entered into the Foodworks database and nutrient content analysed through 
recipe analysis using product information and analytical data from 
microencapsulated fish oil powder. Additional foods from interviews that were not 
found in the database, were substituted with equivalent food items (352).   
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5.2.4 Laboratory procedures5 
Fasting venous blood was collected in EDTA tubes and centrifuged at 4000rpm for 
10 minutes at 4°C to separate erythrocytes from plasma. Subsequently, 
erythrocytes were washed twice with isotonic saline and stored at -80°C prior to 
fatty acid extraction. Erythrocytes membrane lipids were extracted into methanol: 
toluene (4:1, by vol.) and transmethylated according to the method of Lepage & 
Roy (1986). Gas Chromatographic analyses of fatty acid methyl esters (FAME) 
were performed using a Shimadzu GC 20A (Shimadzu Corporation, Kyoto, Japan) 
fitted with a FID and a 50m BPX70 cross-linked 70% cyanopropyl 
polysilphenylene-siloxane capillary column (0.32 mm ID and 0.25 µm film 
thickness, SGE, Australia). Samples were injected at 125°C and held for 1 minute. 
Oven temperature was set to increase in a step-wise manner to a final temperature 
of 220ºC. The injector and detectors were maintained at 260ºC and hydrogen was 
used as the carrier gas. Peak areas and fatty acid percentages were quantified on 
an IBM compatible workstation using Shimadzu software. Individual fatty acids 
were identified by comparison with known FAME standards (Nuchek Prep Inc, 
USA). Results are expressed as percent of total fatty acids. 
                                             
5 This analysis was conducted by researchers at the University of Adelaide. Results obtained were correlated with dietary 
measurements by CP. 
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5.2.5 Data Analysis 
The statistical analysis focused on changes in dietary variables at three time 
points, baseline, 3-month and 6-month. Effects of treatment on dietary intake over 
time were assessed by repeated measures ANOVA based on an intention to treat 
model of analysis. Demographics and dietary intakes of treatment and control 
groups were compared using one-way ANOVA. Non-parametric analysis was 
conducted using the Kruskall-Wallis test.  
Differences between DH and FR data were assessed using Student’s t-tests and 
Pearson’s correlation coefficients were estimated to view relationships. The 
plausibility of estimated intake (EI) was tested against energy expenditure (EE). As 
EE was unavailable, we used the EI:basal metabolic rate (BMR) ratio and 
compared this to EE:BMR or physical activity level (PAL). Comparing the sample 
EI: BMR ratio to the PAL level at which life is not sustained, the level of 
underreporting for both individuals and groups could be determined. The 
calculations were derived by Goldberg et al (353) and Black et al (354). 
Underreporting of energy was determined by taking a group mean reported energy 
intake (EIrep) to basal metabolic rate (BMR) ratio and applying the Goldberg cut-off 
limits of 1.52 for diet histories and 1.50 for food records. These Goldberg cut-off 
were determined using the equation suggested by Black et al (354), using the 
group sample size, number of days dietary reporting as well as a physical activity 
level (PAL) value. The sample size of n = 86, 86 & 74 was used for the time points 
0, 3 & 6-months respectively. The number of days was 3 for food records and 14 
for diet history. Using the World Health Organisation (WHO) recommendations  for 
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energy requirements (355) we made a judgment that a PAL of 1.55 would be used, 
based on self reported exercise frequency, duration and intensity. 
To assess the quality of dietary data, data obtained from diet history interviews and 
food records were compared at 0, 3 and 6 months using Bland-Altman plots (343). 
The ranges for the limits of agreement were set at 840kJ, 2% energy and 1g for 
reported energy, macronutrients and total n-3 fatty acids respectively. Evidence of 
systematic bias was observed if a significant correlation was found between the 
difference (DH-FR) and mean (DH-FR/2) values. SPSS V11.0 (Version 11.0.0; 
19/09/01, SPSS Inc., Chicago, IL, USA) was used for all statistical analyses, with a 
statistical significance level of P < 0.05.  
5.3 Results  
Eighty six men and women commenced the trial. The intervention and control 
groups were well matched for weight, height, BMI, age, daily total energy, protein, 
fat and carbohydrate intake (Table 5-2). There were no withdrawals at 3-months 
whereas at 6-months 12 withdrew (8 in the intervention and 4 in the control group), 
leaving a group randomisation of 36 in the control group and 38 in the intervention 
group. Body weight increased significantly in both groups at the end of 6-months 
by 2.7kg ± 4.7 in the intervention group and 1.4kg ± 2.4 in the control group (P < 
0.001), with no difference detected between the groups. 
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Table 5-2  Baseline characteristics 
 Control 
(n = 22 M, 22 F) 
Intervention 
(n = 19 M, 23 F) 
P-value 
Age (y) 50.2 ± 9.4 50.4 ± 14.5 0.943 
Height (cm) 170.4 ± 9.8 172.3 ± 10.9 0.379 
Weight (kg) 94.6 ± 17.2 93.0 ± 17.6 0.667 
BMI (kg/m2) 31.9 ±4.4 31.2 ± 5.2 0.242 
Waist-to-hip ratio 0.91 ±0.08 0.93 ±0.09 0.495 
Total Energy (kJ/day) 11244.2 ±3136.6 11657.9 ±3805.8 0.574 
Protein (g/day) 115.0 ±31.6 117.3 ±33.2 0.746 
Fat (g/day) 96.6 ±34.0 103.6 ±34.3 0.333 
Carbohydrate (g/day) 322.9 ±105.0 337.6 ±135.5 0.565 
5.3.1 Dietary data 
Dietary intakes of macronutrients and key fatty acids were estimated using the DH 
interview data (Table 5-3). Protein as a percent of energy intake, alcohol and fibre 
intake decreased over the course of the study, but there were no significant 
differences between the two groups. There were no significant changes in total fat 
(%E), SFA (%E) and MUFA (%E) after 6-months but there was a significant 
difference between the groups at each time point. Dietary intake of PUFA (%E) 
increased in the treatment group (≈12%) whereas it decreased in the control group 
(≈5.5%). AA intake was significantly different between groups, but this did not 
change over time, nor was there a significant interaction between the two groups. 
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There were significantly different changes in intake between the control and 
intervention for ALA (≈75%, 25%; P < 0.01), EPA (≈490, -58%; P < 0.001), DHA 
(≈370%, -60%; P < 0.001), LCn-3 (≈365%, -55%; P < 0.001), n-6:n-3 ratio (≈-51%, 
-11%; P < 0.001) and total n-3 (≈122%, 9%; P < 0.001) respectively.   
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Table 5-3  Subjects’ daily intake as estimated by diet history analysis Mean (± s.d.)  
 Baseline 3 months 6 months P-value 
Total energy (kJ) 
  Intervention 
  Control 
 
11716.0 ±3912.0 
10946.6 ±2922.7 
 
11132.6 ±3107.8 
11539.7 ±2703.2 
 
11473.7 ±2764.7 
11268.0 ±2592.0 
0.910 a 
0.760 b 
0.419 c 
Carbohydrate (% E) 
  Intervention 
  Control 
 
45.54 ±6.02 
46.97 ±6.44 
 
46.11 ±4.81 
47.21 ±5.76 
 
44.74 ±5.86 
47.44 ±6.44 
0.845 a 
0.115 b 
0.448 c 
Protein (%E) 
  Intervention 
  Control 
 
16.56 ±2.58 
16.60 ±2.53 
 
15.70 ±2.18 
15.54 ±1.78 
 
16.14 ±2.10 
15.90 ±2.18 
0.050 a 
0.774 b 
0.622 c 
Alcohol (%E) 
  Intervention 
  Control 
 
7.96 ±15.18 
11.03 ±15.14 
 
7.35 ±13.45 
9.61 ±14.74 
 
6.77 ±14.41 
8.85 ±11.62 
0.071 a 
0.437 b 
0.595 c 
Fibre (g) 
  Intervention 
  Control 
 
33.33 ±11.8 
32.33 ±7.9 
 
28.00 ±8.5 
32.50 ±9.6 
 
29.92 ±8.3 
30.44 ±8.3 
0.038 a 
0.428 b 
0.542 c 
Cholesterol (mg) 
  Intervention 
  Control 
 
360.5 ±325.9 
324.9 ±122.3 
 
392.3 ±159.8 
342.2 ±102.0 
 
402.0 ±141.2 
383.8 ±112.8 
0.071 a 
0.722 b 
0.330 c 
Fat (% E) 
  Intervention    
  Control 
 
33.20 ±5.80 
30.58 ±5.86 
 
32.79 ±5.58 
30.98 ±5.53 
 
34.00 ±5.07 
30.62 ±5.54 
0.613 a 
0.005 b 
0.656 c 
SFA  (% E) ‡ 
  Intervention  
  Control 
 
12.93 ±3.03 
11.29 ±3.26 
 
12.70 ±1.46 
11.92 ±2.28 
 
12.86 ±2.26 
11.87 ±2.31 
0.509 a 
0.012 b 
0.400 c 
MUFA (% E) 
  Intervention 
  Control 
 
12.45 ±2.89 
11.48 ±2.92 
 
12.66 ±2.00 
12.18 ±2.77 
 
13.41 ±2.47 
12.05 ±3.08 
0.084 a 
0.049 b 
0.659 c 
PUFA (% E) 
  Intervention  
  Control 
 
5.03 ±1.56 
5.07 ±1.59 
 
5.53 ±0.91 
5.12 ±1.37 
 
5.65 ±1.32 
4.79 ±1.18 
0.466 a 
0.046 b 
0.055 c 
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PUFA:SFA ratio 
  Intervention 
  Control 
 
0.413 ±0.17 
0.500 ±0.27 
 
0.440 ±0.09 
0.442 ±0.12 
 
0.451 ±0.13 
0.419 ±0.14 
0.412 a 
0.499 b  
0.025 c 
n-6:n-3 ratio 
  Intervention 
  Control 
 
8.88 ±4.2 
8.57 ±3.6 
 
3.43 ±0.8 
6.40 ±1.6 
 
4.31 ±1.6 
7.59 ±2.4 
0.000 a 
0.000 b 
0.001 c 
LA 
  Intervention  
  Control  
 
12.92 ±5.59 
12.46 ±5.56 
 
12.79 ±4.46 
13.52 ±4.83 
 
14.07 ±5.16 
11.93 ±4.36 
0.722 a 
0.470 b 
0.336 c 
AA 
  Intervention  
  Control  
 
0.14 ±0.08 
0.14 ±0.12 
 
0.10 ±0.06 
0.14 ±0.08 
 
0.14 ±0.07 
0.18 ±0.07 
0.261 a 
0.035 b 
0.247 c 
ALA 
  Intervention  
  Control  
 
1.34 ±0.69 
1.25 ±0.60 
 
2.60 ±1.19 
2.11 ±1.09 
 
2.33 ±1.18 
1.56 ±0.65 
0.000 a 
0.011 b 
0.011 c 
EPA (mg) 
  Intervention  
  Control  
 
73.0 ±45.8 
83.0 ±70.1 
 
474.0 ±173.6 
49.0 ±48.7 
 
428.2 ±140.0 
35.3 ±28.6 
0.000 a 
0.000 b 
0.000 c 
DHA (mg) 
  Intervention  
  Control  
 
144.0 ±120.1 
186.6 ±166.7 
 
775.1 ±296.2 
94.3 ±78.8 
 
675.7 ±239.8 
80.5 ±74.8 
0.000 a 
0.000 b 
0.000 c 
LCn-3 (mg)  
  Intervention 
  Control 
 
258.2 ±179.7 
313.4 ±248.9 
 
1339.6 ±503.0 
177.6 ±137.3 
 
1195.7 ±401.0 
146.3 ±119.2 
0.000 a 
0.000 b 
0.000 c 
Total n-3 (g)§  
  Intervention  
  Control 
 
1.59 ±0.67 
1.57 ±0.63 
 
3.94 ±1.55 
2.28 ±1.16 
 
3.53 ±1.48 
1.71 ±0.68 
0.000 a 
0.000 b 
0.000 c 
Total n-6 (g) 
  Intervention   
  Control 
 
13.08 ±5.62 
12.63 ±5.62 
 
12.94 ±4.52 
13.68 ±4.87 
 
14.25 ±5.18 
12.14 ±4.39 
0.695 a 
0.346 b 
0.484 c 
Values significant at P < 0.05; a significant differences observed over time, b significant differences 
observed between treatment group, c significant difference with time and treatment group. 
‡ SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated acids; LA, 
Linoleic acid, AA; Arachidonic acid; ALA, α –linolenic acid; EPA eicosapentaenoic acid; DHA, 
docosahexaenoic acid. § Includes ALA + EPA + DPA (Docosapentaenoic acid, 22:5 n-3) + DHA. 
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5.3.2 Relative Validity 
Energy reported using DH correlated significantly with that reported in the FR (r = 
0.55, P < 0.001) at baseline. Significant correlations were also found between the 
DH and FR for all macronutrients and fatty acids (with the exception of PUFA (%E) 
and n-6:n-3 ratio at baseline) at all time points, including protein (%E), 
carbohydrate (%E), fat (%E), SFA (%E), MUFA (%E) and PUFA (%E) as well as 
the P:S ratio, n-6 PUFA, n-3 and EPA + DHA. Correlation coefficients are listed in 
Table 5-4. 
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Table 5-4  Correlation coefficients of dietary variables using the diet history and 3-day food 
record 
 Baseline 3 month 6 month 
Total energy (kJ)   0.55** 0.70** 0.64* 
Carbohydrate (% E) 0.56** 0.55** 0.48** 
Protein (%E)  0.24* 0.34** 0.48** 
Alcohol (g)  0.71** 0.86** 0.71** 
Fibre (g) 0.49** 0.49** 0.42** 
Fat (% E)   0.50** 0.49** 0.38** 
SFA  (% E) ‡ 0.59** 0.35** 0.35** 
MUFA (% E) 0.36** 0.40** 0.29* 
PUFA (% E) 0.18 0.52** 0.33** 
PUFA:SFA ratio 0.60** 0.38** 0.32** 
n-6 (g) 0.40** 0.47** 0.22 
n-3 (g)  0.28** 0.65** 0.62** 
EPA + DHA (g)  0.35** 0.82** 0.71** 
n-6:n-3 ratio 0.13 0.68** 0.59** 
Pearson’s correlation coefficient; * P < 0.05; **P < 0.01. 
‡ SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated acids; 
EPA eicosapentaenoic acid; DHA, docosahexaenoic acid.  
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5.3.3 Underreporting 
Underreporting was more common in FR than DH. However, both methods 
reported plausible energy intakes when compared to the Goldberg cut-off at all 
time points (Table 5-5).   
Table 5-5  Group mean reporter EIrep:BMR and Goldberg cut-off as an indicator of under 
reporting 
Record Time-point (month) Group Mean EIrep:BMR Goldberg cut-off 
DH 0 1.84 1.52 
FR 0 1.60 1.50 
DH 3 1.89 1.52 
FR 3 1.65 1.50 
DH 6 1.83 1.52 
FR 6 1.57 1.50 
5.3.4 Bias 
No systematic bias was detected using Bland-Altman plots for all macronutrients 
and fatty acids, and at all time points. Only baseline data for total fat and LCn-3 are 
presented (Figures 5-1 & 5-2). The DH data compared well with FR as the mean 
difference between the two methods was close to zero for each variable, and the 
range for the limits of agreement lay within the acceptable values. Site differences 
for each dietary assessment method were determined and showed that BMI was 
significantly different between the sites at baseline (P = 0.024) and 3-months (P = 
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0.048). After adjusting for BMI, only site differences were observed for the 3-month 
assessment of total n-6 (P = 0.031) and total n-3 (P = 0.034) using the DH. 
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Figure 5-1  Bias of fat versus mean fat (g/day) intake at baseline 
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Figure 5-2  Bias of LCn-3 versus mean intake (mg/day) at baseline 
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5.3.5 Compliance 
Daily log books revealed the consumption of study foods decreased over time 
(Figure 5-3). There was no significance between the groups, with both groups 
consuming on average between 6 and 7.5 serves of enriched foods per day 
(~750mg – 940mg LCn-3 per day) 
 
Figure 5-3  Daily mean (± s.d.) number of study food serves consumed 
Values significant at P < 0.05; * significant differences observed over time, but not between groups 
using repeated measures ANOVA. 
5.3.6 Food pattern analysis 
Table 5-6 shows the contribution of different food groups to the overall LCn-3 
intake. After 6-months, the major sources of LCn-3 in the intervention group were 
enriched milk, cereal and bread. All other enriched products combined contributed 
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a further 28.2% of the total LCn-3. In contrast, the major sources of LCn-3 in the 
control group were fish (fatty and white) (approximately 1 serve per week) and 
meat. 
Table 5-6  Major food group contributors to overall LCn-3 intake (% contribution to total LCn-
3) 
Baseline (n = 86) 6-month (n = 74) 
Control Intervention Control Intervention 
Fatty fish (36.7%) Fatty fish (52.3%) Fatty fish (32.4%) Enriched milk (13.8%) 
Chicken (19.3%) Meat (12.6%) White fish (22.8%) Enriched cereal (12.1%) 
Meat (14.8%) White fish (12.1%) Meat (19.3%) Enriched bread (11.3%) 
   Fatty fish (9.9%) 
   Enriched biscuit (8.1%) 
   Enriched chocolate (7.5%) 
   Enriched dip (6.4%) 
   Enriched margarine (6.3%) 
Total - 70.8% 
LCn-3 intake – 0.3g/d 
Total - 77.0% 
LCn-3 intake – 0.3g/d 
Total - 74.5% 
LCn-3 intake – 0.1g/day 
Total – 75.4% 
LCn-3 intake – 1.2g/day 
5.3.7 Food preferences 
At the conclusion of the study, participants in the intervention group rated the oats 
and milk slightly favourable (1.4 and 0.5 respectively; items scored between -3 to 
+3) whereas they rated the bread as relatively unfavorable (0.3) which was 
significantly different (P < 0.05) from the control group (1.1). Apart from the salad 
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dressing, all other food items were rated as tasting favorable with no reported 
significant differences between the groups (Figure 5-4). 
 
Figure 5-4  Mean (± s.d.) taste ratings of study foods (scores ranged from unfavourable (-3) 
to favourable (+3)) 
5.3.8 Dietary Biomarkers 
There were significant increases in the proportions of EPA, DHA, LCn-3 and total 
n-3 in the intervention group by 96%, 79%, 59% and 25% respectively (Table 5-7). 
A significant difference in the proportion of n-6 between the groups was observed 
at 3-months, but not baseline or at 6-months.   
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Table 5-7  Plasma fatty acid biomarkers at each time point for each group (% total fatty 
acids)† 
 Baseline 3 months 6 months P-value 
LA‡ 
  Intervention (n=34) 
  Control (n=40) 
 
6.72 (1.37) 
6.98 (1.22) 
 
6.93 (0.732) 
7.24 (0.97) 
 
7.00 (0.71) 
7.27 (0.99) 
*0.058 
**0.144 
***0.951 
AA 
  Intervention (n=34) 
  Control (n=40) 
 
10.20 (4.61) 
11.64 (2.98) 
 
11.08 (2.89) 
12.24 (2.23) 
 
11.61 (2.33) 
11.49 (3.69) 
*0.254 
**0.138 
***0.162 
ALA 
  Intervention (n=28) 
  Control (n=31) 
 
0.390 (1.582) 
0.100 (0.030)
 
0.110 (0.026) 
0.111 (0.028)
 
0.111 (0.026) 
0.136 (0.076)
*0.429 
**0.305 
***0.278 
EPA 
  Intervention (n=35) 
  Control (n=40) 
 
0.594 (0.386) 
0.617 (0.240) 
 
0.984 (0.382) 
0.619 (0.176)
 
1.165 (0.338) 
0.683 (0.286)
*0.000 
**0.000 
***0.000 
DHA 
  Intervention (n=35) 
  Control (n=40) 
 
3.314 (1.339) 
4.109 (1.394)
 
5.058 (1.438) 
4.044 (0.913)
 
5.927 (1.178) 
3.921 (1.078)
*0.000 
**0.000 
***0.000 
LCn-3  
  Intervention (n=35) 
  Control (n=40) 
 
5.933 (2.185) 
6.824 (2.126)
 
8.339 (2.101) 
6.864 (1.418)
 
9.411 (1.870) 
6.708 (1.695)
*0.000 
**0.000 
***0.000 
Total n-3  
  Intervention (n=35) 
  Control (n=40) 
 
8.93 (4.85) 
8.64 (1.86) 
 
10.39 (2.60) 
8.70 (1.17) 
 
11.16 (1.81) 
8.45 (1.55) 
*0.022 
**0.001 
***0.007 
Total n-6  
  Intervention (n=35) 
  Control (n=40) 
 
20.76 (6.40) 
22.91 (4.86) 
 
21.96 (3.48) 
24.00 (3.24) 
 
22.15 (2.68) 
24.02 (4.39) 
*0.087 
**0.007 
***0.839 
† Mean (s.d.)  
‡LA, Linoleic acid, AA; Arachidonic acid; ALA, α – linolenic acid; EPA eicosapentaenoic acid; DHA, 
docosahexaenoic acid. *significant differences observed over time, ** significant differences 
observed between treatment groups, *** significant difference with time and treatment groups. Two-
way repeated-measures ANOVA.   
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5.3.9 Relationship between dietary intake and dietary biomarkers 
The correlation coefficients (r) between dietary intake as recorded by DH and 
erythrocyte membrane was significant at 3-months and 6-months for EPA, DHA, 
LCn-3 and total n-3 (Table 5-8). The correlation coefficients between the FR and 
erythrocyte membrane EPA, DHA and LCn-3 showed a similar trend, but weaker 
relationship. In addition the total n-3 was only correlated at 6-months and there 
was a small but significant correlation between dietary intake recorded by FR and 
erythrocyte membrane linoleic acid (LA) at 3-months. 
    
126   
Table 5-8  Pearson’s correlation between reported dietary intake and equivalent plasma fatty 
acid biomarkers† 
Variable  Baseline 3 months 6 months 
LA‡ 
  Diet history 
  Food record 
 
0.024 (0.825) 
-0.016 (0.883)
 
0.084 (0.445) 
0.335 (0.002)***
 
0.124 (0.328) 
0.080 (0.506) 
AA 
  Diet history 
  Food record 
 
0.110 (0.318) 
-0.001 (0.995)
 
0.172 (0.117) 
0.115 (0.308) 
 
0.070 (0.582) 
-0.097 (0.420) 
ALA 
  Diet history 
  Food record 
 
-0.052 (0.672) 
0.154 (0.203) 
 
0.022 (0.842) 
0.002 (0.985) 
 
0.036 (0.785) 
-0.041 (0.739) 
EPA 
  Diet history 
  Food record 
 
0.123 (0.259) 
-0.131 (0.228)
 
0.463 (0.000)*** 
0.374 (0.001)***
 
0.743 (0.000)*** 
0.555 (0.000)*** 
DHA 
  Diet history 
  Food record 
 
0.151 (0.166) 
0.095 (0.384) 
 
0.418 (0.000)*** 
0.288 (0.010)** 
 
0.663 (0.000)**** 
0.497 (0.000)*** 
LCn-3  
  Diet history 
  Food record 
 
0.101 (0.354) 
0.050 (0.645) 
 
0.421 (0.000)*** 
0.305 (0.006)***
 
0.641 (0.000)*** 
0.450 (0.000)*** 
Total n-3  
  Diet history 
  Food record 
 
-0.164 (0.132) 
-0.018 (0.871)
 
0.341 (0.001)** 
0.202 (0.720) 
 
0.515 (0.000)*** 
0.266 (0.240)* 
† Mean (s.d.). ‡LA, Linoleic acid, AA; Arachidonic acid; ALA, α – linolenic acid; EPA 
eicosapentaenoic acid; DHA, docosahexaenoic acid. * P < 0.05; **P < 0.01; ***P < 0.001 
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5.4 Discussion  
This study demonstrated that replacement of foods with n-3 enriched equivalent 
foods for 6 months significantly increased total n-3, LCn-3, EPA and DHA intake as 
verified by analysis of FR and DH completed by participants. These findings may 
be important as an increased n-3 fatty acid intake has been associated with a 
substantially reduced risk of death in subjects with existing coronary heart disease 
(CHD) (82, 108) and epidemiological evidence has demonstrated a reduced risk of 
CHD mortality in those who eat fish regularly (79, 95, 99, 100). With a large 
number of the population unable to consume enough of these essential fatty acids 
from fish alone (18), enriched processed foods may have positive public health 
implications. In addition to the total intake of LCn-3, the ratio of n-6:n-3 is also 
important as it may be associated with improved health outcomes (347, 356) 
whereas excess amounts of LA and associated eicosanoids may promote 
thrombosis and inflammation (160). This study showed a reduction of the ratio of n-
6:n-3 to 3:1 and increased the daily intake of n-3 in the intervention group. In 
addition there was no alteration of the PUFA, MUFA, SFA or the PUFA:SFA ratio 
which are also important when considering the overall dietary affect on heart health 
risk (14). 
Detailed analysis of the dietary data indicated a sense of confidence in these 
findings. Strong positive correlations were found between both measures of dietary 
intake for energy and major macronutrient intakes reported using DH and FR and 
within the range of coefficients found in other studies of similar-aged subjects (309, 
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357, 358). The weakest, although still significant, correlation was found in reported 
intakes of PUFA. It can be speculated that this weak correlation was due to over-
reporting of PUFA in the DH as this was a focal point of questioning. Subjects were 
asked specific questions about intakes of foods that were good sources of PUFA, 
and may have over-reported their intakes as they interpreted these to be healthy or 
desirable foods (359). Although significant correlations can suggest that two dietary 
assessment methods possess relative validity, there is still considerable 
unexplained error within each of the methods. Correlations are used to 
demonstrate the strength of association between two methods, but provide no 
guide as to the accuracy or precision of the methods (359). 
Both over- and underestimation has been reported in other studies (307). The level 
of underreporting in this study was considerably smaller than, or similar to, that 
found in previous studies (309, 314, 315, 357, 360-362). The proportion of under-
reporters was considerably less in the DH than the FR, indicating that the DH is a 
better method of estimating energy intake in this study population. Under-
consumption may be more likely than underreporting in the FR, since recording all 
food consumed for more than one day is known to modify behaviour to reduce 
intake (307). However, while some studies show that the DH over-estimates intake 
relative to the FR, others have shown using metabolic studies that both the DH and 
the FR underestimated intake (313). Rothenberg et al (1998) showed that energy 
expenditure reported in activity diaries matches energy intake reported in DH, but 
doubly labeled water tests concluded that both must have been underreported 
(363). This may explain why we observed a significant weight gain over the study 
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period with no apparent increase in reported energy intake. Both methods may 
have overestimated intake of LCn-3. A dose response study into EPA + DHA 
intake and subsequent rises in erythrocyte fatty acids found that this index rose 
from 4.7 ± 0.9% to 7.9 ± 1.7% with supplementation of 0.5g/day (P < 0.001), to 9.9 
± 2.9% with 1g/day (P < 0.001), and 11.6 ± 2.4% with 2g/day (P = 0.02) (9). Based 
on the estimated dietary intake of 1.2g/day an expected increase in erythrocyte 
fatty acid level of > 8% would be expected, whereas an increase of 7.1 ± 1.9% was 
reported. Results from the food logs also suggest that the intake of LCn-3 may 
have been lower. 
There are other components of error relevant to the DH and FR in an intervention 
trial in addition to under-reporting. These include random error, error in portion size 
estimates and method-related bias resulting in consistent over- or under-
representations (359). Method-related bias was addressed using Bland-Altman 
plots. No systematic bias was found in this study, indicating that any misreporting 
was random in nature and does not indicate specific error in reporting of 
macronutrients in the DH relative to the FR. This may in part be attributed to 
standard study food portion sizes as well as using well-trained research dietitians 
to collect the data. In addition, apart from n-6 and n-3 intake at 3-months, there 
were no significant differences between the sites in reported intake using the DH 
after adjusting for BMI. Others have reported that the diet history is subject to 
observer bias, with the bias appears to be macronutrient specific with energy, fat 
and SFA consistently underreported (310). 
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The question of validity can be addressed by comparing both dietary assessment 
methods to fatty acids accumulated in the erythrocytes. The correlation between 
the dietary intakes measured by DH of EPA, DHA, LCn-3 and Total n-3 and the 
equivalent erythrocyte fatty acid was stronger that that observed using the FR. This 
relationship ranged from 0.34-0.46 at 3-months to 0.52-0.74 at 6-months for the 
DH and 0.29-0.37 at 3-months to 0.27-0.55 at 6-months for the DH. This is the first 
study to investigate the relationship of the DH with erythrocyte fatty acids. Parra et 
al (2000) exploring the relationship between FFQ and usual dietary patterns in 
Mexican women reported modest correlations with erythrocyte ALA, DHA and EPA 
against their dietary counterparts (r = 0.32, 0.35 and 0.36 respectively) (322). 
Others have investigated the relationship between FR and serum fatty acids for 
LCn-3 with reported correlations of between 0.49-0.75 (364, 365), and between 
FFQ and serum fatty acids for LCn-3 (r = 0.49-0.51) (366, 367). Results at 3 and 6-
months are comparable with these studies; however no significant correlations at 
baseline were found. Study design and population characteristics may explain 
these differences. Anderson et al, reported strong correlations on LCn-3 at 
baseline using a larger sample than ours (n = 579) men and women (365), 
whereas cross sectional studies reporting strong correlations were conducted in 
Japan where fish intake is habitually high (364, 366, 367). In this study, baseline 
habitual intake of LCn-3 (~200mg/day) was not correlated to the equivalent 
erythrocyte fatty acid, however once the LCn-3 enriched study foods were added to 
the diet this relationship emerged. Finally, there is an apparent anomalous 
correlation with LA to the equivalent fatty acid in the erythrocyte membrane at 3-
months as reported by the FR which may be explained by the difference in dietary 
    
131   
assessment methods or a statistical artifact. Interestingly, this result was mirrored 
by an equally anomalous absence of correlation for total n-3 using the same 
assessment method at the same time point. It is important to be aware that the 
biochemical marker used can be confounded by the fact that they reflect relative 
percentage and not absolute amounts (322). The method of collection, sampling 
site and analytical technique may also influence the results (322).  
Through the consumption of enriched novel foods an increase in EPA + DHA 
levels from 4.09% at baseline to 7.10% was observed. Harris and von Shacky 
propose that a combined EPA + DHA level of ≥ 8% is associated with the greatest 
cardioprotection, compared to ≤4% (9). However, an unintended negative impact of 
this study was the increase in body weight in the intervention group. Weight gain 
has the potential to worsen all elements of the cardiovascular risk profile, including 
blood pressure, dyslipidemia, glucose tolerance, left-ventricular hypertrophy, 
hyperuricaemia, and fibrinogen levels (368). As the design of this study was to 
simply replace food items in an ad libitum fashion, ‘whole of diet’ advice was not 
provided upfront, and only discussed once any weight gain was detected. A whole 
of diet approach considers advice of the number of portions of all food groups and 
may be necessary to ensure energy balance as well as controlling for the 
background diet in supplemental studies (369). The finding reinforces the need for 
caloric consideration in the design of novel foods as well as education about how 
the whole diet may emerge when such foods are incorporated.  
This study also provides an insight into how consumers may use novel enriched 
foods. Although providing a wide range of food products, we found that staple 
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foods such as milk, cereal and bread were the most significant contributors to the 
overall LCn-3 intake in the intervention group. This finding is consistent with 
qualitative research suggesting that consumers prefer staple foods as potential 
vectors for this functional ingredient (370). Of particular note was the finding that 
participants in the intervention group rated the taste of the bread as being 
unfavourable, with comments suggesting that it tasted ‘fishy’. Despite this, the 
enriched bread was the third most significant contributor to the increase in LCn-3 
intake and suggests that improving the taste of this product has the potential for it 
to be an important vector for delivery of LCn-3.  
In conclusion, the dietary intakes of LCn-3 were significantly increased, reaching 
recommended targets (145), through the use of enriched novel foods in overweight 
subjects. The validity of the dietary data was confirmed; however unintended 
weight gain has the potential to nullify any positive cardiovascular benefits of an 
increase in dietary LCn-3. The ability to extrapolate results from these studies to a 
population approach is limited by the controlled nature of the study design. 
Therefore, the compliance levels observed in this study may not be achieved 
outside of the confines of such a controlled environment highlighting the need to 
study consumer behaviour. Therefore, an investigation into consumer beliefs and 
attitudes about n-3 functional foods will be presented.  
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CHAPTER 6  
 
CONSUMER BELIEFS ABOUT FUNCTIONAL FOODS INFLUENCE UPTAKE6 
6.1 Introduction 
For n-3 functional foods to be effective in the primary prevention of CHD 
widespread consumer acceptance and dietary inclusion would be required. To date 
the understanding of consumer beliefs and attitudes towards this concept has 
received very little research effort. This is confounded by the fact that there is no 
universally accepted definition for functional foods and they seem to fall into a grey 
area, somewhere between foods and medicines, with the precise boundaries on 
either side far from clear (371). From the viewpoint of nutrition education, the 
functional food category does not fit straightforwardly into any of the long-
established food educational models and there are concerns relating to consumer 
acceptability and perception (25). With evidence showing that food choice affects 
dietary quality as measured by intake (372, 373), it seems appropriate that greater 
                                             
6
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attention be given to the factors that facilitate or constrain the use of functional 
foods.  
The field of behavioural psychology suggests that the best predictor of human 
behaviour is a person’s conscious decision to perform the behaviour. The Theory 
of Planned Behaviour (TPB) provides a model that can help explain consumers’ 
purchase intentions to use functional food products. A person’s behavioural 
intention is determined by the attitude they hold towards the behaviour, the degree 
of social pressure felt by the person to perform or not perform the behaviour, and 
the degree of control that the person feels they have over performing the behaviour 
(19). These three factors in turn are determined by a number of beliefs and 
subsequently how each is evaluated. It has been demonstrated that the TPB, or 
modified versions of it, is applicable in explaining consumers’ food choice (20-22), 
including supplement use (23) and genetically modified products purchasing (24). 
However, to date this model has not been applied to understanding consumer 
behaviour regarding the use of functional food products. 
Focus groups can be used to access a diverse range of opinions and viewpoints 
and determine salient beliefs. These may then be tested on a larger sample in 
quantitative surveys to access their generalisability. A focus group discussion is 
defined as “a carefully planned discussion designed to obtain perceptions on a 
defined area of interest in a permissive, non threatening environment” (329). This 
approach is suggested by Ajzen & Fishbein (1980) as the method of choice to 
determine salient beliefs about the topic area of interest (19.). In the present study, 
the utility of the method was strengthened by focusing on specific products rather 
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than investigating functional food products in general (19.). In addition, consumers’ 
attitude toward functional food could be expected to be influenced by general 
attitudes such as attitude toward technology or food neophobia (374), beliefs about 
the production process, perceived healthiness (288) and beliefs about the quality of 
the resulting product. This is particularly relevant as the range of n-3 functional 
foods entering the market place is increasing. 
The aim of this study was to gain an understanding of the salient beliefs underlying 
Australian consumer attitudes and purchase intentions with regard to n-3 enriched 
functional foods. Using focus group discussions, consumer beliefs and attitudes 
were determined for the purpose of developing a survey instrument to test the 
generalisability of these opinions in a larger population sample.  
6.2 Methods 
Focus group interviews examining salient beliefs and attitudes regarding functional 
foods were conducted with a cross-section of adult consumers in the Illawarra 
region of New South Wales (NSW), Australia. Compared to the NSW average, the 
population residing in the Illawarra is more socially disadvantaged and 
hospitalisation rates from coronary heart diseases in the Illawarra were 20% higher 
in men and 14% higher in women than the state average in 2001 (375). The study 
employed a qualitative research design, with overweight participants recruited via 
media release (Appendix L). This group reflects a potential target population for 
functional foods enriched with n-3 due to their likelihood having a high 
cardiovascular risk. 
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6.2.1 Participants 
Participants were recruited through general advertising in local media. Fifty 
potential participants expressed interest in the study and all were invited to attend 
one of six focus group discussions. An information sheet and a consent form were 
mailed to each potential participant. Each participant was offered a small payment 
(AUS$20) to offset any inconvenience that might have resulted from involvement in 
the study. Approval for the conduct of the study was provided by the University of 
Wollongong / Illawarra Area Health Service Human Research Ethics Committee 
(Appendix M). 
6.2.2 Focus group procedure 
The focus groups were conducted between July and August 2002. All groups were 
conducted in a community centre located in the Illawarra region. Focus groups 
were audio taped and later transcribed to allow systematic analysis of the 
discussion. Each focus group ran for approximately one hour and was conducted 
by a moderator and an observer. To ensure consistency between the groups the 
same trained moderator ran each group and all groups were monitored by an 
independent observer for quality assurance purposes (329). An interview guide 
was developed by the research team (CP, LT, PW) following the general guidelines 
provided by Krueger (1994) (329). Using the TPB theoretical framework, 10 
questions were devised to determine consumer awareness, beliefs, attitude and 
barriers to using n-3 fatty acid functional foods (Figure 6-1). The question guide 
was pre-tested using undergraduate nutrition students and reviewed by the 
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research team. At the beginning of each session instructions were provided to the 
group, the purpose of the interviews was outlined and it was emphasised that there 
were no right or wrong answers. During the sessions, participants were 
encouraged to speak until no more views were expressed, and then the moderator 
probed and clarified points. In short, probes were primarily used to encourage 
participants to clarify meanings or explain points of incongruence in their answers. 
To introduce the concept of functional food, sample products were provided as 
prompts for discussion (Questions 1 – 5)-, Flora’s Pro-activ® and Meadow Lea’s 
Logicol™ (margarines with added plant sterols), Yakult’s fermented milk drink (a 
probiotic beverage) and Buttercup’s Wonder White® bread (with high-amylose 
resistant starch). Specific n-3 enriched food products were used as prompts for 
discussion (Questions 6 – 10) - Tip Top’s Up™ bread and Meadow Lea’s Hi 
Omega® margarine (both enriched with n-3 fatty acids).  
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1. Have you seen these foods and what do you think of them? [Probe: Has anyone used them and 
why? If no one has, do you know anyone who has? Do you think they are useful and necessary?] 
2. What do you see as the difference between these foods today and the foods of yesteryear? 
[Probe: Do you think we should be going back to foods with fewer additives or less technology?] 
 
3. Do you think you can improve your health by choosing foods with health benefits? Why? 
 
4. How would you decide if you were going to use these products?  
[Probe: Would you be influenced by other people’s view –professional, family, and friends?] 
 
5. Why wouldn’t you use these products? 
[Probe: Cost factors, availability in supermarket] 
 
6. What do you think about this new margarine/bread (Meadow Lea n-3 and Tip Top Up)? 
[Probe: Who do you think should use this?] 
 
7. What health conditions should we be designing new foods for? 
[Probe: Would it be better to add these health-promoting ingredients to food or make them into a 
supplement? Have you taken supplements before?] 
 
8. We all buy food for lots of different reasons; do you specifically buy foods for your health? Why? 
[Probe: increase performance, reduce cholesterol, bowel health] 
 
9. Do you believe what you read on the labels about the products? 
[Probe: Do you think they will do what they claim to do? What else would help convince you that 
they really work?] 
 
10. If you were convinced that they work would you still buy these products? 
[Probe: explore the ‘it depends’ issues] 
Figure 6-1  Moderator question guide for salient beliefs focus groups 
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6.2.3 Data Analysis 
Each focus group discussion was tape-recorded and transcribed, producing on 
average 30 pages of transcript. A computer software package for qualitative 
research analysis, NVivo 2.0 (2002, QSR International Pty Ltd), was used for data 
management and coding (334). Using the TPB model, transcribed conversation 
was categorised into one of the three areas of belief related to behaviour: 
behavioural beliefs, which are assumed to influence attitudes toward the 
behaviour; normative beliefs, which constitute the underlying determinants of 
subjective norms; and control beliefs, which provide the basis for perceptions of 
behavioural control. Content analysis was carried out and sub-categories were 
developed to capture the emerging themes. An iterative process of 
subcategorisation was conducted as suggested by Knodel (1993) (376). After the 
preliminary analysis by a single coder, two other members of the research team 
assessed the categorisation of conversation as well as the content of each 
category and sub-category. All three members of the team discussed areas of 
disagreement and a consensus was reached. Because the purpose of this study 
was exploratory, with an aim to elicit salient beliefs about functional foods, 
quantification (e.g. frequency counts) was not undertaken; rather, examples from 
the discourse are presented to illustrate the interpretive frames that emerged, 
along with the corresponding themes (377). 
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6.3 Results/Discussion 
Of the 109 people who responded to media advertisements 50 agreed to attend a 
focus group; however 8 people failed to attend on the day leaving a final number of 
42. Of those who originally expressed interest and subsequently declined to 
participate, the major reason cited was that they expected to be involved in a 
dietary intervention trial. Six focus groups were scheduled and conducted at the 
same venue. Each focus group included between 6-9 participants and lasted 
between 50 and 80 minutes. The mean age of participants was 48 years with the 
majority being female (65%). Fifty seven percent of participants were married, 27% 
single and 16% living in a live in relationship. Group characteristics are shown in 
Table 6-1. 
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Table 6-1  Focus group characteristics 
 Focus group number  
 1 2 3 4 5 6 Total 
Number of participants 9 9 6 7 6 5 42 
Gender (n) 
  Males 
  Females 
 
6 
3 
 
0 
9 
 
2 
4 
 
2 
5 
 
3 
3 
 
0 
5 
 
13 
29 
Age (years) 49 42 47 50 51 51 48 (Mean) 
Marital status (n) 
  Single 
  Live in relationship 
  Married 
 
2 
2 
5 
 
3 
2 
4 
 
3 
0 
3 
 
2 
0 
5 
 
0 
2 
4 
 
1 
0 
4 
 
11 
6 
25 
Focus group duration (min) 50 80 60 65 60 55 - 
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6.3.1 Salient Behavioural beliefs  
Table 6-2  Categories of salient behavioural beliefs related to the use of n-3 enriched 
functional foods 
May be at risk of 
overexposure or 
inadequate intake of a 
nutrient 
If they’re putting in enough to be beneficial [n-3], you could get to a 
point where you are taking too much…particularly if it’s being put into 
nearly every food or if you can never get to a stage where you are 
taking too much, therefore they are not putting in enough to be 
useful. 
Group 1, F 
 I take my own supplements and that way I would know how much I 
am taking. I am not having my food doctored up and not knowing 
exactly the levels I am taking. 
Group 1, F 
Category Sample Quote Speaker 
Provide long term 
health benefits 
But do you think, if we started eating healthy, things like this [omega 
enriched bread], as young as [name] is, then it would make a 
difference over time, instead of starting when you’re older!  
Group3, F 
Help to manage 
chronic disease 
I’ve got heart disease and n-3 oil is good if you have heart disease. Group 1, F 
 Well as you get older the fish oil definitely helps your arthritis. In a lot 
of people the fish oil helps arthritis. 
Group3, M 
 Because I heard it’s good for asthma, arthritis…It’s for a whole range 
[of conditions] not just for lowering cholesterol.  So I am pretty happy 
that these are on the market now that I can give to him. 
Group 2, F 
 Well I know that it’s a very good brain food and it keeps us 
functioning and the brain needs n-3. But also possibly, people that 
suffer or a suffering from Alzheimer’s. 
Group 4, M 
Otherwise deliver the 
health benefits of fish 
Because of the fact that I’ve got two boys that won’t eat tuna - one of 
them will eat a bit of fish - and this is a way of supplementing that 
then [yeah]. 
Group 4, F 
Have an advantage 
over supplement  
Put it this way, I would rather not take it in tablets whatsoever, I’d 
rather not take any stuff like that in tablets, my wife does, but none of 
my children [do]. 
 
Group 5, F  
May undermine the 
concept of a healthy 
diet 
But we get two different messages. We get a message that everyone 
should be eating a balanced diet and exercise and the other 
message were getting is, hey, you don’t need to, [because you can 
take this instead] yeah, because you can take this instead.  So many 
people won’t eat a balanced diet.  
Group 3, F 
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Categories of statements displaying behavioural beliefs, or outcomes beliefs 
relating to using n-3 enriched foods, are outlined in Table 6-2. Most participants 
indicated they believed that n-3 fats were good for them, often describing them as 
being good for general health. In addition, there was strong agreement that most 
people, from children to the elderly, could gain health benefits from including more 
n-3 fats in the diet. When participants were asked about their beliefs about eating a 
diet high in n-3 (or foods high in n-3 or foods enriched with n-3) a most prevalent 
view was that they had a role in the prevention and treatment of heart and vascular 
disease. There was confusion about the mechanism of action, with a number of 
participants stating that n-3 fatty acids were important in lowering cholesterol; 
however this did not detract from the believed importance of this nutrient in the 
diet. In addition a number of participants were strong advocates of the benefits in 
ameliorating inflammatory diseases, most notably arthritis. The importance of n-3 
fatty acids in improving visual function and asthma was a belief held by relatively 
few participants. There was a belief expressed by some individuals that n-3 fatty 
acids had both a brain health promoting role, as well as a therapeutic role in the 
treatment of Alzheimer’s disease.   
There was a commonly expressed view that the health benefits of dietary n-3 fats 
were only achievable when they were included in the diet over a long period of 
time. However, there was also a prevailing belief that the ongoing use of these 
products was largely determined by how effective these products were for the 
individual; that is, did they alleviate symptoms or make the individual feel better 
and did these benefits take long to be observed? Many people expressed the view 
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that functional foods enriched with marine n-3 fatty acids were a good way of 
delivering this nutrient in the diet, particularly as an alternative to fish, and more 
specifically, a fish alternative for children. In general, participants saw functional 
foods as a logical dietary option (e.g. fibre is good for you and children prefer white 
bread, therefore white high fibre bread is a sensible innovation). Also, these foods 
were seen to overcome other barriers to good nutrition such as access to fresh fish 
products.  
Research in the US has suggested that CHD remains the largest health concern 
for consumers. Moreover, after CHD, Americans were concerned with eyesight, 
cancer and joint pain (378). Research has shown positive associations with beliefs 
about n-3 intakes and all of these health concerns (123, 379-381). These results 
reflect this, with participants acknowledging the wide range of health benefits of n-3 
fatty acids. Despite this, participants still demonstrated some reservation over 
whether these health benefits could be extrapolated to novel foods enriched with 
this ingredient.   
Some participants raised the concern that n-3 enriched functional foods may not 
contain enough of the functional ingredient to be effective and the dosage would 
need to be clearly stated for use. This was the reason that supplements had 
greater appeal for some over functional foods. However, the opposite was 
apparent when considering the nutritional needs of children. Functional foods were 
seen as a more practical and appropriate option than supplements for children and 
adolescents and the elderly, a finding that has also been reported elsewhere (382).   
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From the literature it is known that companies selling functional food products and 
nutritional supplements share a similar market place and therefore compete for 
market share. Reports have indicated that the market for ‘natural’ or ‘organic’ 
produced foods equals the growth of functional foods and may exceed it when 
there is a reported food scare (383). It is also known that the perceived 
wholesomeness of the overall product is also an important factor in food purchase 
behaviour (384). Previous research into health behaviours shows that consumers 
regard “healthy” eating as eating natural foods and “unhealthy” eating in terms of 
eating manufactured or processed food (384) and our study suggests this may also 
be the case when considering functional foods. Participants indicated that foods 
that were not perceived as being healthy (e.g. chocolate or soft drink) were 
regarded as less acceptable carriers for n-3 fatty acids despite acknowledging the 
logical argument for the contrary – a finding which has been reported elsewhere 
(382).  
Overall this data showed a strong support for the concept of functional food 
products as a convenient and logical way to achieve a healthy diet. Some 
participants expressed concerns that functional foods had the potential to 
undermine a person’s ability to achieve a healthy diet by creating confusion about 
what constitutes a healthy food and that a total diet approach was preferred. 
Concerns were also raised about the risk of overexposure of active ingredients. For 
example, if recommended daily doses were provided in a typical number of daily 
serves, an excessive intake of the food may lead to overexposure and potentially 
undesirable side effects. Overall though, functional foods were viewed as an 
    
147   
important part of a total diet approach by providing consumers with more healthy 
food options.   
6.3.2 Salient Normative beliefs 
Table 6-3  Categories of salient normative beliefs related to the use of n-3 enriched 
functional foods 
Table 6-3 outlines the major normative beliefs affecting the use of n-3 fatty acid 
enriched functional foods as expressed by participants. Communication between 
family members was important in spreading the word about new or novel foods 
entering the market. Furthermore, the incorporation of these foods into the diet 
depended on overall acceptance by the family unit. Similarly the opinions 
Category Sample Quote Speaker 
Normative beliefs 
generated with reference 
to: 
  
Family members With different products, we just see if it’s one the family 
will like 
Group 4, F 
Friends It’s my best mate that told me about fish oil for arthritis. Group 3, M 
Medical practitioner If a doctor or medical person said that it would improve 
my health, I’d have a serious look at it.  But advertising 
[by] itself wouldn’t influence me. 
Group 1, F 
Nutritionist It’s not just these people [food industry] making the claim, 
it’s the nutritionists and all that across the country and 
across the world are making the same claim. 
Group 2, F 
Scientists 
 
And the other thing too is who did the research?  
Because if they do their own research it doesn’t mean 
that it’s honest. 
Group 5, F 
Food Industry 
 
There are lots of loopholes in the labelling of foods they 
[Food industry] can get around the legislation. 
Group 5, F 
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expressed by friends appeared to be an important factor in at least exposing 
consumers to novel food products. Medical and health professional opinion was 
also an important factor in influencing participants’ behaviour in using functional 
foods as a part of an overall health strategy, with nutritionists being regarded as an 
independent credible source of information. Participants considered the 
independence of health professional advice as being very important along with a 
proven scientific basis to the claims, even though they found it difficult to interpret 
and evaluate scientific results. There was a general belief that scientists and 
scientific evidence was inconsistent, confusing and probably biased. These beliefs 
were amplified when related to functional food products and industry-sponsored 
research. In general participants were very skeptical of advertising campaigns as a 
result of being more informed and less inclined to be coerced into purchasing. 
Also, there was apparent distrust of labelling and the legislation controlling claims 
on food packages. 
The normative influences on participants’ use of functional foods such as family, 
friends, food companies, health professionals and scientists revealed in our study 
are consistent with the results of other studies that have investigated other more 
general health related behaviours (23). The high level of trust in the opinion of 
nutritionists compared to scientists and medical practitioners, when it came to 
matters of nutrition, was of interest. The major factor contributing to this view was 
their perceived level of independence. Conversely, food companies and their 
advertising were not valued very highly. However, there was acknowledgement of 
the need to inform the market of new food innovations through advertising. 
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Participants place trust in family and friends and their advice affects willingness to 
try a new product. 
6.3.3 Salient Control beliefs 
Table 6-4  Categories of salient control beliefs related to the use of n-3 enriched functional 
foods 
Category Sample Quote Speaker 
Salient control beliefs 
based on perceptions of: 
  
Availability at the 
supermarket and lack of 
control over purchasing 
I do most of my shopping at Woolies or Coles, 
and if it’s not there I’m not going to buy it am I! 
Group 3, M 
Taste/Texture No! [I would not eat these products] because of 
my fish hate, I’d be turned off [laughter] 
Supposing I didn’t have that fish taste maybe yes 
I’d buy it. 
Group 1, F 
Lack of clarity in dosage 
and effect 
I’d like to know the difference.  If I was going to 
start taking some n-3 tablets…I want to know 
what my benefits are going to be.  If I don’t feel 
any different next week, how long will it take? 
Group 5, F 
Lack of time to read labels I honestly don’t have time to get there and read 
labels and decipher all this stuff as you say and 
every time you buy a product… 
Group 1, F 
Cost …a discussion came up about them [functional 
foods] at work day, and one of the comments was 
the cost, because they are expensive and a lot of 
people because of their financial situation have to 
take that into consideration [mmm]…I think with 
the food supply that if it is generally proved to do 
what they claim then the next avenue to go would 
be to lower them down to everybody’s reach.  If 
that’s their claim, that they’re doing it not for profit 
or only partially for profit and for the good of 
peoples health and the average family, they 
should lower it down to everybody’s reach 
Group 1, M 
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Stated control beliefs, or factors out of the control of participants that could be 
barriers to the purchase of functional foods, are listed in Table 6-4. It has been 
shown that socially disadvantaged families disproportionately live in areas where 
there are fewer large supermarkets (385). Other food outlets typically stock a 
limited range of foods where prices are higher thus limiting access to functional 
foods (385). However, there was little evidence that this is a real concern held by 
the participants. Likewise, lack of control over purchasing is another potential 
barrier, but only minor reference was made to this as a legitimate concern for 
individuals within the groups. Taste and texture was fundamentally important to all 
food purchasers. There was no evidence to suggest that participants would trade 
taste for health and they expressed the view that if the tastes weren’t at least equal 
to comparable products then they would not buy them, which is consistent with 
many studies investigating dietary habits (386). Some participants expressed the 
view that a major barrier that prevented them from purchasing functional food 
products was the fact that they had little time during shopping to decipher the 
positive and negative attributes of various products and to determine the 
appropriate place for them within their own diet. Of all the discussion areas, cost of 
products generated the most discussion as well as consistent attitudes. Most 
participants believed that foods promoted as having health benefits cost more. This 
cost was not always seen as worth the investment, particularly if the health claims 
were not believed or ambiguous. 
As an adjunct to the TPB model utilised in this analysis, participants’ views about 
which were the potential products that could best be used as carriers of n-3 fatty 
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acids were also investigated. The responses were consistent, with participants 
framing the importance of the wholesomeness of the products as an important 
factor. Also, participants felt that is was better for everyday products such as milk, 
bread, margarine and yoghurt to be the carriers of this functional ingredient, 
although participants also expressed the belief that snack and occasional foods 
would also be appropriate carriers of functional food ingredients. Further probing 
revealed that although this may be logical (people don’t eat enough n-3 fat but 
people drink diet coke, therefore the addition of n-3 fatty acids in diet coke is 
logical), overall participants were suspicious of this strategy and viewed it as a 
gimmick, rather than a legitimate health proposition. Participants believed that the 
overall health proposition of the functional foods should be consistent with other 
health messages, i.e. low fat, low salt, low sugar. 
6.3.4 General beliefs about functional foods 
There was no evidence of negative salient beliefs related to healthiness of 
functional foods, which was surprising. Compared to conventional foods, functional 
foods are often processed with a relatively high degree of technological 
manipulation, which has parallels with the manufacturing of genetically modified 
(GM) foods. Attitudinal studies into consumer views of GM foods have indicated 
that this is a factor attributable to the general resistance to use of these products 
(387). Furthermore interactions between enrichments and product types of 
functional foods were found to be important determinants of consumers’ 
perceptions of the healthiness in a cross-national study of Danish, Finnish and 
American consumers (288). The authors of that study described prevailing cultural 
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values of ‘mastery’ or ‘harmony’ that help to explain these attitudes (288). People 
or cultural values that can be described as high in mastery emphasise active 
mastery of the social and natural environment through self-assertion. These people 
tend to view functional foods positively (288). On the other hand, ‘harmony’ refers 
to values that co-exist with nature and deference of the technological manipulation 
of natural resources, therefore would most likely oppose the use of functional 
foods. It is possible that participants in our study were not aware of the level of 
technical manipulation involved in the development of these products – as there 
was national media coverage from the market release of several n-3 enriched 
products in Australia preceding the interviews which may have attributed to an 
understanding and acceptance of the concept– or that Australians in general (or at 
least those that self selected for focus group interviews) have a value system that 
can be described as high in ‘mastery’. 
In the past food purchasing behaviour has formed the focus of many promotion 
and health education campaigns with the aim of improving food and nutrient 
intakes (388). With the emergence of functional foods there is a need to develop 
education campaigns and design behaviour change models to ensure that those 
segments of the population who can benefit the most from these novel products 
actually use them (389). To this end understanding consumer beliefs and attitudes 
toward functional foods is critical to both commercial success and achieving 
positive health outcomes from the introduction of enriched functional foods. 
However, more targeted research is required, as these results alone provide 
limited value in guiding education and marketing disciplines alike. In this study we 
    
153   
uncovered the salient beliefs in relation to n-3 enriched functional foods from a self-
select Australian sample and therefore caution is required in interpreting these 
results. The nature of this focus group study was exploratory and these results 
were next used to expand on the TPB theoretical model to help examine consumer 
behaviour in relation to the use of n-3 enriched products. These salient beliefs 
formed the basis for question development for a quantitative survey tool which was 
used in the following study.  
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CHAPTER 7  
 
ATTITUDES AND INTENTIONS TOWARDS PURCHASING FUNTIONAL FOODS 
PREDICT UPTAKE7 
7.1 Introduction 
Although understanding consumer beliefs and attitudes provides interesting 
insights, it is the ability to predict purchasing behaviour that will ultimately assist in 
the promotion of this primary prevention strategy. Functional food products are 
distributed through traditional food markets and to be effective must first be 
purchased, and then incorporated into an individual’s eating pattern. This presents 
unique challenges to health educators when considering the ability and potential of 
functional foods to deliver population health benefits. Efforts to increase intake 
depend, in part, on understanding the factors determining selection and intake. 
With this knowledge health promotion strategies can be targeted to maximise their 
effectiveness. 
                                             
7A significant portion of this chapter is about to be published in the following peer reviewed journal: 
Patch CS, Tapsell LC, Williams PG. (In press) Attitudes and intentions towards purchasing novel foods enriched with omega-
3 fatty acids. Journal of Nutrition Education & Behavior. 2005. 
CP was responsible for the design of the study, organisation and leading the study, data collection and analysis, critical 
discussion of the analysis and preparation of the manuscript. LT and PW were responsible for critical discussions of the 
study design, critical discussions of the analysis and preparation of the manuscript. 
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The reasons for consuming functional foods are likely to be multifactorial, with a 
combination of social, psychological, knowledge based and economic factors. 
Earlier market segmentation studies in the US described the average functional 
food user to be female, well educated, with a higher income, aged between 35-55 
years old and actively interested in health as a result of illness (390). More 
recently, Bech-Larsen and Grunert (2003) examined attitudes relating to perceived 
healthiness of functional foods across different cultures (288). They found that 
different processing methods, the use of different health claims, types of 
enrichments and types of products were determinants of consumers’ acceptance of 
functional foods. Some studies have investigated demographic characteristics of 
users and non-users, however, they note that characteristics are specific to the 
functional food under study (391). Overall, research into factors that determine 
choice of functional food is limited and no studies to date have investigated the 
specific factors affecting the use of foods enriched with n-3 fatty acids.   
One model that has been used to explain health related behavior in the past is the 
Theory of Planned Behavior (TPB) (19). It has been applied to food-related 
behaviors such as supplement use (23), genetically modified foods (387), dairy 
product intake (326) and organic vegetable consumption (392). According to the 
theory, behavior is directly predicated by intention to perform this behavior, as well 
as control factors, when behavior is not under complete volitional control. Intention 
in turn is determined by attitudes (A) toward the behavior, subjective norms (SN) 
and perceived control over the behavior (PBC). Intention can be viewed as the 
conscious plan to carry out a particular behavior and the motivation to perform it. 
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Each of these determinants is formed from a set of referent beliefs. Attitudes are 
determined by a behavioural belief about performing a particular behavior. This is 
the combination of strength of the belief (BS) combined with the belief that 
performing a particular behavior will result in the outcome (OE). Also, Subjective 
Norm is determined by the social pressure and beliefs held by significant others, or 
normative beliefs (NB), combined with the motivation of the individual to comply 
with this pressure (MC). Perceived behavioural control is determined by the 
likelihood of various factors outside of direct control to facilitate or inhibit a certain 
behavior. Therefore, a person who has a positive attitude toward a behavior, 
perceives social pressure to perform the behavior and believes that they have 
control over their decision to perform the behavior is more likely to carry out that 
behavior. The aim of this study was to identify the nature, strength and relative 
importance of influences on intention to purchase foods that are enriched with n-3. 
7.2 Methods 
7.2.1 Questionnaire development 
Survey questions were developed using results obtained from focus group 
interviews, as recommended by Ajzen & Fishbein (1980) (19). The details of those 
interviews are described in Chapter 6 (370). Each focus group was tape-recorded, 
transcribed and content analysed using NVivo 2.0 (2002, QSR International Pty 
LTD). Sub-categories were developed to capture emerging themes. These formed 
the basis of the questions used in the questionnaire. A draft of the questionnaire 
was pre-tested on 10 subjects who were representative of the study sample. 
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Comments attained resulted in minor changes being made to the final 
questionnaire (Appendix N). Example foods enriched with n-3 fatty acids were 
included in the instructions on filling out the questionnaire. 
Behaviour (B) - Use of foods enriched with n-3 was assessed 2 weeks after 
implementation of the questionnaire. A question was asked: Did you eat any of the 
following foods high in n-3 over the previous 2 weeks (canola margarine, enriched 
bread, milk, enriched eggs, enriched bread etc)? 
Intention (I) - The dependent variable was measured by a global question using a 
seven point bipolar differential scale as suggested by Ajzen and Fishbein (1980) 
(19). Respondents could choose extremely unlikely, quite unlikely, slightly unlikely, 
neither, slightly likely, quite likely or extremely likely (+3 to -3) to the statement: I 
intend to eat one or more foods with added omega-3 oils over the next two weeks. 
Attitude (A) - The independent variable, attitude, was also directly measured by a 
global question using a seven point bipolar differential scale. Respondents could 
choose favourable to unfavourable (+3 to -3) responses to the statement: Overall, 
my attitude toward my eating foods with added omega-3 oils over the next two 
weeks is. 
Belief strength (BS) - Eleven independent variable statements were used to assess 
belief strength towards purchasing foods enriched with n-3 fatty acids: provide 
long-term health benefits, importance of obtaining the health benefits, may be at 
risk of inadequate intake of nutrient, may be at risk of over exposure of this 
nutrient, importance of scientific proof, developing new ways to make it easier to 
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choose a diet high in n-3, provide heart health benefits, provide brain health 
benefits, provide eye health benefits, improve arthritis and improve asthma. Each 
statement was anchored on a bipolar differential 7-point scale ranging from 
extremely important to extremely not important.  
Outcome evaluation (OE) - The TPB assumes that having a positive attitude 
towards a behavior is based on believing that the behavior will be likely to lead to 
positively evaluated outcomes, or will be unlikely to lead to negatively evaluated 
outcomes. Therefore for each of the BS there was an equivalent outcome 
evaluation statement. Each statement was anchored on a bipolar differential 7-
point scale ranging from extremely likely to extremely unlikely. 
Beliefs relating to n-3 functional foods were transformed into consequences of 
purchasing by multiplying the belief strength by the outcome evaluation (BS X OE) 
and a mean computed (possible range +9 to –9) and reflect an overall behavioural 
belief scale. 
Subjective Norm (SN) - The TPB assumes that normative factors are based on 
perceptions of whether specific significant others believe you should perform the 
behavior or not (Normative Belief), and the motivation to comply with the wishes of 
these significant others. Therefore beliefs relating to n-3 functional foods were 
transformed into consequences of purchasing by multiplying the normative belief 
by the motivation to comply and a mean was computed (possible range +9 to –9). 
This reflects an overall subjective norm scale (SN). The independent variable, 
subjective norm, was also measured by a global question using a seven point 
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bipolar differential scale. Respondents could choose extremely likely to extremely 
unlikely (+3 to -3) to the statement: most people who are important to me think I 
should eat foods with added omega-3 fats. 
Normative beliefs (NB) - Groups or individuals whose views might influence 
functional food use were also explored. Seven normative beliefs (NB) were 
assessed: family, friends, medical practitioners, nutritionists, scientists and food 
industry. For example one statement is “most members of my family think that I 
should eat foods with added omega-3 oils” (extremely likely – extremely unlikely). 
Normative belief statements were scored from +3 to –3.  
Motivation to comply (MC) - Motivation to comply with the beliefs of significant 
others was also determined. For each of the NB there was a question relating to 
the motivation to comply. For example one statement is “Generally speaking, I 
want to do what my family thinks I should do.” Motivations to comply statements 
were scored from +3 to –3. Each statement was anchored on a bipolar differential 
7-point scale ranging from extremely likely to extremely unlikely.    
Perceived Behavioural Control (PBC) – Factors which might facilitate or inhibit 
functional food use, are termed control beliefs (CB). Included in our questionnaire 
were availability at the supermarket, control over shopping, cost, taste, time, and 
suitability for the family. In addition a global question of control was included: “how 
much control do you have over whether you do or do not eat foods with added 
omega-3 oils” (seven point scale: complete control - very little control). Unlike other 
determinants of intention, CB does not correspond with measures of intention. The 
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TPB assumes that the higher CB would be found in those intending to purchase 
functional foods. In this case it was expected that a high CB would result in both 
intention to purchase or not to purchase functional foods, whereas a lower CB 
would result in no intention to purchase.  For this reason CB was transformed into 
a binomial scale. The transformation involved estimating whether motivation was 
either positive or negative from the determinant variables, therefore placing PBC 
as either (a) having control over purchasing or not purchasing, or (b) no control.   
7.2.2 Sample 
This study was conducted in the Illawarra region of New South Wales, Australia. At 
the time of the study health claims on food products were prohibited, however a 
regulatory system for health claims is currently being developed. Two sub-samples 
were surveyed via questionnaire: general consumers who responded to media 
advertisement and subjects with Type 2 diabetes participating in an intervention 
trial. These sub-samples were selected as we wanted to investigate if there were 
differences in intention and attitude between those with an existing disease (in this 
case type 2 diabetes mellitus) and those without, as suggested by Childs (1997) 
(390). General consumers were recruited from advertisements in the local media. 
Potential participants phoned in their contact details to a study-specific answering 
service and these calls were returned and a brief outline of the study was 
explained. They were screened and excluded if they were undergoing treatment for 
chronic illness. Those expressing interest were sent an information sheet and 
consent form to sign and return. Once consent was obtained a questionnaire was 
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sent via post. Questionnaires not returned after 2 weeks were followed up via 
telephone communication. 
Subjects were recruited from advertisements in the local media and on local 
institutional email networks (University and Technical College). Potential 
participants phoned in their contact details to a study specific answering service 
and these calls were returned with a screening questionnaire. Inclusion criteria 
were: aged 35-75yrs, diagnosed with type 2 diabetes mellitus for at least one year 
and generally well. Exclusion criteria were: on insulin therapy (or with HbA1c >9%), 
BMI > 35kg/m2, with major debilitating illness, food allergies or food habits 
inhibiting their participation in the study, illiteracy and inadequate conversational 
English. Subjects at the first clinic appointment of this 6-month trial completed the 
questionnaire. Approval for the conduct of the study was provided by the University 
of Wollongong / Illawarra Area Health Service Human Research Ethics Committee 
(Appendix O). 
Using the database of eligible consumers responding to the local media 
advertisement, 134 questionnaires were sent out. After 3 weeks (including a 
reminder call after 2 weeks) 79 were returned representing a response rate of 
61%. Fifty-five adults with type-2 diabetes who had volunteered separately for 
participation in a dietary intervention trial were asked to fill out the questionnaire 
and five declined to participate. The final sample size of the two sub-samples was 
129. 
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7.2.3 Data Analysis 
Internal consistency reliability of the scales used to measure the variables was 
determined by calculating the Chronbach’s alpha and questions with an alpha < 
0.3 were deleted. All variables that constituted attitude were included in the 
analysis, and the alpha value was 0.89. The questions relating to the influence of 
friends and food companies were deleted as they showed a low level of internal 
reliability (0.222 and 0.204 respectively). Chronbach’s alpha for SN in the final 
analysis was 0.77. Control over food choice also showed a low level of internal 
reliability and once deleted the Chronbach’s alpha value for PBC increased from 
0.71 to 0.74. 
There were no significant differences between the two sub-samples in both 
demographic parameters and measured variables (apart from the proportion 
reporting a chronic illness); therefore the results were combined for analysis. 
Respondents were dichotomised into intenders (47.7%) and non-intenders (52.3%) 
(Positive scores were classified as intenders; neutral and negative scores were 
classified as non-intenders). Independent t-tests where used to compare mean 
scores of TPB components and other continuous variables. Non-parametric data 
were compared using Mann Whitney U-tests. Correlations between the variables 
were measured using both Pearson’s and Spearman’s correlation coefficients. The 
influence of the TPB components of use of n-3 enriched functional foods was 
investigated by multiple logistic regressions. The determinants of intention as per 
TPB were investigated using multiple linear regressions. According to the TPB, 
Attitude, Subjective Norm and Perceived Behavioural Control are direct 
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determinants of intention. The first step involved entering global measures of 
attitude, subjective norm and perceived behavioural control into the model. The 
second step involved the addition of the attitudinal beliefs, normative beliefs and 
control beliefs. This allows us to determine if beliefs are mediated through attitude.  
Additional demographic variables (age, income and education) were added to the 
model to investigate any associations. Estimates were computed at the overall 
means for the data set. All analyses were carried out using SPSS for Windows 
version 7.0 (SPSS Inc.) 
7.3 Results 
The mean (± s.d.) age of the participant sample was 53 (± 12.8) years (range 17 – 
80 years) and the mean body mass index (BMI) 28.6 (± 6.6) kg/m2. Two thirds of 
the participants were female (66.7%) and the majority of subjects were currently in 
a relationship with no children under the age of 18 living at home (75.2%). Ninety 
four percent of participants were the main shopper in the household, or shared the 
shopping in the household. Income range was relatively evenly distributed between 
the five income brackets – 22.6% earned < $20K per year, 19% earned between 
$20K-$40K per year, 13.9% earned between $41K-$60K per year, 16.1% earned 
between $61K-$80K per year and 12.4% earned between $81K-$100K per year. 
The smallest number (7.3%) earned greater than $101K per year. The highest 
level of education of participants was 0.8% finished primary school, 31% finished 
high school, 24.8% finished technical college and 38.8% graduated from 
University.  
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Spearman’s or Pearson’s correlation between the various TPB components and 
those above 0.3 are reported. Attitude (r = 0.56; P = 0.01) and Subjective Norm (r 
= 0.41; P = 0.01) were correlated to Intention. In turn, each set of beliefs was 
correlated with the corresponding global measure. For example BB X OE 
correlated strongly with attitude (r = 0.75; P = 0.01) and NB X MC correlated 
strongly with Subjective Norm (r = 0.48; P = 0.01). Perceived behavioural control 
beliefs did not correlate with any of the variables under investigation.  
There were no differences between the two sub-samples in intention to use 
functional foods or any of the determinant variables. Table 7-1 summarises the 
differences between intenders and non-intenders of n-3 enriched functional foods. 
Perceived behavioural control and control beliefs were not different between 
intenders and non-intenders. Those who intended to use these products had a 
more positive attitude toward them and perceived normative pressure to use them. 
Similarly scores on belief items also showed the same trend. There were no 
difference in age, income or education between the intenders and non-intenders. 
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Table 7-1  Comparison of variable rating scores between those intending or not intending to 
use n-3 enriched products in the following two weeks [mean ± s.d.] 
 Intenders  
(n = 61 [47.7%]) 
Non Intenders  
(n= 67 [52.3%]) 
Significance a 
(P- value) 
Attitudeb 2.2 (0.6) -0.5 (1.5) 0.00 
Behavioural beliefs (BS x OE) c 4.2 (1.9) 1.6 (2.5) 0.00 
Subjective Norm b 0.8 (1.4) -0.2 (1.5) 0.00 
Normative beliefs (NB x MC) c 1.9 (2.0) 0.7 (1.6) 0.00 
Perceived behavioural control b 2.2 (1.1) 1.9 (1.4) 0.13 
Control Beliefs (CB)b 0.5 (1.1) 0.4 (1.2) 0.95 
aStudent’s t- test between intenders and non-intenders.   
bScores are from +3 to –3 
cScores are from +9 to –9 
The results (Table 7-2) showed that the first step intentions were a significant 
predictor of n-3 enriched food use, with overall 78.5% of subjects correctly 
classified as users or non-users based on intentions and PBC. Twenty-nine 
percent of the variation in behaviour was explained by the regression (R2 = 0.298; 
P < 0.001). The odds of using n-3 functional foods increased 0.75 fold for every 
increase of one unit in intention score. PBC was not a significant predictor of use. 
At the second step, the addition of attitude and SN the predictive power slightly 
decreased and none of the variables were significant. Thus as predicted by the 
TPB, the effects of attitude and subjective norm on behaviour were mediated by 
intention. At the third step, the predictive power of the model decreased to 75.3% 
with none of the variables being significant. Thus as predicted by TPB, the belief 
components have no unmediated effects on behaviour.  
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Table 7-2  Logistic regression of behaviour onto TPB componentsa,b 
Variablec Odds ratio 95% CI Significance  
Step 1 
   Intention 
   Perceived behavioural control (PBC) 
 
0.75 
1.03 
 
 
0.14 
0.26 
 
 
P = 0.04 
P = 0.92 
 
Step 2 
  Intention 
  Perceived behavioural control (PBC) 
  Attitude 
  Subjective Norm 
   
Step 3 
  Intention 
  Attitude 
  Subjective Norm 
  Perceived behavioural control (PBC) 
  Behavioural beliefs (BS X OE) 
  Normative beliefs (NB X OE) 
  Control beliefs (CB) 
 
0.65 
1.03 
1.33 
0.84 
 
 
0.51 
1.03 
1.66 
0.77 
0.99 
0.60 
1.25 
 
0.32 
0.26 
0.39 
0.26 
 
 
0.38 
0.28 
0.44 
0.29 
0.18 
0.31 
0.21 
 
P = 0.65 
P = 1.03 
P = 1.33 
P = 0.84 
 
 
P = 0.78 
P = 0.93 
P = 0.25 
P = 0.36 
P = 0.97 
P = 0.09 
P = 0.28 
a Non significant variables were retained in the model to determine the effect of the additional 
variables when existing TPB variables were taken into account; b R2 = 0.298 (P < 0.001);c Percent 
correctly classified: step 1 78.5%; step 2 = 77.9%; step 3 = 75.3%;  
A further question is the extent to which intentions are predictable. By entering the 
direct predictors of intention (attitude, subjective norm, PBC) at the first step and all 
the other beliefs at the second we are able to test whether the effects of belief 
components are mediated by other TPB variables. At step 1 in the development of 
the linear regression model of intention, attitude was significantly positively 
associated with intention, whereas SN and PBC was not significant (Table 7-3). 
Thus stronger intentions to use n-3 enriched foods were associated with having 
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positive attitudes toward the use of these foods. Overall the equation accounted for 
72.4% of the variance of intentions (P < 0.001). Assumptions of multiple 
regressions were validated using residual plots. At step 2, the belief variables 
explained a marginal amount of variation in intentions 72.5% (P <0.001). Thus as 
predicted by TBP, the effect of belief components have no unmediated effects. 
Therefore, the next phase was to examine how beliefs about the consequences of 
using n-3 enriched foods were associated with intention to use. 
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Table 7-3  Linear regression of intentions onto TPB componentsa 
Variable B Beta  SE Significance  
Step 1 
  Attitude 
  Subjective Norm 
  Perceived behavioural control (PBC)
 
1.01 
0.02 
0.02 
 
0.85 
0.01 
0.01 
 
0.07 
0.07 
0.08 
 
P < 0.001 
P = 0.82 
P = 0.87 
Step 2 
  Attitude 
  Subjective Norm 
  Perceived behavioural control (PBC) 
  Behavioural beliefs (BS X OE) 
  Normative beliefs (NB X OE) 
  Control beliefs (CB) 
 
0.97 
-0.05 
-0.01 
0.06 
0.08 
0.00 
 
0.81 
-0.04 
-0.01 
0.07 
0.07 
0.00 
 
0.07 
0.09 
0.09 
0.06 
0.06 
0.09 
 
P < 0.001 
P = 0.57 
P = 0.88 
P = 0.32 
P = 0.22 
P = 1.00 
a B = regression coefficient; SE = standard error; R2 = 0.724 (P < 0.001) for Step 1, R2 = 0.725 (P < 
0.001) for Step 2. 
Based on the dichotomised categorisation of self-reported intention to use, 
differences in responses to each belief question between intenders and non-
intenders were examined using independent t-tests (Table 7-4).  
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Table 7-4  Mean scores for belief items: comparison of intenders and non intenders [mean ± s.d.] (n = 126) 
Variable Intenders Non-intenders Intenders Non-Intenders Intenders Non-intenders 
 Belief strength (BS)a Outcome evaluation(OE)a BS X OEb 
Importance of general health 2.85 (0.40) 2.74 (0.82) 2.1 0(0.65) ††† 0.92 (1.32) 6.08 (2.15) ††† 2.48 (3.9) 
Importance of health benefits n-3 2.48 (0.57) ††† 1.43 (1.33) 2.15 (0.64) ††† 0.92 (1.41) 5.49 (2.40) ††† 2.05(3.19) 
Contain enough n-3 to be useful 2.41 (0.70) ††† 1.28(1.46) 1.7 (0.10) †† 0.48 (1.45) 4.42 (2.99) ††† 1.35 (2.94) 
Little risk of over exposure 1.32 (1.81) 1.16 (1.69) 0.98 (1.72) 0.42 (1.60) 1.21 (4.45) -0.09 (3.58) 
Food development based on 
science 
2.82 (0.50) 2.52 (1.19) 1.80 (1.14) †† 1.05 (1.44) 5.14 (3.37) ††† 2.43 (4.41) 
New ways to make n-3 intake easy 2.43 (0.62) ††† 1.51 (1.20) 1.69 (1.09) ††† 0.45 (1.6) 4.34 (3.03) ††† 1.59 (3.12) 
Improving heart health 2.85 (0.36) 2.76 (0.46) 1.97 (0.62) ††† 0.86 (1.40) 5.64 (2.02) ††† 1.97 (4.10) 
Brain health 2.82 (0.39) 2.69 (0.55) 1.32(1.32) †† 0.63 (1.39) 3.73 (3.95) †† 1.78 (4.01) 
Eye health 2.79 (0.45) 2.68 (0.58) 0.98 (1.32) 0.55 (1.36) 2.81 (3.77) 1.54 (3.90) 
Improving Arthritis 2.74 (0/48) 2.68 (0.53) 1.39 (1.10) †† 0.63 (1.39) 3.98 (3.09) †† 1.86 (3.88) 
Asthma 2.83 (0.38) 2.69 (0.50) 0.91 (1.26) †† 0.23 (1.40) 2.67 (3.58) †† 0.85 (3.67) 
 Normative beliefs(NB)a Motivation to comply(MC)a NB X MCb 
Family 0.75 (1.41) ††† -0.56 (1.60) 0.56 (1.76) 0.18 (1.70) 1.88 (2.89) † 0.51 (3.20) 
Friends 0.53 (1.39) ††† -0.52 (1.51) -0.03 (1.68) -0.38 (1.52) 1.05 (2.92) 0.97  (3.01) 
Dietitians 1.47 (1.24) † 0.92 (1.52) 1.80 (0.93) ††† 0.98 (1.57) 3.14 (3.05) † 1.83 (2.90) 
Doctors 1.26 (1.36) † 0.69 (1.44) 1.80 (1.01) † 1.34 (1.36) 3.12(2.91) †† 1.33 (2.90) 
Scientists 1.43 (1.33) †† 0.78 (1.39) 1.30 (1.13) †† 0.63 (1.41) 2.43 (2.91) †† 0.88 (2.50) 
Food companies 1.14 (1.60) 1.20 (1.40) -0.72 (1.64) -1.09 (1.63) -0.47 (4.10) -1.42 (3.92) 
 Control beliefs(CB)a     
Availability at the supermarket -0.25 (1.77) † 0.19 (1.5)     
Control over purchase 1.16 (2.25) †† 1.51 (1.68)     
Cost 0.28 (1.93) 0.06 (1.87)     
Taste/texture 0.49 (1.76) 0.52 (1.66)     
Time required to find 0.64 (1.85) 0.22 (1.73)     
Suitability for family 0.38 (1.88) 0.04 (1.91)     
† P < 0.05; †† P < 0.01; ††† P < 0.001 equal variances not assumed; a Items scored between +3 to -3; b Items scored between +9 to –9
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7.3.1 Behavioural beliefs  
Intenders differed from non-intenders in 3 behavioural beliefs; “importance of the 
health benefits of omega-3 fats”, “that foods enriched with omega-3 contain 
enough of this nutrient to be of benefit” and “how important is it that we make new 
ways to make omega-3 intake easy”. When considering how each group evaluated 
these outcomes on n-3 enriched food intake, intenders differed significantly in 9 of 
the 11 beliefs. With the multiplicative measure of belief strength and outcome 
evaluation (BS X OE) there was a significant difference between intenders and 
non-intenders for the 9 beliefs. These results suggest that intenders are more likely 
to believe that eating n-3 enriched products specifically will provide a variety of 
health benefits despite the fact there was little difference between how intenders 
and non-intenders rated the overall importance of these effects.  
7.3.2 Normative beliefs  
Normative beliefs differed between intenders and non-intenders for 5 of the 6 
variables. Differences were observed for family members, friends, dietitians, 
doctors and scientists with more positive ratings for intenders. This was consistent 
when considering motivations to comply as well as the multiplicative value of NB X 
MC, with all variables except for family members (MC) differing. There were no 
differences between the groups in the normative belief relating to food companies, 
with both groups responding negatively when rating motivation to comply with their 
recommendations. 
7.3.3 Control beliefs  
Only 2 out of the 6 control beliefs differed significantly between intenders and non-
intenders: availability in the supermarket and control over purchasing. Interestingly, 
intenders did not perceive availability as being a barrier to purchase (indicated by 
the negative response), whereas non-intenders believed that this was a barrier. 
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Non-intenders were more likely to believe that a lack of control over purchasing 
was a significant reason for not purchasing these products. 
7.4 Discussion 
Using a questionnaire based on the TPB, the model explained 72.5% of the 
variance of intention to use n-3 enriched foods. This result is comparable with other 
studies investigating intentions to use genetically modified foods and supplements, 
using the TPB, which have reported R2 = 0.35 and 0.75 respectively (23, 387). 
These results, in light of this earlier work, highlight the importance of studying 
specific food products, processing techniques and health effects in order to 
understand the complex nature of food selection. For example, whilst these results 
are valid in understanding consumer behavior in selecting n-3 enriched foods, they 
do not translate to an understanding of the use of fish oil supplements, nor n-3 
enriched products enriched using GM technology. 
These findings into the determinants of intention extend on previous work using the 
TPB. In relation to n-3 enriched foods, attitude was found to be the sole 
determinant of intention to eat these products and was the sole significant 
predictor. It was found that both normative beliefs and control were not significant 
determinants of intention to eat these products in this study. It is apparent from the 
literature that the relative importance of these factors is variable and is dependent 
on the behavior, demographic and particular food under investigation. For 
example, dairy product use by the elderly is predicted by both attitudes and control 
beliefs, whereas the use of genetically modified foods is predicted by attitude, 
control beliefs as well as subjective norms (326, 387). This adds weight to the 
importance of investigating single action, specific behaviors as suggested by Azjen 
and Fishbein (19). 
It appears that selection of n-3 enriched foods remains largely a personal choice. 
Although marketers, health professionals and family members may suggest the 
use of these novel products, ultimately use is an individual decision having minimal 
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influence from normative factors. Similarly as perceived behavioural control was 
not predictive of intention to eat n-3 functional foods in our sample; it can be 
speculated that selection of these products is under volitional control, although 
control factors may act directly on behavior. In summary, the selection of n-3 
functional foods appears to be a cognitive process based on underlying beliefs, 
leading to overall attitudes which in turn have a significant impact on food choice. 
The incorporation of functional foods into the diet has the potential to improve 
individual and population health (393). A survey of American dietitians found that 
over three quarters had recommended the use of functional foods in the last year 
(394). Results from this study can be used in a practical sense with the upstream 
determinants of attitude providing nutrition educators with cognitive targets that can 
be used to improve the specificity and assist in the development of nutrition 
education programs. Intenders had a greater belief in the importance of n-3 fats 
and their associated health benefit and a belief that it is important to provide these 
novel foods on the market, but insisted it was important that they contain enough of 
the active ingredient to be useful. Most significant was the belief that eating foods 
enriched with n-3 fats specifically would lead to a number of health benefits. 
Subjects believed in a wide range of health benefits attributed to n-3 enriched 
foods despite varying degrees of empirical scientific evidence to support these 
claims. However, both intenders and non-intenders alike rated the importance of 
these health parameters similarly. This would suggest that changing individual 
beliefs about the importance in health issues alone will not translate into the use of 
these foods. Efforts to influence consumers may best be channeled into 
demonstrating and communicating a cause and effect relationship between a 
specific product and a health parameter or benefit. Therefore, the role of health 
claims might be important in promoting these foods. However, more research is 
required to determine the effectiveness of this approach in increasing the use of 
omega-n-3 functional foods. 
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There are a number of limitations to this study. Despite the lack of differences 
between our two sub-samples, the combined sample was not representative of the 
general population and was both time and context specific. In addition, these study 
participants were more likely to be interested in nutrition than the general 
population. Intention to use n-3 functional food was high (54%) and may have been 
a result of the recent product launches which coincided with the study. Also, this 
study provides a static view of attitudes towards n-3 enriched foods and follow-up 
over time, as more of these foods enter the market, would be useful. Another 
limitation was that the questionnaire did not account for more general beliefs to do 
with healthfulness, naturalness and altruism, which previous studies have been 
shown to be significant determinants of GM food selection (387). However, these 
issues did not emerge as salient beliefs from earlier focus group work (370). This 
implies a more general limitation to the TPB. 
In summary, to be initially effective in maintaining and encouraging positive 
intentions and behaviour, a likely strategy for promoters of n-3 enriched functional 
foods would be to direct their promotions towards changing attitude, and 
specifically belief in the effectiveness of enriched products in achieving specific 
health benefits. Independently, environmental factors are also important in 
determining the attitudes of consumers towards n-3 functional foods. For example, 
consumer beliefs can be affected by the way n-3 functional foods are portrayed in 
the media, which in turn is a product of the level of stakeholder agreement or 
disagreement. The final study of this thesis investigated the stakeholder beliefs and 
attitudes that may impact on the consumer environment. 
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CHAPTER 8  
 
STAKEHOLDER BELIEFS AND ATTITUDES DISPLAY MIXED IDEOLOGIES 
THAT MAY HAVE AN IMPACT ON THE CONSUMER ENVIRONMENT8 
8.1 Introduction 
To ensure the success of functional foods in the market place, an active 
collaboration of all stakeholders in the promotion of these novel foods is required to 
ensure a positive consumer attitude (395). McConnon et al (2002) have argued 
that a dissonance in ideology, beliefs, views and motivations between stakeholders 
could lead to a consumer lack of confidence in this concept, and ultimately 
undermine the potential for both commercial success and public health gain (25). 
To increase a favourable public perception they propose that the future of 
functional foods is dependent upon communication and trust between the 
stakeholders and warn how misperception can threaten their potential (25). The 
real challenge is to create an environment for the development and promotion of 
functional foods through collaboration between the various stakeholders (294).  
The area of functional foods has attracted interest from a wide range of 
stakeholders, including government personnel, consumers, and members of the 
food industry, scientists and health professionals. The rising popularity of functional 
foods has resulted from the concomitant advances in food technology, nutrition 
science and consumer awareness in health and wellbeing (396, 397). The 
                                             
8 A significant portion of this chapter has been submitted to the following peer reviewed journal: 
Patch CS, Tapsell LC, Williams PG. (Submitted 19 November 2004) Australian stakeholder beliefs and attitudes about 
functional foods. Food Policy.  
CP was responsible for the design of the study, organisation and leading the study, data collection and analysis, critical 
discussion of the analysis and preparation of the manuscript. LT and PW were responsible for critical discussions of the 
study design, critical discussions of the analysis and preparation of the manuscript. 
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landscape of the food supply is changing at an unprecedented rate, with the 
emergence of novel functional foods in most food categories thus creating many 
business opportunities for the food industry (383, 398). Equally as exciting is the 
advanced emphasis on preventing chronic illness and disease as well as 
promoting better health and wellbeing through an improved food supply (399).  
Because the topic of functional foods is relatively new, there remains confusion 
amongst stakeholders surrounding this concept (395). Areas of confusion and 
debate include the lack of a clear definition and categorisation of functional foods, 
the lack of inclusion of functional foods in established nutrition education models as 
well as concerns relating to consumer perceptions and acceptability (25), social 
and cultural differences (288) and regulatory concerns about health claims (25, 
400). This confusion amongst stakeholders has the potential to erode consumer 
confidence and dissipate the potential benefits if not managed effectively (27). 
There is evidence to suggest that with appropriate legislation, good scientific 
support and effective marketing, it is quite possible that any general consumer 
skepticism can be overcome (401). Many countries either have health claim 
legislation in place or are currently in the process of review (402). In addition, 
attempts are being made at an international level by the Codex Alimentarius 
Commission to establish guidelines for health claims about foods (403). However, 
there is continuing disagreement in these policy developments which is often 
fuelled by the interests of a range of stakeholders who seek to exert control over 
the marketing and product landscape of the food supply (26).  
Stakeholders can be conceptualised as networks of human beings, actors or 
agents with diverse interests and somewhat bound by their role (404, 405). This 
metaphor highlights the problematic notion of rational decision-making as the sole 
basis for matters such as functional food evaluation, strategic direction and policy 
development. For consumer interests to be placed at the centre of policy direction 
it is essential that stakeholders come to an agreement free from restraint due to 
their roles. It has been suggested that this emancipation can be achieved by 
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recognising and challenging ideology (405). In this sense ideology can be defined 
as ideas that are so commonplace and familiar that they are taken for granted as 
objective fact or truth (406). Ideology becomes a coherent and widely accepted set 
of ideas that permeate a group and has a role in shaping political activity, often in 
an unconscious way (407). By surfacing and challenging underlying assumptions 
and making ideologies explicit, emancipation may be possible (405). The aim of 
this qualitative investigation was to explore the beliefs and attitudes and ideologies 
of different stakeholders toward the development and communication of functional 
foods and attempt to categorise underlying ideological positions.  
8.2 Method 
8.2.1 Participants 
Semi-structured interviews were undertaken by using purposive sampling. Twenty 
potential participants were identified from a database of contacts to the recently 
created National Centre of Excellence in Functional Foods (NCEFF) (408). This 
centre was funded by the Australian government to provide leadership for 
functional foods in Australia, with an emphasis on integrating science and business 
interests. Twenty individuals representing general practitioners (GPs), nutritionists, 
industry, media, regulatory bodies and authoritative health organisations from 
various States were contacted initially via e-mail and an expression of interest to 
participate was requested. Quotas were set for each category, priority lists 
compiled (Table 8-1) and each individual contacted via e-mail. For those 
interested, an information sheet and a consent form were mailed to each potential 
participant, and interviews were conducted at a mutually convenient time.  
Forecasted quotas were not reached for the GPs and journalists. The interviewees 
included two nutrition researchers, two food industry marketers, two public health 
nutritionists, one general practitioner, two clinical dietitians, two nutrition 
consultants, one prominent spokesperson, one journalist, one research consortium 
executive, two food policy experts, one food legislation enforcer and one food 
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industry lobbyist. The proportions of females and males were 50% each and all 
States and Territories (except Northern Territory) were represented. 
Table 8-1  Profile of interviewees 
Stakeholder group Quota State/territory Gender  
General practitioners 2 South Australia, Queensland Male, Female 
Nutrition Researchers 2 Western Australia, Victoria 2 Males 
Food Industry 
Marketers 
2 Western Australia, New South Wales Male, Female 
Public Health 
Nutritionist 
2 Queensland, Victoria 2 Males 
Clinical Dietitian 2 New South Wales, Victoria 2 Females 
Industry consultants 2 New South Wales Male, Female 
Prominent 
spokesperson 
1 New South Wales Female 
Journalist 2 Queensland, New South Wales 2 Female 
Research Director 1 New South Wales Female 
Policy expert 2 Victoria, New South Wales Male, Female 
Industry lobbyist 1 Australian Capital Territory Male 
Regulatory enforcer 1 New South Wales Male 
Total 20  10 Males; 10 Females 
Details of the participants and organisations have been suppressed in order to 
maintain confidentiality in view of the sensitive issues involved. Approval for the 
conduct of the study was provided by the University of Wollongong / Illawarra Area 
Health Service Human Research Ethics Committee (Appendix P). 
8.2.2 Study context 
In qualitative research, transparency of the study context is an important aspect of 
validity (409). The study context comprised the current regulatory framework, the 
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positions of the authors and those of the stakeholders interviewed. The authors did 
not receive financial gain from the study. One of the authors (CP) was in receipt of 
an Australian Research Council scholarship through a linkage grant co-funded by 
Goodman Fielder Ltd, Sydney, Australia with the scholarship provided by 
government funds. In addition the Smart Foods Centre is part of a consortium that 
forms the National Centre of Excellence in Functional Foods that has received 
Federal Government funding. LT is the Director of this Centre and PW is the 
Regulatory Affairs Cluster coordinator within this organisation. All three authors 
hold Accredited Practicing Dietitian status. In December 2003, the Australian and 
New Zealand Food Regulation Ministerial Council agreed to a policy guideline on 
nutrition, health and related claims. The policy guideline provided the policy 
principles to underpin the regulation of nutrition, health and related claims which 
included the regulatory system. At the time this study was conducted, the initial 
assessment report on a proposal for Nutrition, Health and Related Claims 
(Proposal P293) was drafted by Food Standards Australia New Zealand (FSANZ) 
and released for public comment (410).  
To enhance the quality and credibility of qualitative analyses there is a particular 
need to highlight the professional and social pressures on the author which may 
have an effect on the reporting of these results (409). Further, as this study 
interprets attitudes and beliefs from the perspective of ideology, it is important to 
state the author’s own political ideology. To date our research is based on the 
belief that a functional-food led intervention is effective in ameliorating many life-
style diseases. Our own liberal view transcends a purely scientific view that tends 
towards promoting functional food within the food supply, but does not preclude 
objectivity at the expense of ideology. 
8.2.3 Semi-structured interview procedure 
The interviews were conducted during the months of April to June 2004. Interviews 
were pre-arranged and carried out over the telephone (except for two face to face 
interviews given the proximity with the interviewer’s location). Interviews were 
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audio taped and later transcribed to allow systematic analysis of the discussion. An 
interview guide was developed following the general guidelines provided by 
Krueger (329). Using the theoretical framework proposed by McConnon et al 
(2002) (25), as well as reviewing the literature pertinent to this area (26, 27), ten 
open-ended questions were devised to determine stakeholder awareness, beliefs 
and attitudinal issues regarding the development and promotion of functional foods 
(Figure 8-1). After a definition of functional foods was provided, interviewees were 
asked for their views on the processing and production of functional foods, the 
ability of functional foods to improve health, evidence supporting functional foods 
and resultant claims, the regulatory environment, intellectual property and 
propriety, and finally, the perceived roles of stakeholders. During the interview, 
participants were encouraged to speak until no more views were expressed, and 
then the moderator probed and clarified points. In short, probes were primarily 
used to encourage participants to clarify meanings or explain points of 
incongruence in their answers.  
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Figure 8-1  Moderator question guide for stakeholder interviews 
General impression about these foods 
1. Given the definition of functional foods we have provided; 
We have seen the emergence of a number of foods with added health benefits such as foods 
enriched with plant sterols and foods enriched with fish oils…what do you think about these?   
[Probe:  Is this something that we should be doing to our food supply?] 
Processing/Production 
2. What do you see as the important factors when considering the development and promotion of 
functional foods in the food supply?  
[Probe: Environmental concerns, production/processing technologies etc[ 
Ability to achieve health benefits 
3. Do you believe that functional foods have the potential to improve health or promote health? 
4. Do you see any alternative to the promotion of functional foods in the food supply in improving 
public health?  
[Probe:  Do you see this as a realistic approach? What do you consider as being the ideal balance 
between functional foods and the alternative approach?[ 
Determining evidence 
5. What do you see as the type of scientific evidence that would be required to substantiate claims 
for functional foods?   
[Probe:  Consider draft discussion paper on levels of evidence.] 
6. Do you believe that consensus can be reached about the scientific evidence about the effect of 
a food?  
Regulatory environment 
7. Do you believe that consensus can be reached about the scientific evidence about the process 
of approval or regulation regarding functional foods and claims? 
8. Which body should ultimately be the authority for substantiating, authorisation of claim wording? 
[Probe:  Should this be a national body, ‘competent’ body or self-regulation? [ 
9. Who do you see as being responsible for post-launch surveillance of these novel products? 
Intellectual property  
10. Should evidence for a health claim be available to the public?  How could the intellectual 
property of the claimant be protected?  Do you think that this is an important issue? 
Perceived role of stakeholder 
11. What do you see as your role in the area of functional foods and claims about these foods? 
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8.2.4 Data Analysis  
Each interview was tape-recorded and transcribed, producing on average 6 pages 
of transcript. A computer software package for qualitative research analysis, NVivo 
2.0 (2002, QSR International Pty Ltd), was used for data management and coding 
(334). Content analysis was carried out by CP and sub-categories were developed 
to capture the emerging themes. An iterative process of subcategorisation was 
conducted as suggested by Knodel (376). After the preliminary analysis, other 
members of the research team (LT and PW) assessed the content of each 
category and sub-category. Because the purpose of this study was exploratory, 
with an aim to elicit salient beliefs about functional foods, data were presented as 
examples from the interview discourse that illustrated the interpretive frames that 
emerged, and the corresponding themes (377). The analysis attempted to 
represent the full spectrum of beliefs within the study sample. 
8.3 Results/Discussion 
From the initial sampling frame (n = 20), 16 key stakeholders agreed to participate 
(representing a participation rate of 80%). None of the initially targeted GP’s or 
journalist’s agreed to participate. A further five people were approached from each 
of these two groups with only one from each group agreeing to participate, 
resulting in a final number of 18 interviews.  
As a way of introduction into the interview participants were asked about their 
overall impression of functional foods. As would be expected diverse views were 
expressed ranging from positive and supportive of functional foods to negative in a 
number of areas (Table 8-2) 
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Table 8-2  Views expressed on functional foods 
 
Supportive views Non-supportive views 
• Functional foods have a role where 
there is strong evidence 
• Functional foods are problematic due to 
conflicting industry and health goals 
• Functional foods are a necessary and 
logical development of the food supply 
• Functional foods may be seen as a 
magic bullet approach to a very complex 
public health issue 
• Functional foods provide innovative 
solutions to deliver health benefits to the 
community 
• There is ambiguity over the definition of 
functional foods 
• Functional foods provide the potential to 
increase the healthy choices of the 
population 
• The success of functional foods will 
ultimately be determined by consumer 
acceptance 
 • There is potential for functional foods 
only to be available to those who can 
afford them 
The notion that functional foods are at odds with public health goals is one that has 
been expressed in the literature. Some believe that functional foods will undermine 
the most important determinants of public health by making them out of reach of 
those that need it most (389, 411) because of issues such as price (412), and 
access (412). Like the assumption that functional foods will contribute to public 
health gains, neither is substantiated by strong evidence. Both of these positions 
need to be tested, monitored and reviewed. 
A range of views were expressed on matters concerning processing and 
production, achievement of health benefits, determining evidence, regulatory 
issues and intellectual property (Table 8-3 to 8-7). With respect to processing and 
production, concerns about the use of GM technology, shelf stability, safety and 
environmentally sound practices (Table 8-3) have been found by others in relation 
to personal predictors of consumers’ food and health concerns and are generally 
well described factors (413). However, the notions that these foods should be 
produced with a justifiable health need in mind as well as the need for functional 
ingredients to be bioavailable appear to be unique to functional foods. Whilst 
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stakeholders expressed concerns regarding the scientific validity of functional food 
claims, consumers are more concerned with honesty in food labelling and disease 
concerns in general (413). In this way a scientific paradigm expressed by 
stakeholders is expressed in a different way to consumer concerns. The link 
between the two creates a challenging territory for those working in the field of 
functional foods. 
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Table 8-3  Key issues identified by stakeholders relating to processing and production of 
functional foods 
 
The ability of functional foods to deliver health benefits lies at the heart of their 
production and promotion. Those who held the belief that these foods would have 
a positive impact on public health also believed that this impact would only be in 
certain individuals who also had a specific medical condition and would be 
conditional upon there also being an education program about use of these foods 
(Table 8-4). Others believed that the negative impacts outweighed the potential 
public health gains. For example the risks of unintended overexposure, misleading 
and confusing labelling and inappropriate advertising were all seen as having a 
potentially negative effect on public health. Other stakeholders appeared less 
concerned, indicating that energy balance is the current key issue for promoting 
widespread public health, so unless functional foods could address this issue, their 
effects would be insignificant. Some believed cost barriers and the inability to prove 
the benefit would undermine the widespread use of these foods. A final view 
expressed was that the effort (human and financial) invested in the research, 
development, promotion and regulation of these novel foods would be better spent 
Major sub-category Exemplar Quote 
Technological considerations (e.g. GM 
technology) 
It’s [GM technology] an area where you should look at 
research and what can be done with it 
Justifiable need Well I would want to approach it [functional food 
production] from a public health perspective 
Shelf stability They’ve got to be shelf stable 
Safety No dispute over safety, that has to be there 
Bioavailability My perspective is that if these products are informed 
by clinical trials and they’ve got some powerful 
evidence that they have an impact on, say biomarkers 
in a certain population group, then you would expect 
that when it’s produced it actually retains the qualities it 
was tested for 
Environmentally sound practices …much more consideration of the whole food chain. 
What might turn out to be the most important functional 
food might be organically grown. 
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in alternative public health campaigns such as mass education, mandatory 
fortification where there is a demonstrated benefit, promotion of minimally 
processed foods and promoting more politically risky approaches such as taxing 
‘unhealthy’ foods.  
Despite the assertion that the production and promotion of functional foods has the 
potential to promote public health benefits (266, 269), these data suggest large 
dissention in particular stakeholder categories. These respondents believe that 
functional foods are best targeted to those with specific health concerns rather than 
mass markets, a point discussed in the position paper of the American Dietetic 
Association (414) and an Australian review paper on dietetics and functional foods 
(415). This issue is clearly debatable, making further research specifically 
addressing effectiveness of a functional food led intervention of benefits desirable. 
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Table 8-4  Stakeholder beliefs about a functional food-led intervention and the promotion of 
public health benefits 
Major sub-category Minor sub-category Exemplar Quote 
Positive impact In conjunction with education 
 
 
 
 
 
For certain individuals with specific 
medical concern 
‘[regarding plant sterol margarines] I 
doubt that it will have an impact 
unless a person at the same time 
reduced the saturated fat in the diet, 
knows what cholesterol is and gets 
it monitored, measures their blood 
pressure and tries to increase 
exercise and lose weight’ 
‘I believe that in certain 
circumstances some of them may 
help individuals. I am not convinced 
that they will have a wide spread 
public health benefit’ 
Neutral (insignificant 
impact) 
Energy balance is the real concern 
 
 
 
Those in need are least likely to use 
due to cost barriers 
 
Unable to prove or disprove the 
public health benefit 
‘The modern lifestyle diseases are 
largely related to too much food and 
not enough exercise. I am not sure 
that any sort of functional food will 
address that’ 
‘ I suspect that the population 
groups that are likely to use these 
things are least likely to need them’ 
‘Whether they [functional foods] 
have a protective effect for the 
whole of the population and one 
which is unproblematic, I think has 
never really been tested’ 
Negative impact Unintended exposure of added 
functional ingredient 
 
 
Misleading and confusing labelling 
 
 
Misleading marketing and 
promotion 
 
 
Promoted in inappropriate context 
‘…I think plant sterols [products] is 
a good one because we know that 
there are a number of groups that 
might not benefit from the 
consumption of these foods’ 
‘…I’ve written a bit about food 
labelling and there’s a lot of room to 
interpret. For instance what ‘lite’ 
might mean’ 
‘Well the negatives from my 
perspective are it the information 
that’s used to promote these foods 
is misleading or inaccurate so that 
consumers get the wrong message’ 
‘I think that on that issue that to me 
is the way in which food is 
developed as a drug for a specific 
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 group. And is then promoted 
broadly to people that do not have a 
particular problem’ 
Lost opportunity cost - 
alternative Public 
health strategies 
Mass education (dietary guidelines 
and fruit/veg messages) 
 
Mandatory fortification where 
benefit clear 
 
Promotion of minimally processed 
foods 
 
Political approaches (such as taxing 
of unhealthy foods) 
‘I think it is a fantastic alternative to 
treating people when they are 
sick…I think it is under the umbrella 
of wellness’ 
‘I mean if it is established that 
calcium enrichment is important 
than it should be in all milk’ 
‘My personal belief is that as the 
first line of defense I would be 
promoting natural foods first’ 
‘I’d be arguing for a more public 
health model which is look at 
dismantling the barriers to people 
choosing healthy food’ 
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Because the most distinctive feature of functional foods is their claimed “health 
benefit”, health claims are often used to distinguish between functional foods and 
ordinary foodstuffs (27) and the establishment of a legal framework for the 
management of claims is seen as imperative. Stakeholders identified a range of 
regulatory issues and the organisations for dealing with them that should be 
responsible (Table 8-5). The views on the latter ranged from a competent body to a 
suitable government agency such as FSANZ or a body set up by government, 
models described to varying degrees in other countries (333). There was less 
variation in the opinions about an appropriate body to authorise wording of health 
claims with most believing this should lie under the auspices of FSANZ. However, 
there was a strong view from some that there should be involvement from 
communications and marketing experts to help establish and manage the process. 
Views about who should be responsible for post-launch surveillance were diverse. 
In part this was due to the expressed lack of experience and knowledge in this 
area. One statement was made that the problem with post-launch surveillance lies 
with the current legislation that the health authorities in each state are working with, 
not the absence of mandate. In fact it was suggested that the current regulatory 
structure, which now primarily deals with food safety, could easily be extended 
(given appropriate guidelines and funding) to the monitoring of functional foods.  
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Table 8-5  Opinions on the regulatory environment for substantiation, claim wording and 
monitoring of health claims 
 Major sub-category Organisation responsible 
Authority for substantiation Food Standards Australia New Zealand (FSANZ) 
Government body 
Independent body 
Authoritative body 
Competent body 
Authority for wording of claims Food Standards Australia New Zealand (FSANZ) 
Expert panel (communication experts) 
Post-launch surveillance Food Standards Australia New Zealand (FSANZ) 
State/Territory health authorities 
Australia Competition and Consumer Commission 
Consumer Association 
Australia Food & Grocery Council and peers 
Independent body 
Removal of regulatory hurdles  
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Despite there being insufficient data on the possible influences of health claims on 
eating behaviour (416) there is a demand for health claims, particularly from the 
food industry (27), whereas others warn of the potential threat they may pose to 
public health (417). Not surprisingly then, in this study, a range of stakeholder 
beliefs regarding the level of evidence required for the substantiation health claims 
was found (Table 8-6). Putting the relative merits to one side, it was widely 
accepted by participants that evidence is required to support health claims. 
However, details regarding the level of evidence required and the type of evidence 
varied. It was apparent from the interviews that a clearly articulated structured 
approach to the assessment of evidence is warranted. The consideration of 
functional foods within the context of the total diet of the intended population was 
also regarded as an important consideration. Participants expressed the need to 
consider the totality of the evidence relevant to the proof of claim. Policy related to 
the establishment of evidence for health claims needed to address the challenge of 
determining the appropriateness of extrapolating evidence from a controlled 
research environment to the general population, an issue already debated in the 
literature (10).  
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Table 8-6  Categories of evidence identified as required for substantiation of health claims 
for functional foods 
There was unanimous agreement that evidence used to support a health claim 
should be available to the public, however the timing of this availability was an 
issue (Table 8-7). In order to gain first to market benefits, some suggested that the 
evidence should only be made available once communication commenced. This 
raises the larger issue of claimant protection. There were disparate views ranging 
from the belief that claimant protection only served the interest of industry, whilst 
undermining public health goals, to a fundamental requirement of the legislation to 
support innovation. In addition, some believed that while patenting legislation, trade 
marks and fair trading legislation provide some protection for innovation, 
procedural changes to the review process would assist claimant protection. 
Disparity between stakeholders emerged on the necessity of claimant protection. 
Some stakeholders believed that protection was unnecessary and that the benefit 
for the greater good (through decreased competition and increased process) would 
Major sub-
category 
Minor sub-
category 
Exemplar Quote 
Cochrane-type 
review 
Established 
evidence 
 
‘What I have a lot of respect for are Cochrane reviews and 
the reason I have a lot of respect for those is that they give 
you the criteria under which they are reviewing’ 
Food modelling 
studies 
 ‘Food is not drugs. There is a whole lot of contingencies 
associated with this and the main one is the reference to the 
whole diet and the variation that occurs within usual dietary 
pattern and somehow we need to get a grip on that as well’ 
Totality of the 
evidence 
 ‘certainly human experimental research is essential but then 
there is the issue in terms of substantiating the link between 
the claim and the functioning of that particular food’ 
Effectiveness trials  ‘The testing and the efficacy of those foods are often 
undertaken through clinical trials. Often using fairly small 
groups and then through really a slight of hand they are then 
promote it to wider populations outside the clinical trials 
themselves’ 
Bioavailability  ‘…but its important that it actually works in that product 
because it might be that one product would bind the active 
ingredient and that it would not be bio-active anymore’ 
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be compromised if there was significant claimant protection, whereas others 
believed that company investment should be protected to ensure continuing 
investment in innovation. One way to view this disparity is to investigate these 
beliefs as a function of ideology. According to Eccleshall et al (2003) (407), 
recurrent controversies through several centuries of Western thought reveal a 
polarity that extends from extreme “left-wing” humanism to an extreme “right wing” 
normative position. Here the desire for a greater good can be viewed as a 
humanist feature and claimant protection of rights as a normative feature. 
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Table 8-7  Categories of responses on intellectual property 
8.4 Conclusion 
The findings of this research need to be interpreted in the context of the limited 
sample frame of stakeholders, with the omission of ‘average consumers’ noted. 
There is also solely an Australian perspective on an issue that is legislated in 
partnership with New Zealand. A cautionary note is also required on the 
examination of ideology. In an effort to draw out insights of ideology from beliefs 
expressed by participants the clear link between stakeholder views and the 
Major sub-
category 
Minor sub-category Exemplar Quote 
Evidence 
available to 
the public 
Evidence provided to the 
public unconditionally 
Evidence provided to the 
public conditionally 
‘Absolutely, because for people like me who 
are interested in it you want more information’ 
‘I think [evidence available to the public] once 
a company starts to talk to consumers about 
it’ 
Claimant 
protection 
Unnecessary 
 
 
 
Covered under IP 
regulation 
 
 
Need to protect investment 
and promote innovation 
 
 
Change of FSANZ act on 
public comment 
 
 
Has potential to undermine 
Public Health goals 
‘…the public health outcome is the greater 
good and if there is a copycat product out 
there in the market then there is a greater 
opportunity for consumers to take advantage 
of these benefits [bringing cost down] we 
should support that’ 
‘…I think in terms of intellectual property there 
are things like patenting or identifying an 
actual process of manufacturing [which] could 
potentially be patented, rather than the actual 
ingredient or formulation’ 
‘if you were sinking hundreds of millions of 
dollars which some of them do, it is 
reasonable that if you’re first to market you 
should get some protection’ 
‘… a company produces a new product but 
they’re restricted from putting it on the market 
until they go through a rigorous consultation 
process where all their IP is made publicly 
available before the product is launched’ 
‘Public health [and the public] would probably 
benefit more if it [IP]was accessible to 
anybody or any company so it can be more 
widely distributed for cheaper’ 
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ideologies they represent needs to be considered in terms of everyday realities. 
For example, to assume that the ideology of a normative position can be drawn 
neatly from the beliefs expressed by those who represent the food industry is to 
reduce the complexity of both normative ideology and food industry politics to 
banal caricatures. Also, despite the characterisation of the humanist and the 
normative orientations as opposites, at an individual level they are often 
orthogonal, that is, both can be held by the same person when considering 
different aspects of the topic of functional foods. 
This research has revealed that there are a number of areas of agreement 
between stakeholder positions. Stakeholders in this study agreed that there was a 
role for functional foods in specific cases where the evidence supported the use. 
There were consensus that these functional foods should be safe, stable, and the 
bioactive agent available in the products. There was also agreement amongst 
stakeholders that regulation was required, and there was a need for evidence to 
substantiate claims. One feature of this research is that it also started to distinguish 
areas of disagreement. The most significant incongruity between stakeholders was 
related to the beliefs about the process of substantiation and regulation of health 
claims, as well as the evidence required for substantiating these claims. 
Interestingly the areas of disagreement are often characterised by the lack of clear 
scientific evidence available to inform stakeholder views. Examples included the 
beliefs expressed that plant sterol foods are only effective with adjunct education, 
contrasted with an alternative belief that they may be harmful for certain sub-
groups. Stakeholders thus sometimes rely on pre-existing ideology to form beliefs 
and attitudes and this is in stark contrast to the stated beliefs regarding evidence 
for claims. We have categorised these ideologies as examples of “humanism” vs. 
“normative”. Emancipation from these ideologies is required to ensure consumer 
interests, from both a public health and market demand perspective, remain at the 
heart of decision making on functional foods. 
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In the formulation of regulation in relation to functional foods it may be tempting to 
hold off decision making until conclusive evidence is available. With this being 
unlikely, the process is inevitably political, and in making political decisions the 
concept of emancipation from ideologies is a very useful one. The clarification of 
differences and their ideological bases can help find common ground between 
stakeholders and lead to different approaches to the problem. The issue of political 
uncertainty thus can be managed by transparency of decision making (333). In 
countries like Australia where current legislation is under review, it is important that 
policy is founded on dialogue that is responsible and reflective, genuinely inclusive 
and free from domination from any one stakeholder group. 
The effectiveness of the functional food concept as a means for primary prevention 
of CHD ultimately relies on consumer acceptance and the main priority of all 
stakeholders should be the protection of consumer interests. Differences in beliefs, 
attitudes and ideologies of stakeholder groups potentially distract from this goal. 
When stakeholders are relying on ideology rather than evidence they do not 
always make this explicit and sometimes people do not use evidence to support 
their arguments in a rigorous way. It is suggested that the next step from this 
exploratory work should be to focus on the identified areas of disagreement and 
attempt to examine in more detail those issues using a scientific approach. 
Particularly there needs to be an understanding about what evidence there is (or is 
lacking) about how consumers are likely to understand and use health claims. Also 
there needs to be agreement from stakeholders with differing views about what the 
key consumer questions are and what study methods would be appropriate to 
answer them. Some consensus meetings to do this might help inform national 
research priorities. 
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CHAPTER 9  
 
CONCLUSION 
9.1  Summary  
This research set out to examine the effectiveness of a functional food-led 
intervention in the primary prevention of CHD by addressing the question: ‘can the 
use of functional foods be used to help overcome a person’s natural aversion to 
dietary change in a way that results in an observable health benefit?’ Analysis of a 
variety of data collected through dietary trials, focus group interviews, surveys and 
in-depth interviews suggest that it can. In the context of clinical practice where 
patients present with clear diagnosis of hypercholesterolaemia, the dietary 
prescription of plant sterol enriched margarine leads to clear improvements in 
biochemical markers, without compromising the whole of the dietary profile. 
However, targeting individuals with identified risk factors is only one part of the 
solution, targeting healthy populations is also an important aspect of primary 
prevention. As the chapter on increasing LCn-3 through enriched foods indicates, 
functional foods can overcome LCn-3 deficiency as indicated by dietary analysis 
and erythrocyte fatty acid fractions, but further benefits may be masked by the 
unintended weight gain. It is important to stress that an attempt to investigate the 
biological effects still leaves us wondering about the true ‘effectiveness’ of such an 
approach. The chapters on consumer beliefs and attitudes not only provide 
evidence for a relationship between beliefs, intention and behaviour, but also 
demonstrate a complex picture of consumer use of n-3 enriched foods that 
involves cognitive processes above and beyond taste and convenience which are 
often regarded as primary determinants of food related behaviour. Factors affecting 
beliefs about the effects of LCn-3 are not clearly understood, but it is believed that 
negative publicity as a result of conflict between stakeholders is an important 
factor. The final chapter on stakeholders argued that significant incongruence in 
beliefs and attitudes lie not in the notion of functional foods per se, but the way in 
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which they are promoted and advertised. Effective health claim legislation lies at 
the heart of functional food promotion. If policy fails to consider consumers’ 
interests the potential public health gains could be negated through diminished 
consumer confidence caused by conflict between stakeholder groups.  
9.2 Theoretical significance 
The findings of this study support the hypothesis that a functional food-led 
intervention can be an effective preventative health strategy, but a note of caution 
is required at this point lest their significance be extrapolated inappropriately. More 
specifically, a functional food-led intervention using a single food, in a clinical 
context, with the support of a health professional, supports the hypothesis that this 
approach was more effective than usual practice. However, there are three main 
considerations which may limit the applications in healthy populations. Firstly, the 
nutritional composition of the vector or carrier of the functional ingredient needs to 
be considered. It may be the case that vectors are high in fat and energy 
concentration which may contribute to weight gain, which is counterproductive to 
all nutrition interventions. Secondly, concentrations of the functional ingredient 
must be incorporated into the vector in large enough quantities to be consumed 
readily, otherwise an excess in energy intake is required to consume the desirable 
intake. A final cautionary note concerns the way the functional food will be 
consumed and therefore the effect on other foods in the diet and the ultimate diet 
matrix. Subtle shifts in individual foods in the diet can lead to a dietary imbalance 
when the entire diet profile is considered. This is exemplified by the importance of 
the n-6 to n-3 ratio on CHD risk independent on total n-3 intake. 
Notwithstanding the difficulties mentioned above, this research supports the claims 
of behavioural theorists who argue that the merits of the Theory of Planned 
Behaviour can be applied to food related behaviour, including the use of functional 
foods enriched with LCn-3. Given the complex nature of human behaviour, this 
gives us a method of prediction that again supports the theory that this approach 
will be supported through individual changes in diet. 
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The significance of this research is not, however, confined to the narrow realm of 
utility of behavioural theory. Identifying stakeholder belief incongruence also 
illuminates the wider theoretical issue of social power. This confrontation usually 
takes place around the formation of health claim legislation. Underlying the 
arguments are significant differences in ideology between the profit motives of the 
food industry and the public health motives of health professionals. The 
environmental context is an essential part of the epidemiological triad and is 
essential in the effectiveness of primary prevention interventions (418). 
9.3 Limitations and areas for further research 
As the cautionary note above suggests, there are some limitations to this study, the 
principal one being, as with all primary prevention interventions, the lack of 
definitive evidence for the effect on mortality and morbidity in the population. In 
low-risk populations without identifiable risk factors the likelihood of clinical events 
is infrequent, necessitating a larger study group to achieve statistical power in 
detection. Even when investigating at-risk individuals, large, expensive trial designs 
are required to show any positive effect. This raises the question of the degree to 
which conclusions about the effectiveness of this functional food approach can be 
applied to primary prevention based on causal inference. In the absence of 
definitive clinical trials cohort studies and population follow up may be the only way 
to determine the ultimate effectiveness of this approach.  
Another limitation concerns the quality of evidence obtained from behavioural 
research. At best, models that have attempted to explain human behaviour have 
only managed to explain up to 30% of the behaviour under investigation. 
Therefore, most of the reasons for human behaviour cannot be explained through 
questionnaire sampling and quantitation. Compared to the precision of biochemical 
measurements, one cannot be as confident of conclusions based on these 
sources. 
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Although pre-clinical research into functional ingredients is well established, 
research into the application of this knowledge is in its infancy and further research 
is warranted. Not only is this needed to offset some of the limitations, but also to 
pursue some important theoretical questions arising from this research. 
Concerning dietary trials three studies are suggested. First, conducting an 
intervention in patients within a clinical context, again using plant sterols, but this 
time incorporating functional foods to reach n-3 targets. In addition this would need 
to include a larger sample which would probably require a multi-centre trial. A 
second trial, again using healthy subjects, could be designed to incorporate LCn-3 
enriched functional foods but with greater emphasis placed on achieving fatty acid 
targets with fewer foods (higher LCn-3 concentrations). By basing the intervention 
on staple foods, and considering the energy and fat contribution to the overall diet, 
the likelihood of observing positive effects in cardiovascular biomarkers would be 
improved. In addition, due to the wide inter-individual variation in biomarkers (such 
as lipid and lipoprotein) responses to dietary change, and the impact of the 
presence of hypo and hyper-responders, which is related to genetic variation, 
methodologies from the fields of nutrigenomics and nutriproteinomics will emerge 
as an important component of this research (419). Thirdly, the logical conclusion to 
these studies is to test the effectiveness of a portfolio approach to dietary 
interventions incorporating functional foods – i.e. low fat, high sterol, high cereal 
fibre, high folate, high n-3 fatty acids, low GL. This has also been suggested by 
others (281). 
Also, further research is required to pursue the nature of human behaviour in 
relation to the use of these novel foods. Having identified cognitive targets for 
intervention, research efforts could be focused on evaluating the effect that both 
education campaigns and health claim on labels have on the beliefs, intentions and 
ultimately behaviour of consumers. Also, this model could be extended to include a 
wider range of psychosocial variables to build a more comprehensive picture of the 
factors affecting consumer behaviour in relation to these foods. Finally, the 
approach used in this research focused specifically on n-3 enriched functional 
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foods. It would be worth researching the utility of this model with other functional 
food ingredients, thus devising a range of product specific behavioural models 
relating to functional food choice. 
9.4 Policy implications 
CHD remains a significant cause of chronic disease, our scientific understanding of 
nutrition is expanding, innovation in the food supply leading to novel foods is 
increasing and governments around the world are managing this through 
legislative changes. These are immovable facts. It is clear that despite the lack of 
definitive evidence on the effectiveness of primary prevention strategies, action is 
required. It is necessary for the practical immediate application of the existing 
knowledge regarding functional foods. Given the current legislative changes in 
Australia it is timely that we look at the policy implications of this research. At the 
centre of these suggestions is the consideration of consumer interests. As argued 
earlier, despite the best scientific and technologic intent, without consumer 
confidence the potential health benefits will be eroded. 
The scientific design of these dietary trials provides a good model for the 
substantiation of health claims. Often the launch of a functional food is preceded by 
a body of animal, mechanistic, epidemiological, clinical trials. However, as argued 
earlier the translation of results in the controlled context does not necessarily 
translate into the free-living context. This is a point that is often overlooked. In 
establishing evidence for the substantiation of health claims consideration should 
be given to the demonstration of the effect in the proposed food, where trials in a 
‘free-living’ context and with due consideration given to the effect on the whole diet. 
With the knowledge that we can never replicate the true nature of human 
behaviour in a study design, it is important to gather intelligence on consumer 
beliefs and attitudes. For example, the widespread backlash against the 
introduction of GM foods might have largely been averted by an understanding of 
consumer attitudes. This has meant that the potential gains obtained from this 
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technology will not be realised for a much longer time frame. Traditionally much 
information about consumer views has been gathered by food companies with very 
little being published and peer reviewed. It is in the interest of all stakeholders that 
this information be available and should constitute part of the evidence required 
when evaluating health claims.  
Methods of communicating the functional efficacy of foods may be needed to 
provide end users with a more accurate and complete view of the health effects of 
foods than can be provided by health claims or food composition alone in view of 
the complexity of the whole diet and whole foods (420). The health related effects 
of foods are often so dependent on food properties that the effects cannot be 
adequately represented by food composition alone (420). As a result, nutrient data 
can be unhelpful, or even misleading to end users, and there is a need for 
measures of functional efficacy that can be used to accurately guide evidence-
based food choices for health (421).  
Thus the balance between education and confusion is a fine one, and one that 
requires continual assessment. Stringent monitoring and disincentives for thin or 
misleading claims is one measure. Another is the research of consumer reactions 
to claims built from widespread intelligence gathering of consumers. What is 
suggested here is not that dissimilar to what is already known to industry but not in 
the scientific domain. Equally important is a regulatory environment that supports 
innovation and building incentives that reward innovation and protect industry 
investment needs to be considered. 
A functional food-led intervention is no longer a futuristic approach to ameliorating 
lifestyle diseases. A new paradigm for diet, nutrition and lifestyle can be developed 
utilising the social capital available within the interested stakeholders. Through the 
development of scientifically based new functional foods, as well as education of 
the public about their role in a healthy diet, the potential to reduce the burden of 
lifestyle disease is great. The introduction of functional foods into the market place 
must be accompanied by extensive evaluation of functional foods, from both a 
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scientific effectiveness standpoint as well as a consumer standpoint. It is in the 
interest of all that regulatory policy should be founded on dialogue that is 
responsible and reflective, genuinely inclusive and free from domination by any 
single stakeholder group. In addition there is a responsibility of all stakeholders to 
advise on public health policy and the best ways of translating new science into 
practical information to ensure that these new foods enter the market in an 
equitable way that supports the health of both high-risk individuals and the 
population at large. 
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APPENDIX A 
STEROL/STANOL STUDY RECRUITMENT ADVERTISEMENT 
 WANTED 
 
Patients with hyperlipidaemia who are considered 
candidates for cholesterol lowering medication. 
 
 
The joint ethics committee of the Illawarra Area Health Service and the University of 
Wollongong has approved a dietary intervention ‘field’ trial to be held at Port Kembla 
Hospital.  The aim of the study is to measure the effectiveness of a novel dietary 
strategy in improving dietary compliance and improving biochemical parameters in 
patients with hyperlipidaemia.  
 
How to access the study 
• Patients can be referred to the Port Kembla Dietitian clinic; Phone outpatients on 
42238202 
• Patients who do not fit the inclusion criteria or do not wish to participate in the 
study will undergo routine nutritional assessment and counselling 
• Written consent will be obtained prior to commencement of the study and 
participation is voluntary 
• In referring patients to the clinic, GP’s are asked to ensure information is included 
on serum lipids, routinely assessed in clinical practice: total serum cholesterol; 
LDL cholesterol; HDL cholesterol; triglycerides. This information will be required 
at first referral and again after 3 months follow up. 
 
Cost 
• Free 
 
Who will be conducting the research 
• Mr Craig Patch, a qualified clinical Dietitian and  PhD student 
• supervised by Associate Professor Linda Tapsell from the Department of 
Biomedical Science at the University of Wollongong 
 
Benefits to General Practitioners 
• Nutritional assessment and counselling of patients considered candidates for 
cholesterol lowering medication 
• Individual patient progress reports provided to the GP 
• Results of study circulated to the members of the Illawarra Division of General 
Practice 
 
For further information contact: 
• Craig Patch, Dietitian (PhD student), Port Kembla Hospital; phone: 42238166; e-
mail: patchc@iahs.nsw.gov.au 
• Associate Professor Linda Tapsell, Director Smart Food Centre, Department of 
Biomedical Science, University of Wollongong; phone:  42213152; e-mail: 
linda_tapsell@uow.edu.au 
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APPENDIX B 
STEROL/STANOL STUDY LETTER TO TARGETED GP’S 
 
 
 
 
 
 
 
 
 
 
 
Dr Frank Goderie 
Woonona Medical Practice 
380 Princess Hwy 
Woonona  2517 
 
10 May 2002 
 
 
Dear Dr Goderie 
 
Re: Patients with hyperlipidaemia wanted  
 
As part of our efforts to develop quality dietetic services, we have recently started a dietary 
lipid clinic at Port Kembla Hospital.  This not only extends our services to the community, 
but also enables us to evaluate models of effective dietetic practice in lowering blood lipids.  
We feel this service is also important to general practitioners, in view of the recent budget 
announcement aimed at raising prescriber awareness on trialing dietary therapy prior to 
commencement of lipid-lowering medication. 
 
Patients referred to our clinic for lipid management will be invited to participate in a research 
trial. This study involves a prospective, randomised, dietary intervention trial. The aim of the 
study is to measure the effectiveness of a novel dietary strategy in improving dietary 
compliance and thereby biochemical parameters in patients with hyperlipidaemia.  We will 
be comparing dietary prescription of plant-sterol enriched margarines with standard dietary 
practice.  Patients that decline will receive dietary assessment and counselling as per standard 
practice. 
 
Dietary intake patterns will be monitored using research methodologies, and clinical 
outcomes will include dietary and weight change and biochemical parameters, routinely 
provided in referrals by GP’s in clinical practice include: total serum cholesterol; LDL 
cholesterol; HDL cholesterol; triglycerides. The joint ethics committee of the Illawarra Area 
Health Service and the University of Wollongong has approved the research.  
 
Details of the study as well as access details are attached.  Please feel free to refer any of your 
patients with hyperlipidaemia. 
 
Regards 
 
 
 
 
 
 
 
Craig Patch MBA APD 
PhD Candidate 
Smart Foods Centre 
University of Wollongong 
Northfields Av, Wollongong NSW 2522.  Australia 
 
Phone:  +61 2 42214232 
Fax:  +61 2 42214844 
Mobile:  0408 266832 
Email:     csp03@uow.edu.au  
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APPENDIX C 
STEROL/STANOL STUDY PATIENT CONSENT AND INFORMATION FORM 
UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH 
SERVICE INFORMATION FORM 
The efficacy of functional food prescription in free-living subjects with Hyperlipidaemia, 
Craig Patch APD 
The positive aspects of nutrition and heart health are very well established.  A lot of 
media attention is focussed on telling people what to eat; however the information is 
often confusing.  Helping people achieve an optimal dietary intake‐ that is good for 
your heart‐ is the primary role of a dietitian.  This study aims at investigating the best 
strategy for achieving a healthy diet.  In taking part of this study you will undergo the 
following procedure.  The first interview will involve the dietitian collecting 
information about your usual food intake via a dietary history and a 3‐day food 
record; Instructions measuring equipment (scales, measuring spoons, measuring 
cups) will be provided.  This will be followed up with dietary advice and counselling 
based on the National Heart Foundation’s dietary guidelines.  You will be allocated 
into one of two groups.  One month after your first appointment you will be reviewed 
and further dietary advice will be provided.  At three‐months and six‐months, a 
follow‐up dietary history and 3‐day food record will again be performed.  Your GP 
will also follow your progress at this stage and will order a blood test.  A phone call 
reminder will be made one week prior to remind to start your food record and a time 
will be made for a follow‐up appointment.  Dietary advice will be provided as 
necessary and follow‐up negotiated.  Extensive work is involved in participating in 
the study. 
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UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH 
SERVICE CONSENT FORM 
The efficacy of functional food prescription in free-living subjects with Hyperlipidaemia, 
Craig Patch APD 
This project is being conducted as part of a Doctor of Philosophy (PhD).  The research 
is supervised by Assoc Prof Linda Tapsell, Smart Food Centre, University of 
Wollongong. 
Your participation in this research is voluntary, you are free to refuse to participate 
and you are free to withdraw from the research at any time.  Your refusal to 
participate or withdrawal of consent will not affect your treatment in any way/your 
relationship with Port Kembla Hospital, the Department of Nutrition & Dietetics or 
your relationship with the University of Wollongong.  All results and information is 
confidential and your name will not be used.  All data will be collected by me and 
stored (confidentially) in the department. If you would like to discuss this research 
further please contact Craig Patch on 4223 8166 or Assoc Prof Linda Tapsell on 4221 
3152.  If you have any enquires regarding the conduct of the research please contact 
the Secretary of the University of Wollongong, Human Research Ethics Committee on 
4221 4457. 
I,..................................................................................(Participant’s name) consent to 
participate in the research conducted by Craig Patch as it has been described to me in 
the information sheet.  I understand that the data collected will be used for research 
and I consent for the data to be used in this manner. 
Signed Date 
......................................................................................    ......../......../......... 
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APPENDIX D 
STEROL/STANOL – CONTROL & INTERVENTION MEAL PLANS 
Eating for a Healthy Heart 
Suggested Meal Plan 
 
BREAKFAST 
Breakfast cereal with Low fat milk 
Fresh, tinned, dried fruit or juice 
Toast with margarine with a scrape of Peanut butter, honey etc 
 
LUNCH 
Wholemeal bread or roll or flat bread with Margarine 
Add salad or vegetables with a low fat or olive oil or avocado 
Add a small serve of lean meat, chicken or fish (twice a week) 
Finish meal with fruit (fresh, dried, tinned or pureed) 
 
EVENING MEAL 
An optional start to the meal - soup (broth, vegetable or creamed - use low 
fat evaporated milk instead of cream) 
Select starchy vegetables (potato, sweet potato or corn), rice, pasta or 
legumes (eg kidney beans, lentils) 
Add salad or vegetables with a low fat or olive oil or avocado 
Add a medium serve of lean, eats (fat trimmed from pork, lamb or beef) or 
skinless poultry (chicken or turkey) or fish, fresh or tinned (eg Tuna in 
water, spring water or drained of oil) or egg or reduced fat cheese. 
Finish meal with fruit based dessert- fresh or tinned served with low fat ice 
cream or yoghurt 
When dining out, limit deep-fried, battered or pastry based foods 
 
AT MID MEAL SNACKS 
Choose from a small tub of low fat yoghurt fruit or plain, or a piece of fruit, 
or a slice of raisin toast with Margarine or a glass of low fat milk or a couple 
of plain biscuits, scones etc. 
 
 
Department of Nutrition & Dietetics 
Port Kembla Hospital 
PO Box 21 Warrawong 2502  ARC Key Centre of Teaching and ResearchUniversity of Wollongong  
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APPENDIX E 
STEROL/STANOL STUDY DIET HISTORY QUESTIONNAIRE 
The University of Wollongong 
Metabolic Research Centre 
Illawarra Dietary Intervention Studies 
 
Name of study: The Efficacy of functional food prescription  in free‐living
subjects with hyperlipidaemia 
 
 
 
 
Research Diet History 
 
 
 
 
 
Participant code: 
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APPENDIX F 
STEROL/STANOL STUDY FOOD RECORD QUESTIONNAIRE 
The University of Wollongong 
Metabolic Research Centre 
Illawarra Dietary Intervention Studies 
 
Name of study: The Efficacy of functional food prescription  in free‐living
subjects with hyperlipidaemia 
 
 
 
 
3‐Day Food Record 
 
 
Please record everything that you eat and drink for 3 days (two 
consecutive weekdays and one weekend day) 
 
 
 
Participant code: 
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APPENDIX G 
OMEGA STUDY INFORMATION FORM AND CONSENT 
versity Department of Medicine 
dical Research Foundation Building 
el 4, Rear 50 Murray Street 
h, Western Australia 6000 
Dr Trevor A Mori 
Telephone 61 8 9224 0273 
Facsimile 61 8 9224 0246 
Email tmori@cyllene.uwa.edu. au
 
 
SUBJECT INFORMATION SHEET 
DEVELOPMENT AND EVALUATION OF NOVEL FOODS ENRICHED WITH 
VERY LONG CHAIN OMEGA-3 FATTY ACIDS 
 
Purpose of the Study: 
There is considerable evidence that omega-3 fats found mainly in fish and fish oils have 
wide-ranging health benefits. Consequently, the National Heart Foundation of Australian, 
health authorities and nutritionists, now recommend that we eat more omega-3 fats. 
Increased consumption of omega-3 fats may reduce heart disease and stroke by 
improving blood pressure and heartbeat disturbances, by reducing blood clotting, and 
favourably altering blood fats (i.e. reducing triglycerides and increasing HDL-cholesterol, 
the “good” fraction of cholesterol). 
Most Australians consume less omega-3 fats than recommended by health authorities. 
This means that the majority of Australians do not receive the potential benefits of 
dietary omega-3 fats. While fish remains the best source of omega-3 fats, Australians 
consume relatively little fish. One possible reason for the failure to achieve the dietary 
recommendations for omega-3 fats is the limited range of readily available foods that can 
deliver these nutrients. A potential solution is the development of novel foods enriched 
with omega-3 fats. We propose to develop foods enriched in omega-3 fats and test the 
effectiveness of these foods on heart risk reduction. 
 
Subjects and Groups: 
40 non-smoking men and women, aged 20-65 years, who are overweight (i.e. have a 
body mass index > 25 kg/m2, a waist circumference > 100 cm, a waist/hip ratio > 1), and 
have elevated blood triglycerides (>1.6 mmol/L), but are otherwise healthy, will be 
recruited from the general community. People not eligible include those with diabetes, 
recent symptomatic heart disease, a history of heart disease or stroke, peripheral vascular 
disease, major surgery within the last 3 months, high blood pressure (>170/100 mmHg), 
liver or kidney disease, regular users of non-steroidal anti-inflammatory drugs, drugs for 
high cholesterol or high blood pressure control, and those eating more than one fish meal 
per week or regularly taking fish oil supplements. 
 
Procedures: 
A. At the beginning of the study volunteers will attend the University Department of 
Medicine Research Unit at Royal Perth Hospital (Murray St) for 1 visit (approx 30-45 
minutes). 
At the screening visit volunteers will: 
1. Complete a lifestyle questionnaire; 
2. Complete a brief medical history questionnaire; 
3. Have height, body weight and waist circumference recorded; 
4. Have blood pressure measured sitting, at 1 min intervals for 5 minutes;  
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1. Provide a small blood sample (~10 ml). A blood donation at the blood bank is ~500
ml. This procedure may cause mild bruising at the site where the blood is taken. 
 
B. Volunteers who meet the entry criteria will be invited to participate in the study. Over a 2
week period they will be asked to attend our Department for 2 visits (approx 30-45
minutes each). At each visit, volunteers will be required to fast (water is allowed) for 12
hours prior to their visit. They will: 
 
1. Maintain usual diet and drinking habits; 
2. Have measurements of body weight taken at each visit; 
3. Complete a lifestyle questionnaire detailing alcohol consumption and physical
activity at one visit; 
4. On one occasion, complete 24 hour dietary diaries on 3 separate days of the week; 
5. Provide a small blood sample (~50 ml) at one visit; 
6. Have blood pressure measured by an automated recorder at each visit. Volunteers
will be rested for 10 minutes, then blood pressure and heart rate will be measured
every 2 minutes for 20 minutes while lying down and every minute for 5 minutes
while standing. 
7. Undertake assessment of blood vessel function. This is a non-invasive test that is
similar to having your blood pressure taken. The test measures stiffness of the blood
vessels determined from an artery in the arm. 
 
C. Volunteers will then be randomly allocated (i.e. by chance) to one of two groups, either:
(1) a treatment group, that will be consuming a range of omega-3 fatty acid enriched
foods (the total amount of fish oil-derived omega-3 fats consumed will be approximately
1g per day), or (2) a control group, that will consume the same quantity of test foods as
the treatment group, but versions of these foods will not contain omega-3 fatty acids.
Low fat, moderate sodium intakes will be advised for both groups, in keeping with
Australian dietary guidelines. Individual dietary intake will be determined at baseline
ensuring minimal change from usual eating patterns but accommodating the test foods. A
list of foods will be provided to enable variety within constraints of desired macronutrient
consumption patterns. All participants will be asked to continue their usual lifestyle and
physical activity throughout the 6-month intervention period. 
 
D. At the end of 3 and 6 months, volunteers will be asked to attend our Department for 2
visits (approx 30-45 minutes each) during which they will have all measurements as
outlined in B.2-7 above repeated. 
 
 
 
Participants are free to withdraw from the study at any time and their records will be
destroyed, unless otherwise agreed by the participant. Any medical treatment needed
during the trial will not be prejudiced. All personal information collected in this study
will be kept strictly confidential. Your participation in this study does not prejudice any
right to compensation, which you may have under statute or common law. The Human
Research Ethics Committee at the University of Western Australia has given approval for
this study. Any concerns regarding the project can be directed to the Secretary, Human
Research Ethics Committee, Registrar’s Office, University of Western Australia, 35
Stirling Highway, Crawley, WA 6009 (telephone number 9380-3703). Any questions
concerning the study can be directed to Dr Trevor Mori or Professor Ian Puddey of the
Department of Medicine, Royal Perth Hospital on Telephone: 9224 0273 or 9224 0252.  
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versity Department of Medicine 
dical Research Foundation Building 
el 4, Rear 50 Murray Street 
h, Western Australia 6000 
Dr Trevor Mori 
Telephone 61 8 9224 0273 
Facsimile 61 8 9224 0246 
Email tmori@cyllene.uwa.edu.au
  
 
CONSENT FORM 
 
 
DEVELOPMENT AND EVALUATION OF NOVEL FOODS ENRICHED WITH 
VERY LONG CHAIN OMEGA-3 FATTY ACIDS 
 
1. I have read a summary of the study and its nature has been fully explained to me. I 
consent to take part. 
 
2. During screening I will be required to attend the University Department of Medicine 
Research Unit at Royal Perth Hospital (Murray St) for 1 visit (approx 30-45 minutes). 
I will be asked to: 
(a) Complete a lifestyle questionnaire; 
(b) Complete a brief medical history questionnaire; 
(c) Have height, body weight and waist circumference recorded; 
(d) Have blood pressure measured sitting at 1 min intervals for 5 minutes; 
(e) Provide a small blood sample (~10 ml). A blood donation at the blood bank is ~500 
ml. This procedure may cause mild bruising at the site where the blood is taken. 
 
3. If eligible for participation in the study, I will over a 2 week period be asked to attend the 
UDM Research Unit at RPH for 2 visits (approx 30-45 minutes each) during which I will: 
(a) Maintain usual diet and drinking habits;  
(b) Have measurements of body weight taken, at each visit; 
(c) Complete a lifestyle questionnaire detailing alcohol consumption and physical 
activity, at one visit; 
(d) On one occasion, complete 24 hour dietary diaries on 3 separate days of the week; 
(e) Provide a small blood sample (~50 ml) at one visit; 
(f) Have blood pressure measured by an automated recorder at each visit. I will rest for 
10 minutes, and then blood pressure and heart rate will be measured every 2 minutes 
for 20 minutes while lying down and every minute for 5 minutes while standing. 
(g) Undertake assessment of blood vessel function at each visit. This is a non-invasive 
test that is similar to having blood pressure taken. The test measures stiffness of the 
blood vessels determined from an artery in the arm. 
 
I understand that I will be randomly allocated (i.e. chance) to one of 2 groups, a control group 
or a treatment group. I may be required to either: (1) consume a range of omega-3 fatty acid 
enriched foods (the total amount of fish oil-derived omega-3 fats consumed will be 
approximately 1g per day), or (2) consume the same quantity of test foods as the treatment 
group, but versions of these foods will not contain omega-3 fatty acids. Low fat, moderate 
sodium intakes will be advised for both groups, in keeping with Australian dietary guidelines. 
My dietary intake will be determined at baseline ensuring minimal change to my usual eating   
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3. patterns, but accommodating the test foods. I will receive a list of foods to enable variety
within constraints of desired macronutrient consumption patterns. I will be asked to
continue my usual lifestyle and physical activity throughout the 6-month intervention
period. 
 
4. At the end of 3 and 6 months, I will be asked to attend the University Department of
Medicine Research Unit at Royal Perth Hospital for 2 visits (approx 30-45 minutes each)
during which I will have all measurements as outlined in 3 (a)-(g) above repeated. 
 
 
I have read the Subject Information Sheet and the information above, and any questions I
have asked have been answered to my satisfaction.  I agree to participate in this activity,
realising that I may withdraw at any time without reason and without prejudice, or without
prejudice to my future medical treatment. 
 
I understand that all information provided is treated as strictly confidential and will not be rele
 
I agree that research data gathered for the study may be published provided my name or other 
 
 
 
 
 
 
 
 
_____________________________ ______________ 
 
Signature of Participant Date 
 
 
 
 
 
 
 
 
_____________________________ ______________ 
 
Signature of Investigator Date 
 
 
 
 
 
 
 
 
 
The Human Research Ethics Committee at the University of Western Australia requires that all 
participants are informed that, if they have any complaint regarding the manner, in which a research 
project is conducted, it may be given to the researcher or, alternatively to the Secretary, Human 
Research Ethics Committee, Registrar’s Office, University of Western Australia, 35 Stirling Highway, 
Crawley, WA 6009     
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APPENDIX H 
OMEGA STUDY DIET SHEET AND OMEGA LOG 
Study Diet Sheet 
 
D
ie
t 
gu
id
el
in
es
 • Eat your usual diet and substitute the test foods in to your usual eating 
pattern.   
• Consume a total of at least 8 omega points per day (You may have 
additional test foods as desired) 
• Limit to one fish meal per week – this includes tuna sandwiches and 
anchovies on pizza 
• Avoid omega enriched foods other than the study foods 
• Foods are only to be consumed by study participants 
• Try not to overeat so that you do not put on weight 
 
Consume your usual diet to include: 
S
ug
ge
st
ed
 O
m
eg
a 
P
la
n 
 
Breakfast Muesli or oats plus 250ml milk 
  or 
 2 Toast with 4 tsp spread 
  or 
 1 Toast with 2tsp spread plus 2 eggs 
  or 
 3 pancakes with 20g spread 
 
Morning Tea Le Snak or muffin or Biscuits or dip or 250 ml  
                                    milk 
 
Lunch 2 slices bread with 20g spread
  plus 
 Egg or soup or Caesar dressing or 
 250ml milk 
 
Afternoon Tea Le Snak or muffin or 2 Biscuits or dip or 
                                    250ml milk or 3 pancakes 
  
Dinner/Supper Caesar dressing or 2 chocolates or Le Snak 
                                   or dip or  250ml milk 
Omega 
points 
2 
 
 
 
 
 
 
1 
 
 
3 
 
 
 
 
1 
 
 
1 
 
O
m
eg
a 
po
in
t 
sy
st
em
 
Test food Serve size Omega points 
 
Bread 2 slices 1 
Spread 20g (4 tsp) 1 
Milk 250ml 1 
Cereal  1 packet 1 
Soup 1 packet 1 
Biscuits 2 biscuits (1pkt) 1 
Eggs 2 eggs 1 
Le Snak 1 serve (dip) 1 
Chocolate 2 serve 1 
Dip 1 serve 1 
Muffin 1 (as per directions) 1 
Pancake 3 (as per directions) 1 
Caesar Dressing       40ml (2Tbs)                             1 
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Additional information 
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Food item 
 
Serve size = 1 
omega point 
 
Mon 
__/__/__ 
  
 
Tue 
__/__/__ 
 
Wed 
__/__/__ 
 
Thu 
__/__/__ 
 
Fri 
__/__/__ 
 
Sat 
__/__/__ 
 
Sun 
__/__/__ 
 
Bread  
 
2 slices 
       
 
Margarine  
 
20g (4tsp) 
       
 
Cereal  
 
1 packet 
       
 
Milk  
 
250ml 
       
 
Biscuits  
 
2 biscuits 
       
 
Soup  
 
1 packet 
       
 
Eggs  
 
2 eggs 
       
 
Le Snak  
 
1 packet (dip) 
       
 
Chocolate  
 
2 items 
       
 
Dip  
 
1 packet 
       
 
Muffin  
1 as per 
directions 
       
 
Pancake 
3 as per 
directions 
       
 
Dressing  
 
40ml (2Tbs) 
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APPENDIX I 
OMEGA STUDY DIET HISTORY QUESTIONNAIRE   
 …/1 
Code: 
Date: 
Site: 
© dhq 2002. Tapsell LC, Patch CS. 
diet history (Base) 2042 
Return to: 
Smart Foods Centre 
University of Wollongong 
Northfields Av, Wollongong NSW 2522.  Australia 
Phone:  +61 2 42214232 
Fax:  +61 2 42214844 
 
d i e t  h i s t o r y  
 q u e s t i o n n a i r e  
ARC Key Centre of Teaching and Research
University of Wollongong  
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Interviewer: _________________       
 
DOB:   _________________ Age: ____________    
 
 
Ht:     ____________cm   Weight:   ______________  
 
BMI:  ___________ _  BMR:      _______________ 
 
Medications:  ___________________________________________________________ 
 
History of health conditions: _________________________________________________ 
 
Supplements: _____________________________________________________________ 
 
Physical activity level: _______________________________________________________ 
 
 
 
 
 
 
 
 
Core Food Choices: Please indicate the type of foods you select in these 
categories 
 
Food group Type Food group Type 
Milk (full fat, 
skim) 
 Spread (margarine 
etc) 
 
   
 
 
  Oils (olive, canola) 
 
 
Bread (white, 
grain) 
   
  Drinks (sweetening) 
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Part 1: Breakfast 
How often do you eat this meal?_____________________Home_______________Away_________ 
Breakfast Cereals/Porridge  
Type Amount Frequency 
   
   
   
   
   
Milk with cereal   
Sugar with cereal   
 
 
Toast/Bread/Muffins etc (including toppings) 
Type Amount Frequency  
   
   
   
   
Spread with toast   
Topping on toast   
 
 
Eggs and other cooked dishes  
Type Amount Frequency  
   
   
   
   
   
Oil/fat   
 
 
Other Foods (including drinks, fruit, yoghurt) 
Type Amount Frequency  
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Part 2: Light Meal.   Lunch or Dinner  (Circle) 
How often do you eat this meal?_____________________Home_______________Away_________ 
 Sandwiches/Rolls 
Description (include all components) Amount Frequency  
   
   
   
   
   
   
   
   
   
   
Spreads   
Added salt   
 
Salads 
Description (include all components) Amount Frequency  
   
   
   
   
   
   
   
Dressings   
 
Soups  
Description (include all components) Amount Frequency  
   
   
   
   
   
Soup mix   
Added salt   
Bread   
 
Other foods (including drinks, fruit, takeaway meals, cakes) 
Description Amount Frequency  
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Part 3: Main Meal.   Lunch or Dinner  (Circle) 
How often do you eat this meal?_________________________Home_______Away___________ 
Main dishes (include all components) Amount Frequency 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Oils/spreads   
Dressings   
Sauces   
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Other foods (include drinks, bread, side dishes, desserts, fruit) 
Type Amount Frequency  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
  
Part 4: Foods consumed outside meals  
How often do you eat snacks?_____________________Home_______________Away_________ 
Type Amount Frequency  
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Part 5: Food Frequency Checklist  
 
Food category Amount Frequency  
Bread/crumpet   
Biscuits   
Crispbreads/crackers   
Cakes/scones/muffins/pastries   
Pancakes   
Beans/legumes   
Fruit   
Fruit juice   
Soft drinks/cordials   
Chocolate/lollies   
Chips   
Alcohol   
Milk   
Yoghurt   
Ice cream   
Cheese   
Dip/cream cheese/cheese spread   
Soy milk   
Soy yoghurt   
Eggs/omega eggs   
Salmon/tuna (fresh/canned)   
Sardines/Mackerel   
White fish varieties   
Oysters   
Walnuts   
Pecans   
Other nuts   
Seeds   
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 …/1
Part 6: Food Preparation Practices 
 
6.1 Butter/Margarine _   
What type do you usually use? 
Butter        
Dairy blend       
Margarine - polyunsaturated, regular    
Margarine - polyunsaturated, reduced fat   
Margarine - monounsaturated, regular  
Other_____________________________   
6.2 Oil/Fat in cooking 
What type of oil/fat do you use in cooking? 
Butter       Olive oil 
Dairy blend      Canola oil 
Margarine - polyunsaturated, regular  Soybean oil 
Margarine - polyunsaturated, reduced fat Gold’n Canola 
Margarine - monounsaturated, regular  Other _________________________ 
 
 
6.3 Fat on Meats/Chicken________________________________ 
How much fat is trimmed from meat before cooking/eating? 
a)  None 
b)  25% 
c)  50% 
d)  75% 
e)  All 
How much of the skin on chicken to you remove before cooking/eating?  
a)  None 
b)  25% 
c)  50% 
d)  75% 
e)  All 
Other, please specify:   ___________ 
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APPENDIX J 
OMEGA STUDY 3-DAY FOOD RECORD QUESTIONNAIRE   
 …/1 
Code: 
Date: 
Site: 
© fr 2002. Tapsell LC, Patch CS. 
food record (Base) 2040 
Study centre to return to: 
Craig Patch MBA APD 
PhD Candidate 
Smart Foods Centre 
University of Wollongong 
Northfields Av, Wollongong NSW 2522.  Australia 
Phone:  +61 2 42214232 
Fax:  +61 2 42214844 
Mobile:  0408 266832 
Email:     csp03@uow.edu.au  
3 - d a y  f o o d  r e c o r d  
ARC Key Centre of Teaching and Research
University of Wollongong  
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Breakfast and Morning Tea  
 
Checklist 
 
Food 
 
Amount 
Cereal   
Bread   
Eggs   
Cream cheese   
Milk drinks   
   
Soup mix   
   
Caesar 
dressing 
  
   
   
Biscuits   
Le Snak   
Dip   
   
Muffins   
Pancakes   
   
Chocolate   
   
   
   
   
   
   
   
   
   
   
   
   
Date:___________________
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Lunch and Afternoon  Tea 
 
Checklist 
 
Food 
 
Amount 
Cereal   
Bread   
Eggs   
Cream cheese   
Milk drinks   
   
Soup mix   
   
Caesar 
dressing 
  
   
   
Biscuits   
Le Snak   
Dip   
   
Muffins   
Pancakes   
   
Chocolate   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
Date:___________________
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Dinner and Supper 
 
Checklist 
 
Food 
 
Amount 
Cereal   
Bread   
Eggs   
Cream cheese   
Milk drinks   
   
Soup mix   
   
Caesar 
dressing 
  
   
   
Biscuits   
Le Snak   
Dip   
   
Muffins   
Pancakes   
   
Chocolate   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
Date:___________________
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APPENDIX K 
OMEGA STUDY FOOD PREFERENCE QUESTIONNAIRE  
  …/1 
 
 
Food preference questionnaire 
 
 
 
  
  
Thank you for completing this questionnaire.   This should only take a couple of 
minutes.  Please answer all questions.  Please do not identify your name on any part 
of the questionnaire.   
 
For each study food listed answer the five questions (a,b,c,d & e). 
 
     
    
Margarine: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bread: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
 
Directions 
Code: 
Date: 
Site: 
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
a. Please rate the taste of the study food: 
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Milk: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Muesli: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oat temptations (Apple & Sultana): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
   ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
   ' add this product to your normal diet   
a. Please rate the taste of the study food: 
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Ginger biscuit: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chicken Laksa soup: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Creamy Vegetable soup: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
a. Please rate the taste of the study food: 
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Eggs: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Le Snak: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mint Chocolate: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
              ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
              ' add this product to your normal diet   
a. Please rate the taste of the study food: 
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Salsa dip: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cracked pepper dip: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orange & Poppy seed muffin: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
             ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
              ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
    ' add this product to your normal diet   
a. Please rate the taste of the study food: 
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  …/1 
Pancake: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salad Dressing: 
 
 
 
 
 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
              ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Dislike    '      '      '      '      '       '       '   Like 
extremely   quite      slightly   neither   slightly      quite     extremely 
 
b. Comment    
____________________________________________________________________ 
 
c. I consume this food ____ times a week 
 
d. Do you intend to continue to consume this product over the next three months?  '  Yes      
  '  No 
 
e. For you to be able to include this product in your diet did you: ' substitute a similar product already eaten, or  
              ' add this product to your normal diet   
a. Please rate the taste of the study food: 
Thank you for completing this questionnaire 
 
    
312   
APPENDIX L 
FOCUS GROUP MEDIA RELEASE 
 
 
 
 
 
 
 
Research suggests that Australians are not eating enough fish.  Fish, in particular deep-sea 
varieties, are high in omega-3 polyunsaturated fats, which offer a range of heart health 
benefits.   
 
Craig Patch – PhD student with the Smart Foods Centre – says the wide-ranging health 
benefits of fish oil, which is high in omega-3 polyunsaturated fats, are well documented in 
both in the prevention and treatment of cardiovascular disease. 
 
Mr Patch states “Studies reveal that Australians consume on average 1.2 serves per week of 
fish with nutrition authorities now recommending up to 3 serves per week. There is a 
potential to improve heart health if we can get more people to eat marine omega-3 fats.”  
 
 “But not everyone can eat enough fish.  Obviously factors such as food preferences and 
disposable income affect fish consumption.  However, factors such as depleting fish stocks 
and distribution across an expansive continent have led to the proposed development of range 
of foods enriched with fish oil,” said Mr Patch 
 
Researchers at the University of Wollongong in collaboration with Goodman Fielder, 
University of Adelaide and University of Western Australia are now developing and testing a 
range of novel food products enriched with fish oil in order to deliver the health benefits of 
fish to a wider number of consumers. 
 
Dr Peter Williams, Head of the consumer insights program of the Smart Foods Centre said the 
introduction of entire ranges of functional food products has brought with it a whole new set 
of issues.  “We need to understand what consumers think about new foods with added health 
benefits and how to incorporate them into the diet.” 
 
“We are conducting focus group research to find out what Wollongong consumers think about 
these proposed changes to the food supply and how they would want new foods to be labelled 
and advertised,” said Dr Williams 
 
If you are interested in participating or wish to find out about other studies conducted by the 
Smart Foods Centre please phone 42214600 for details on how you can be involved. 
 
 
 
NEWS RELEASE 
 
RESEARCHERS CONCERNED THAT 
CONSUMERS DO NOT EAT ENOUGH FISH 
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APPENDIX M 
FOCUS GROUP SUBJECT CONSENT AND INFORMATION FORMS 
UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE
INFORMATION FORM 
 
Consumer salient beliefs and attitudes with regard to functional foods and food
labelling Craig Patch APD, Peter Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MS
Student 
(Research supported financially by Goodman Fielder foods and the Australian Research Council) 
 
The positive aspects of nutrition and health are well established.   In response  the  fo
industry  has  launched  a  range  of  products with  added  nutrients  beyond  the  norm
ingredients with  health  promoting  affects  eg margarine  to  lower  cholesterol.    Th
products are termed ‘functional foods’. The properties of these products are adverti
via  the  food  label.  It  is  uncertain  how  the  availability  of  functional  foods  or  fo
labelling claims affect food choices and it is important to find out what consumers thi
The aim of this study is to investigate the views of consumers toward both functio
foods and food labels. 
 
In taking part of this study you will required to attend a focus group interview with 8
people.  This will take approximately one and a half hours.  You will be allocated to 
of two groups: one will encourage discussion about functional foods and the other w
encourage discussion about low fat food labelling.   
 
All  conversations  will  be  tape  recorded  and  later  transcribed  for  analysis.    So
information about your age, name and marital status will be collected  for purpose
analysis.   All  comments made during  the  focus groups will be  treated as  confiden
and will not be individually identified.  While we can ensure confidentiality, the ext
of  confidentiality within  the  focus group  cannot be ensured.   Record of  focus gro
discussions  on  food  labelling  will  be  summarised  in  a  report  to  Goodman  Fiel
(Sponsor)  foods  and  published  as  a  scientific  paper.    Results  from  discussions 
functional  foods  will  be  used  in  the  development  of  a  questionnaire  to  be  used
subsequent research.   
 
We ask consent of all participants  to be contacted  in  the  future  to participate  in a s
administered questionnaire survey.  All participants will be reimbursed $20.00 for ti
travel  costs  and  inconvenience.    This  payment  does  not  depend  on  continu
participation. 
 
If you would like to discuss this research further please contact Craig Patch on 42214
or Dr Peter Williams on 4221 4085.   If you have any enquires regarding the conduc
the  research  please  contact  the  Secretary  of  the  University  of Wollongong,  Hum
Research Ethics Committee on 4221 4457. 
Thank you for considering this request. 
Craig Patch 
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UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE
CONSENT FORM 
 
Consumer salient beliefs and attitudes with regard to functional foods and food
labelling Craig Patch APD, Peter Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MS
Student 
(Research supported financially by Goodman Fielder foods and the Australian Research Council) 
 
 
This  project  is  being  conducted  as  part  of  a  Doctor  of  Philosophy  (PhD).   Dr  Pe
Williams and Assoc Prof Linda Tapsell, Smart Food Centre, University of Wollongo
supervise the research. 
 
Your participation  in  this  research  is voluntary, you are  free  to  refuse  to particip
and you are free to withdraw from the research at any time.  Your refusal to particip
or withdrawal of  consent will not affect your  treatment  in any way your  relations
with Port Kembla Hospital, the cardiac rehabilitation team or your relationship with 
University of Wollongong.   All results and  information  is confidential and your na
will  not be used.   All data will  be  collected  by me  and  stored  (confidentially)  in 
department. 
 
I,..................................................................................(Participant’s  name)  consent 
participate in the research conducted by Craig Patch.  Specifically I consent to: 
• Participation  in  a  1.5hrs  focus  group  of  8‐10  people  at  the  University
Wollongong. 
• The focus group will be audio taped, analysed and reported upon. 
• My identity will remain confidential to the researchers. 
 
I understand that the data collected will be used for research and I consent for the d
to be used in this manner. 
 
Signed Date 
 
......................................................................................    ......../......../......... 
 
Consent to be contacted for subsequent survey 
 
I,..................................................................................(Participant’s  name)  consent  to  be
contacted  via  the  phone  by  Craig  Patch  to  be  involved  in  a  survey  as  it  has  b
described to me in the information sheet.  I understand that this does not compel m
participate in the survey. 
 
Signed Date 
 
......................................................................................    ......../......../.........   
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APPENDIX N 
FUNCTIONAL FOOD BELIEF QUESTIONNAIRE 
 
 
 
 
 
 
 
 
f u n c t i o n a l  f o o d  b e l i e f  
q u e s t i o n n a i r e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARC Key Centre of Teaching and Research
University of Wollongong
Code: 
Date: 
Site: 
© f2bq 2002. Patch CS, Tapsell LC, Williams PG. 
f2bq base eatwell2044 2 
Return to: 
Craig Patch MBA APD 
PhD Candidate 
Smart Foods Centre 
University of Wollongong 
Northfields Av, Wollongong NSW 2522.  Australia 
Phone:  +61 2 42214232 
Fax:  +61 2 42214844 
Mobile:  0408 266832 
Email:     csp03@uow.edu.au  
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Part A – General details 
 
 
 
  
  
Thank you for completing this questionnaire.   This should only take 10-15 minutes.   
Please answer all questions.  Please do not identify your name on any part of the 
questionnaire.   
 
Once completed please return to the study center. 
Part A - Please indicate your personal details by ticking (  ) a box. 
 
 
 
1. Please indicate your age: 
  25 or under    
  26-35     
  36-45     
  46-55     
  56-65     
  66 or over   
 
2. Please indicate your gender: 
  Male     
  Female   
 
3. Please indicate your marital status: 
  Single/divorced/separated   
  Married/de facto    
 
4. Do you have Children aged under 18 years old living with you? 
  No         
  Yes     
 
5. Which best describes your shopping practices: 
  I am the main shopper   
  I share shopping with my partner  
  I do not shop for food   
 
6. What is your employment status? 
  In paid work     
  Un paid work     
 
7. Please indicate the income range of your household: 
  Less than $20,000 per year  
  $20,000-$40,000 per year   
  $41,000-$60,000 per year   
  $61,000-$80,000 per year   
  $81,000- $100,000 per year  
  greater than $101,000 per year 
  
Directions 
a
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8.   Please indicate your highest level of education:   Primary school      High school       TAFE          University       Other    Please specify _______________ 
  
9.   Please provide the best estimate of your height and weight:   
Weight   ____ 
Height   ____  
  
      
10.   Please indicate any chronic condition(s) you have:   Diabetes    High blood pressure   Asthma       Lung disease   Heart disease    Cancer     Arthritis or other rheumatic disease   Other   Please specify _______________ 
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Part B 
 
 
 
      
  
  In this part of the questionnaire we are mainly concerned with your views toward foods with  
added omega 3 oils.  Some examples of these products include Meadow Lea’s Hi -Omega  
margarine  and Tip Top’s UP bread.  
 
  
  In the questionnaire you are about to fill out we provide both statements and quest ions which  
we would like you to rate on a scale with seven boxes; you are to make tick  (  ) in the place that 
best describes your opinion.
 
  For example, if you were asked to rate “the weather in Wollongong” on such a scale and  you  
think the weather in Wollongong is extremely good, and then you would place your mark as  
follows: 
  
  The weather in Wollongong is.
 
  bad         good extremely   quite    slightly   neither   slightly    quite     extremely
 
 If you think the weather in Wollongong is quite bad, then you would place your mark as follows:
  
  The weather in Wollongong is.
 
  bad         good extremely   quite      slightly   neither   slightly      quite     extremely  
 
  
  
  
  
  
  
11.   I intend to eat one or more foods with added omega-3 oils over the next 
two weeks: 
  
unlikely         likely                 extremely  quite     slightly   neither   slightly    quite     extremely
 
  
  
  
12.   Overall, my attitude toward my eating foods with added omega - 3 oils 
over the next two weeks is: 
  
  
  
  
  
13.   I believe that improving general health is: 
  
  
  
a 
a 
Directions  
a  
unfavourable         favourable   extremely   quite     slightly   neither   slightly    quite     extremely
 
  
Not important         important      extremely   quite     slightly   neither   slightly    quite     extremely
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14.   I believe that obtaining the health benefits of omega-3 oils is:   
  
  
  
  
  
15.   How important is it for foods that have added omega-3 oils to contain 
enough of this nutrient to provide a health benefit? 
  
  
  
  
  
16.   When eating foods with added omega-3 oils how important is it that 
there is little risk of overexposure of this nutrient? 
  
  
  
  
  
  
17.   How important is it for food companies to base new food development 
on good scientific evidence? 
  
  
  
  
  
18.   I believe that developing new ways to make it easier to choose a 
healthy diet high in omega-3 oils is: 
  
  
  
  
  
19.   I believe that improving heart health for the general population is:   
  
  
  
  
  
20.   I believe t hat improving brain health for the general population is:   
  
  
  
  
21.   I believe that improving eye health for the general population is:   
  
  
Not important          important         extremely   quite     slightly   neither   slightly    quite     extremely   
Not important         important        extremely   quite     slightly   neither   slightly    quite     extremely
 
  
Not important         important       extremely   quite     slightly   neither   slightly    quite     extremely  
Not important  
        important       extremely   quite     slightly   neither   slightly     quite     extremely
 
  
Not important         important        extremely   quite    slightly   neither   slightly     quite     extremely 
  
  
Not important         importa nt        extremely   quite     slightly   neither   slightly    quite     extremely
 
  
  
  
Not important         important          extremely   quite     slightly   neither   slightly     quite     extremely   
Not important         important        extremely   quite     slightly   neither   slightly    quite     extremely  
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22.   I believe that improving arthritis for the general population is:   
  
  
  
  
23.   I believe that improving asthma for the general population is:   
  
  
  
  
24.   My eating foods with added omega-3 oils will improve my general 
health:   
  
  
  
  
25.   My eating foods with added omega-3 oils makes it easy to obtain the 
health benefits of this nutrient: 
  
  
  
  
  
26.   Foods with added omega-3 fats contain enough of this nutrient to 
provide a health benefit: 
  
  
  
  
  
27.   My eating foods with added omega-3 oils puts me at risk of 
overexposure of this nutrient in the diet: 
  
  
  
  
  
  
28.   Foods with added omega-3 oils have been developed and based on a 
good understanding of the scientific evidence: 
  
  
  
  
29.   My eating foods with added omega-3 oils is an easy way to choose a 
healthy diet: 
  
  
  
unlikely         likely   
   
       extremely  quite     slightly   neither   slightly    quite     extremely
 
  
unlikely         likely                extremely  quite     slightly   neither   slightly    quite     extremely 
  
  
unlikely         likely          extremely  quite     slightly   neither   slightly    quite     extremely  
  
  
unlikely          likely          extremely  quite     slightly   neither   slightly    quite     extremely 
  
  
  
  
unlikely         likely          extremely  quite     slightly   neither   slightly    quite     extremely 
  
  
unlikely         likely         extremely  quite     slightly   neither   slightly    quite     extremely
  
  
  
  
Not important  
        important         extremely   quite     slightly   neither   slightly     quite     extremely   
Not important         important         extremely   quite     slightly   neither   slightly    quite     extremely   
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30.   My eating foods with added omega-3 oils will improve my heart health:   
  
  
  
  
31.   My eating foods with added omega-3 oils will improve my brain health:   
  
  
  
  
  
32.   My eati ng foods with added omega-3 oils will improve my eye health:   
  
  
  
  
33.   My eating foods with added omega-3 oils will protect me from or 
improve arthritis: 
  
  
  
  
34.   My eating foods with added omega-3 oils will protect me from or 
improve asthma: 
  
  
  
  
35.   Most members of my family think that I should eat foods with added 
omega - 3 oils: 
  
  
  
  
36.   My close friends think that I should eat foods with added omega -3 oils:   
  
  
  
  
  
37.   Most dietitians think that I should eat foods with added omega -3 oils:   
  
  
  
  
  
38.   Most doctors think that I should eat foods with added omega - 3 oils:   
  
  
  
unlikely         likely         extremely  quite     slightly   neither   slightly    quite     extremely
 
  
unlikely         likely           extremely  quite     slightly   neither   slightly    quite    extremely
  
  
unlikely          likely         extremely  quite     slightly   neither   slightly    quite     extremely
 
  
unlikely         likely          extremely  quite     slightly   neither   slightly    quite    extremely 
unlikely          likely         extremely  quite     slightly   neither   slightly    quite     extremely  
unlikely         likely          extremely  quite     slightly   neither   slightly    quite     extremely 
unlikely         likely         extremely  quite     slightly   neither   slightly    quite     extremely  
unlikely         likely         extremely  quite     slightly   neither   slightly    quite     extremely
 
  
unlikely         likely        extremely  quite     slightly   neither   slightly    quite     extremely
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39.   Most scientists think that I should eat foods with added omega -3 oils:   
  
  
  
  
40.   Most food companies think that I should eat foods with added omega -3 
oils:   
  
  
  
  
41.   Most people who are important to me think I should eat food s with 
added omega-3 fats: 
  
  
  
  
  
42.   Generally speaking, I want to do what my family thinks I should do:   
  
  
  
  
43.   Generally speaking, I want to do what my close friends think I should 
do:   
  
  
  
  
  
44.   Generally speaking, I want to do what the most dietitians think I shoul d 
do:   
  
  
  
  
45.   Generally speaking, I want to do what the most doctors think I should 
do:   
  
  
  
  
46.   Generally speaking, I want to do what the most scientists think I should 
do:   
  
  
  
47.   Generally speaking, I want to do what the food companies think I 
should do: 
  
unlikely         likely           extremely  quite     slightly   neither   slightly    quite     extremely
 
  
unlikely         likely          extremely  quite     slightly   neither   slightly    quite     extremely
  
  
unlikely          likely          extremely  quite     slightly   neither   slightly    quite     extremely
 
  
unlikely         likely          extremely  quite     slightly   neither   slightly    quite     extremely 
  
  
unlikely         likely         extremely  quite     slightly   neither   slightly    quite     extremely 
unlikely         likely         extremely  quite     slightly   neither   slightly    quite     extremely 
unlikely         likely         extremely  quite     slightly   neither   slightly    quite     extremely 
unlikely          likely          extremely  quite   slightly   neither   slightly      quite     extremely
 
  
unlikely         likely          extremely  quite     slightly   neither   slightly    quite     extremely   
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48.   How muc h control do you have over whether you do or do not eat 
foods with added omega-3 oils? 
  
  
  
  
  
49.   Even if I wanted to eat foods with added omega-3 oils they are often 
not available where I buy food: 
  
  
  
  
  
50.   Even if I wanted to eat foods with added omega-3 oils I have no control 
over what is bought from the supermarket: 
  
  
  
  
  
51.   Even if I wanted to eat foods with added omega-3 oils the cost prevents 
me from buying them: 
  
  
  
 
52.   Even if I wanted to eat foods with added omega-3 oils the taste and/or 
the texture prevents me from buying them: 
  
  
  
  
53.   Even if I wanted to eat foods with added omega-3 oils the time required 
searching for these foods prevents me from buying them:   
  
  
  
  
54.   Even if I wanted to eat foods with added omega-3 oils if they were not 
suitable for the entire family I would not buy them: 
  
  
  
 
  
  
   
Very little control         complete control      extremely  quite    slightly   neither   slightly    quite     extremely
 
  
unlikely         likely        extremely  quite     slightly   neither   slightly    quite     extremely 
unlikely         likely   
 
      extremely  quite     slightly   neither   slightly    quite     extremely   
unlikely         likely         extremely  quite     slightly   neither   slightly     quite     extremely  
unlikely  
        likely       extremely   quite    slightly   neither   slightly    quite     extremely 
unlikely         likely           extremely  quite     slightly   neither   slightly    quite     extremely 
  
  
unlikely         likely          extremely  quite     slightly   neither   slightly     quite     extremely 
  
  
Thank you for your participation. 
Please return the questionnaire to the study center on your next visit.  
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APPENDIX O  
VALIDATION OF F2BQ INFORMATION FORM AND CONSENT 
UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE  
INFORMATION FORM  
 
Development and validation of a questionnaire predict the use of functional foods ‐ 
Self administered questionnaire  
Craig Patch APD, Peter Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MSc student  
(Research supported financially by the  Australian Research Council)   
 
  
The positive aspects of nutrition and health are well established.  There are a number of 
products that claim to have health benefits. The latest range of products has nutrients in 
addition to the normal ingredients and claim to have a health promoting effects eg 
lowering cholesterol.  These products are termed ‘functional foods’.    
The aim of this study is to examine consumer beliefs and use of functional foods . 
  
Specifically we will ask you to complete a self ‐administered questionnaire.  This will 
take approximately 20 ‐ 30 minutes.  Questions will be on beliefs toward food and health 
as well as current use of specific functional foods.  All questionnaires will be anonymous 
and results used for research purposes only.  The questionnaire should be returned as 
soon as possible using the self ‐addressed envelope provided.  If we do not receive this 
within two weeks or we need to clarify answers we will contact you by phone.  
  
If you would like to discuss this research further please contact Craig Patch on 42214232 
or Dr Linda Tapsell on 4221 3152.  If you have any enquires regarding the conduct of the 
research please contact the Secretary of the University of Wollongong, Human Research 
Ethics Committee on 4221 4457.  
  
Thank you for co nsidering this request.  
Craig Patch   
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UNIVERSITY OF WOLLONGONG & ILLAWARRA AREA HEALTH SERVICE 
CONSENT FORM 
 
Development and validation of a questionnaire predict the use of functional foods‐ 
Self administered questionnaire 
Craig Patch APD, Pete r Williams PhD APD, Linda Tapsell PhD APD, Chung Sau Chan MSc student  
(Research supported financially by the Australian Research Council)   
 
 
This project is being conducted as part of a Doctor of Philosophy (PhD).  The research is 
supervised by Assoc Prof Linda Tapsell, Smart Food Centre, University of Wollongong. 
  
Your participation in this research is voluntary; you are free to refuse to participate 
and you are free to withdraw from the research at any time.  Your refusal to participate 
or withdrawal of c onsent will not affect your treatment in any way/your relationship 
with the University of Wollongong.  All results and information is confidential and your 
name will not be used.  All data will be collected by Craig Patch and stored in secure, 
confidential  holdings within the Department of Biomedical Sciences.   
  
  
I,..................................................................................(Participant’s name) consent to 
participate in the research conducted by Craig Patch.  Specifically, I consent to: 
•   Completing a self ‐administered questionnaire on functional foods received in the 
mail.   
•   Returning this in the stamp self‐addressed envelope provided.   
•   Being contacted by phone by Craig Patch if any questionnaires are not received 
within 2 weeks or if there is a need to clarify any of my responses.   
I understand that the data collected will be used for research and I consent for the data 
to be used in this manner.   
  
Signed Date  
  
...................................................................................    ......../......../.........  
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APPENDIX P 
STAKEHOLDER STUDY INFORMATION SHEET AND CONSENT FORM 
UNIVERSITY OF WOLLONGONG  
INFORMATION FORM 
Determining stakeholder beliefs and attitudes towards the development of and 
communication about novel foods designed to improve or enhance health (functional 
foods). 
Craig Patch APD, Linda Tapsell PhD APD, Peter Williams PhD APD 
(Research supported financially by an Australian Research Council Linkage grant with Goodman 
Fielder Foods being the industry partner) 
The positive aspects of nutrition and health are well established.  In response the food industry has  
launched a range of products with added nutrients beyond the normal ingredients with health  
promoting affects eg margarine to lower cholesterol.  These products are termed ‘functional foods’.  
To this end the Australia New Zealand Food Regulation Ministerial Council agreed to a range of  
policy initiatives, which included Nutrition, Health and Related Claims to be permitted on food 
labels.  In addition, the existing code on novel foods will be reviewed. This is a policy shift in  
Australia and there are implications for Public Health.   
Regulatory bodies often consult stakeholders on policy options, however there are no studies  
reporting beliefs and attitudes of Australian stakeholders towards functional foods.  Identifying  
contrasting beliefs regarding this issue is important if we are to understand how we can use the food  
supply to improve the health of the population.   
The aim of this study is to investigate views of stakeholders toward the development and 
promotion of functional foods and whether this is an appropriate strategy for improving 
population health through the food supply. 
In taking part of this study you will be required to attend a one-off interview.  This will take 
approximately one hour.  All conversations will be tape recorded and later transcribed for analysis.  
Some information about your age, name and workplace will be collected for purposes of analysis.  All 
comments made during the interview will be treated as confidential and will not be individually 
identified.  Results from discussions will be published in peer reviewed journal articles.  We ask 
consent of all participants and signature on the attached form is required. 
If you would like to discuss this research further please contact Craig Patch on 42214232 or Prof 
Linda Tapsell, on 4221 3152 or Dr Peter Williams on 4221 4085.  If you have any enquires 
regarding the conduct of the research please contact the Secretary of the University of Wollongong, 
Human Research Ethics Committee on 4221 4457. 
Thank you for considering this request. 
Craig Patch 
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UNIVERSITY OF WOLLONGONG   
CONSENT FORM 
 
Determining stakeholder beliefs and attitudes towards the development and communication 
  
 
Craig Patch APD, Linda Tapsell PhD APD, Peter Williams PhD APD  
(Research supported financially by an Australian Research Council Linkage grant with Goodman 
Fielder Foods being the industry partner)   
 
This project is being conducted as part of a Doctor of Philosophy (PhD).  Prof Linda Tapsell and Dr
Peter Williams, National Centre of Excellence in Functional Foods (NCEFF), University of 
Wollongong supervise the research. 
  
Your participation in this research is voluntary, you are free to refuse to participate and you 
ar e free to withdraw from the research at any time.  Your refusal to participate or withdrawal of 
consent will not affect your treatment in any way your relationship with the NCEFF, the Smart Foods  
Centre or your relationship with the University of Wollongong.  All results and information is 
confidential and your name will not be used.  All data will be collected by me and stored 
(confidentially) in the department. 
  
  
  
  
I,..................................................................................(Participant’s name) consent to participate in the 
research conducted by Craig Patch.  Specifically I consent to: 
•   Participation in a 1 hr interview group either via telephone of mutually agreeable venue. 
•   The interview will be audio taped, analysed and reported upon.   
•   My identity will remain confidential to the researchers. 
  
I understand that the data collected will be used for research and I consent for the data to be used in 
this manner.   
  
Signed Date   
  
......................................................................................    ......../......../.........   
  
  
  
of novel foods designed to improve or enhance health (functional foods).
